,Patient,Patient Subgroup,Patient Subgroup_FUL,Oncogenic HPV Status,Course #,Date of Onset,Date Resolved,System Organ Class,Adverse Event Term (v5.0),Adverse Event Description,Grade,Attribution to Research,Attribution to Disease,Attribution to Other,"Other, Specify",Serious,Action,AE Therapy,AE Outcome
107,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,05-01-2018,--,Nervous system disorders,Headache,Intermittent; mild HA approx. 2x a week since starting tx,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
108,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,10.0,09-04-2018,09-18-2018,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Possible,Probable,Lovenox; prior XRT,Not a Serious Adverse Event,None,None,Recovered
109,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,10.0,09-04-2018,10-02-2018,Investigations,White blood cell decreased,,2,Unlikely,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
110,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,11.0,09-18-2018,10-02-2018,Investigations,Neutrophil count decreased,,3,Unlikely,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
111,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,17.0,12-12-2018,12-21-2018,Gastrointestinal disorders,Small intestinal obstruction,Partial SBO per X-Ray,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
112,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,17.0,12-21-2018,01-02-2019,Gastrointestinal disorders,Small intestinal obstruction,Partial SBO per X-Ray,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
113,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-07-2019,01-14-2019,Metabolism and nutrition disorders,Anorexia,TPN indicated d/t inability to eat for several days,3,Unrelated,Unrelated,Probable,SBO,Not a Serious Adverse Event,None,Support,Recovered
114,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-04-2019,--,"Respiratory, thoracic and mediastinal disorders",Cough,Cough syrup and lozenges indicated,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,
115,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-07-2019,01-09-2019,Metabolism and nutrition disorders,Dehydration,,2,Unrelated,Unrelated,Probable,"SBO, hospitalization",Not a Serious Adverse Event,None,Support,Recovered
116,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-07-2019,--,Gastrointestinal disorders,Diarrhea,IV steroids indicated,3,Unlikely,Possible,,,Hospitalized,Regimen Interrupted,Support,
117,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-05-2019,01-08-2019,Metabolism and nutrition disorders,Hypokalemia,Oral supplement indicated,1,Unrelated,,,,Not a Serious Adverse Event,None,Symptom,Recovered
118,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-07-2019,--,Gastrointestinal disorders,Nausea,Ondansetron Injection indicated,3,Unlikely,Possible,,,Hospitalized,Regimen Interrupted,Support,
119,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-07-2019,--,"Respiratory, thoracic and mediastinal disorders",Pleural effusion,Small right and trace left pleural effusions,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,
120,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-02-2019,--,Gastrointestinal disorders,Small intestinal obstruction,"Partial, symptomatic SBO requiring hospitalization",3,Unrelated,Probable,,,Hospitalized,Regimen Interrupted,Symptom,
121,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-07-2019,01-08-2019,"Respiratory, thoracic and mediastinal disorders",Sore throat,Anesthetic sprays indicated,2,Unrelated,Unrelated,Definite,NGT insertion,Not a Serious Adverse Event,None,Symptom,Recovered
122,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-07-2019,--,Gastrointestinal disorders,Vomiting,Ondansetron Injection indicated,3,Unlikely,Possible,,,Hospitalized,Regimen Interrupted,Support,
123,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,18.0,01-03-2019,01-04-2019,Investigations,Weight loss,,1,Unrelated,,,,Not a Serious Adverse Event,None,None,Recovered
124,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,19.0,01-08-2019,01-08-2019,Metabolism and nutrition disorders,Hypokalemia,IV w/potassium supplement,3,Unrelated,Unrelated,Probable,"SBO, hospitalization",Not a Serious Adverse Event,None,Support,Recovered
125,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,19.0,01-09-2019,01-14-2019,Investigations,Weight loss,,2,Unrelated,Unrelated,Probable,"SBO, hospitalization",Not a Serious Adverse Event,None,None,Recovered
126,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,05-16-2018,05-18-2018,Gastrointestinal disorders,Diarrhea,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
127,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,06-06-2018,--,Renal and urinary disorders,Hematuria,Intermittent,1,Unlikely,Possible,Possible,Lovenox,Not a Serious Adverse Event,None,None,
128,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,06-12-2018,06-26-2018,Investigations,Neutrophil count decreased,,3,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
129,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,06-27-2018,06-29-2018,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
130,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-10-2018,08-07-2018,Investigations,Creatinine increased,High Cr so given trial of IVFs for poss dehydration,1,Unlikely,Possible,Possible,Decreased oral intake; 3-dehydration,Not a Serious Adverse Event,None,Support,Recovered
131,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-10-2018,07-24-2018,Metabolism and nutrition disorders,Dehydration,High Cr so given trial of IVFs for poss dehydration,2,Unlikely,Possible,Possible,Decreased oral intake,Not a Serious Adverse Event,None,Support,Recovered
132,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-11-2018,--,General disorders and administration site conditions,Fatigue,Worsening and intermittent,1,Possible,Possible,Possible,Travel; 3-hypothyroid med dosage,Not a Serious Adverse Event,None,None,
133,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-10-2018,07-24-2018,Investigations,Neutrophil count decreased,,3,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
134,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-10-2018,08-21-2018,Investigations,White blood cell decreased,,2,Unlikely,Unlikely,Possible,Med Hx,Not a Serious Adverse Event,None,None,Recovered
135,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,7.0,07-24-2018,--,Skin and subcutaneous tissue disorders,Rash acneiform,Rash on face on b/l cheeks,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,
136,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,08-07-2018,08-21-2018,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unlikely,Probable,Lovenox; prior XRT,Not a Serious Adverse Event,None,None,Recovered
137,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,08-20-2018,08-21-2018,General disorders and administration site conditions,Flu like symptoms,,1,Unlikely,Unlikely,Possible,Infection,Not a Serious Adverse Event,None,Symptom,Recovered
138,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,08-07-2018,08-21-2018,Investigations,Neutrophil count decreased,,3,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
139,b143468311134d27f4f8a7622a1d7235,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,9.0,08-21-2018,09-04-2018,Investigations,Lymphocyte count decreased,,2,Unlikely,Unlikely,Possible,Prior therapy,Not a Serious Adverse Event,None,None,Recovered
149,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,05-09-2018,--,"Respiratory, thoracic and mediastinal disorders","Respiratory, thoracic and mediastinal disorders - Other, specify",Intermittent sneezing and rhinorrhea which resolve with Tylenol,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
150,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,10-30-2018,--,"Respiratory, thoracic and mediastinal disorders",Cough,Intermittent and dry,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,
151,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,10-30-2018,--,"Respiratory, thoracic and mediastinal disorders",Wheezing,Intermittent,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,
152,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,11-26-2018,--,"Respiratory, thoracic and mediastinal disorders",Bronchial obstruction,Required bronchoscopy on 11/26/18,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,
153,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,11-13-2018,11-20-2018,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Oxygen indicated,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,Support,Recovered
154,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,11-20-2018,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Hospital admission indicated,2,Unrelated,Probable,Probable,Tumor obstruction of airway,Hospitalized,Dose Reduced,Support,
155,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,17.0,12-18-2018,01-14-2019,Blood and lymphatic system disorders,Anemia,Symptomatic; transfusion indicated on 1/2/19 as comfort measure  to reduce dyspnea,2,Possible,Unrelated,Definite,Hx gastric ulcer; 4-ong interm GI bleed,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
156,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,05-22-2018,06-05-2018,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unrelated,Definite,Hx gastric ulcer,Not a Serious Adverse Event,None,None,Recovered
157,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,06-05-2018,06-06-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 6/5/18,3,Unrelated,Unrelated,Definite,"Hx gastric ulcer; 5-Ong, interm GI bleed",Hospitalized,Regimen Interrupted,Support,Recovered
158,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,06-06-2018,06-07-2018,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unrelated,Definite,Hx gastric ulcer,Hospitalized,None,None,Recovered
159,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,06-07-2018,06-08-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 6/7/18,3,Unrelated,Unrelated,Definite,Hx gastric ulcer,Hospitalized,None,Support,Recovered
160,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,06-27-2018,07-03-2018,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unrelated,Definite,Hx gastric ulcer,Not a Serious Adverse Event,None,None,Recovered
161,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,06-30-2018,--,Nervous system disorders,Dizziness,,1,Possible,Probable,,,Not a Serious Adverse Event,None,None,
162,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-10-2018,07-11-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 7/10/18,3,Possible,Unrelated,Definite,Hx of gastric ulcer,Not a Serious Adverse Event,None,Support,Recovered
163,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-04-2018,07-07-2018,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unrelated,Definite,Hx of gastric ulcer,Not a Serious Adverse Event,None,None,Recovered
164,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-07-2018,07-10-2018,Blood and lymphatic system disorders,Anemia,,2,Possible,Unrelated,Definite,Hx of gastric ulcer,Not a Serious Adverse Event,None,None,Recovered
165,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-03-2018,07-04-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 7/3/18-admitted to hospital with symptomatic anemia,3,Unlikely,Unrelated,Definite,Hx gastric ulcer; 4-Ong int GI bleed,Hospitalized,Regimen Interrupted,Support,Recovered
166,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-07-2018,10-11-2018,Gastrointestinal disorders,Colitis,Prednisone indicated beginning on 7/12/18,2,Possible,Unrelated,Possible,"XRT,immuno; 4-GI erosive enteropathy",Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
167,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-07-2018,07-07-2018,Metabolism and nutrition disorders,Hypomagnesemia,MgSo4 2 g indicated,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Support,Recovered
168,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-07-2018,07-08-2018,Vascular disorders,Hypotension,"Assoc w/3 episodes hematochezia, also dizziness, diaphoresis; BP in 40s/20s-IVFs indicated",3,Unrelated,Unrelated,Possible,Vasovagal,Hospitalized,None,Support,Recovered
169,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-07-2018,07-07-2018,Nervous system disorders,Presyncope,,2,Unrelated,Unrelated,Possible,Vasovagal rxn,Not a Serious Adverse Event,None,None,Recovered
170,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-06-2018,01-18-2019,Gastrointestinal disorders,Upper gastrointestinal hemorrhage,Diffuse enteropathy  in terminal ileum w/active bleed; prednisone indicated beg 7/12/18,3,Possible,Unrelated,Probable,"Enteritis, colitis, erosive enteropathy",Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
171,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-26-2018,07-26-2018,Blood and lymphatic system disorders,Anemia,,2,Possible,Unrelated,Definite,Hx of gastric ulcer,Not a Serious Adverse Event,None,None,Recovered
172,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-28-2018,07-30-2018,Blood and lymphatic system disorders,Anemia,,2,Possible,Unrelated,Definite,Hx of gastric ulcer,Not a Serious Adverse Event,None,None,Recovered
173,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-25-2018,07-29-2018,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Oxygen indicated during HS and upon discharge.,3,Unrelated,Unrelated,Probable,Thromboembolic event,Hospitalized,None,Support,Recovered
174,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-29-2018,11-13-2018,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Intermittent,1,Unrelated,Unrelated,Probable,Thromboembolic event,Not a Serious Adverse Event,None,None,Recovered
175,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-30-2018,--,Endocrine disorders,Hypothyroidism,HRT indicated-started Levothyroxine 7/31/18,2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
176,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,07-25-2018,--,Vascular disorders,Thromboembolic event,B/L PE's associated with SOB-required Lovenox reinitiation,3,Unlikely,Unrelated,Probable,Med hx and stopping of Lovenox,Hospitalized,None,Symptom,
177,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,08-27-2018,08-27-2018,"Injury, poisoning and procedural complications",Fall,Functional fall; having difficulty walking s/p fall d/t injury,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
178,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,08-27-2018,09-11-2018,General disorders and administration site conditions,Gait disturbance,,2,Unrelated,Unrelated,Definite,Fall,Not a Serious Adverse Event,None,None,Recovered
179,99f8e325b895fb103328c46fcecba780,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,08-27-2018,09-11-2018,Musculoskeletal and connective tissue disorders,Myalgia,Lower extremities,2,Unrelated,Unrelated,Definite,Fall,Not a Serious Adverse Event,None,None,Recovered
201,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,10.0,09-25-2018,12-04-2018,General disorders and administration site conditions,Fatigue,Low energy-sleeps 10-12 hrs/day,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
202,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,10.0,09-25-2018,11-06-2018,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Keratoacanthoma on face & neck,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
203,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,11.0,10-09-2018,11-06-2018,Nervous system disorders,Headache,Intermittent,1,Unlikely,Possible,Possible,Seasonal allergies,Not a Serious Adverse Event,None,None,Recovered
204,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,11.0,10-09-2018,12-18-2018,Metabolism and nutrition disorders,Hypomagnesemia,,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,Support,Recovered
205,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,11.0,10-09-2018,10-23-2018,Investigations,Weight gain,,1,Unlikely,Unlikely,Possible,"Diet, lifestyle, and/or age",Not a Serious Adverse Event,None,None,Recovered
206,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,10-30-2018,12-04-2018,Musculoskeletal and connective tissue disorders,Generalized muscle weakness,,1,Unlikely,Possible,Possible,Influenza vac;3-hypothy;3-kidney func,Not a Serious Adverse Event,None,None,Recovered
207,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,10-23-2018,01-15-2019,Musculoskeletal and connective tissue disorders,Myalgia,,1,Unlikely,Unlikely,Possible,Peripheral neuropathy,Not a Serious Adverse Event,None,None,Recovered
208,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,10-23-2018,11-06-2018,Investigations,Weight gain,,2,Unlikely,Unlikely,Possible,"Diet, life style, age",Not a Serious Adverse Event,None,None,Recovered
209,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,11-06-2018,03-12-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Keratoacanthoma on face/neck-cryotherapy indicated on 11/6/18,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,Support,Recovered
210,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,--,Endocrine disorders,Adrenal insufficiency,,2,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
211,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,12-18-2018,Metabolism and nutrition disorders,Anorexia,,1,Unlikely,Unlikely,Possible,"Depression, anxiety",Not a Serious Adverse Event,None,None,Recovered
212,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,12-18-2018,Investigations,Creatinine increased,2L NS indicated on 12/4/18,1,Unlikely,Unlikely,Possible,Poor oral intake,Not a Serious Adverse Event,None,Support,Recovered
213,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,12-04-2018,Metabolism and nutrition disorders,Dehydration,IV hydration indicated,2,Unlikely,Unlikely,Possible,Poor oral intake,Not a Serious Adverse Event,None,Support,Recovered
214,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,01-15-2019,Psychiatric disorders,Depression,,2,Unlikely,Unlikely,Possible,Med hx per Psych note 12/4/18,Not a Serious Adverse Event,None,Symptom,Recovered
215,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,04-23-2019,General disorders and administration site conditions,Fatigue,Intermittent; sleeps 10-12 hrs/day,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
216,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,01-15-2019,Musculoskeletal and connective tissue disorders,Generalized muscle weakness,,1,Unlikely,Possible,Possible,Influenza vac;3-hypothy;3-kidney func,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
217,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,--,Endocrine disorders,Hypothyroidism,,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,
218,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,12-18-2018,Nervous system disorders,Memory impairment,,1,Unlikely,Unlikely,Possible,"Insomnia, fatigue",Not a Serious Adverse Event,None,None,Recovered
219,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-04-2018,01-15-2019,Nervous system disorders,Peripheral motor neuropathy,Twitching muscles in thighs,1,Unlikely,Unlikely,Possible,Prior chemo,Not a Serious Adverse Event,None,None,Recovered
220,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,12-11-2018,01-29-2019,Investigations,Weight loss,,1,Unlikely,Unlikely,Possible,"Diet, life style change",Not a Serious Adverse Event,None,None,Recovered
221,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,19.0,01-29-2019,02-12-2019,Investigations,Weight loss,,2,Unlikely,Unlikely,Possible,"Diet, lifestyle change, AI",Not a Serious Adverse Event,None,None,Recovered
222,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,06-11-2018,06-12-2018,General disorders and administration site conditions,Flu like symptoms,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
223,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,20.0,02-14-2019,02-26-2019,Infections and infestations,Upper respiratory infection,"Feverish, myalgias/sweats, sinus pain/nose running",2,Unlikely,Unlikely,Probable,Infective process,Not a Serious Adverse Event,None,None,Recovered
224,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,20.0,02-12-2019,04-23-2019,Investigations,Weight loss,,1,Unlikely,Unlikely,Possible,"Diet, lifestyle change, AI",Not a Serious Adverse Event,None,None,Recovered
225,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,22.0,03-12-2019,04-23-2019,Ear and labyrinth disorders,"Ear and labyrinth disorders - Other, specify",Left ear fullness/congestion-ENT consult ordered,1,Unlikely,Unrelated,Possible,Residual of  URI sys from 2/21/19 visit,Not a Serious Adverse Event,None,None,Recovered
226,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,23.0,03-26-2019,04-23-2019,Musculoskeletal and connective tissue disorders,Myalgia,,1,Unrelated,Unlikely,Probable,Gardening/yardwork; positioning,Not a Serious Adverse Event,None,None,Recovered
227,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,25.0,04-23-2019,--,Vascular disorders,Hot flashes,"Intermittent, mostly at night",1,Unlikely,Unlikely,Possible,Prior chemo; 3-hypothyroid,Not a Serious Adverse Event,None,None,
228,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,28.0,06-12-2019,08-27-2019,General disorders and administration site conditions,Fatigue,Increasing fatigue,1,Unlikely,Possible,Possible,"Hypothyroid, AI",Not a Serious Adverse Event,None,None,Recovered
229,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,28.0,06-12-2019,08-27-2019,Nervous system disorders,Headache,Approximate start date of HAs interm and ong for about 3 weeks,1,Unlikely,Possible,Possible,"Tension, stress",Not a Serious Adverse Event,None,None,Recovered
230,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,34.0,08-27-2019,12-17-2019,General disorders and administration site conditions,Fatigue,,2,Unlikely,Possible,Possible,hypothyroid,Not a Serious Adverse Event,None,None,Recovered
231,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,34.0,08-27-2019,01-28-2020,Investigations,Weight gain,,1,Unrelated,Unrelated,Probable,"steroid, diat",Not a Serious Adverse Event,None,None,Recovered
232,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,38.0,11-01-2019,--,Ear and labyrinth disorders,"Ear and labyrinth disorders - Other, specify",fullness/congestion left ear,1,Unlikely,Unrelated,Possible,residual symptom from cold/allergy,Not a Serious Adverse Event,None,None,
233,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,41.0,12-10-2019,04-27-2021,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
234,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,41.0,12-10-2019,02-11-2020,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
235,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,41.0,12-10-2019,12-31-2019,Infections and infestations,Upper respiratory infection,,2,Unrelated,Unrelated,Probable,viral infection,Not a Serious Adverse Event,None,Symptom,Recovered
236,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,43.0,12-31-2019,03-16-2021,Eye disorders,Dry eye,,1,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
237,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,43.0,12-31-2019,--,Gastrointestinal disorders,Dry mouth,,1,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
238,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,43.0,12-31-2019,--,Gastrointestinal disorders,Dry mouth,,1,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
239,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,43.0,12-31-2019,03-24-2020,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unrelated,Possible,winter weather,Not a Serious Adverse Event,None,Symptom,Recovered
240,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,43.0,12-31-2019,02-11-2020,Skin and subcutaneous tissue disorders,Rash acneiform,,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
241,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,43.0,12-31-2019,--,Vascular disorders,Thromboembolic event,,2,Unlikely,Possible,,,Not a Serious Adverse Event,Dose Reduced,None,
242,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,43.0,12-31-2019,--,Vascular disorders,Thromboembolic event,,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,Symptom,
243,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,45.0,02-01-2020,03-24-2020,General disorders and administration site conditions,Fatigue,,1,Unlikely,Possible,Possible,adrenal insufficiency,Not a Serious Adverse Event,None,None,Recovered
244,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,45.0,02-01-2020,03-24-2020,Musculoskeletal and connective tissue disorders,Myalgia,,1,Unlikely,Possible,Possible,adrenal insufficiency,Not a Serious Adverse Event,None,None,Recovered
245,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,45.0,01-28-2020,02-11-2020,Investigations,Weight gain,,2,Unrelated,Unrelated,Probable,"diet,steroids",Not a Serious Adverse Event,None,None,Recovered
246,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,46.0,02-11-2020,--,Musculoskeletal and connective tissue disorders,"Musculoskeletal and connective tissue disorder - Other, specify","TMJ symptoms, Left jaw",1,Unlikely,Unrelated,,,Not a Serious Adverse Event,None,None,
247,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,46.0,02-11-2020,03-24-2020,Investigations,Weight gain,,1,Unrelated,Unrelated,Probable,"diet,steroids",Not a Serious Adverse Event,None,None,Recovered
248,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,48.0,03-24-2020,--,Investigations,Weight gain,,2,Unrelated,Unrelated,Probable,"diet,steroids",Not a Serious Adverse Event,None,None,
249,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,07-17-2018,07-31-2018,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
250,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,53.0,01-05-2021,--,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
251,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,54.0,01-19-2021,--,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
252,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,54.0,01-19-2021,02-16-2021,Metabolism and nutrition disorders,Hypomagnesemia,,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
253,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,57.0,03-16-2021,04-27-2021,Eye disorders,Dry eye,,2,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
254,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,57.0,03-16-2021,04-27-2021,Skin and subcutaneous tissue disorders,Rash acneiform,itchy rash on Bilateral arms & face,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
255,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,59.0,04-27-2021,--,Eye disorders,Dry eye,,1,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
256,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,08-01-2018,03-12-2019,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unlikely,Possible,Dry skin on face,Not a Serious Adverse Event,None,Symptom,Recovered
257,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,08-07-2018,09-25-2018,Skin and subcutaneous tissue disorders,Rash acneiform,On face and spreading to neck as of 8/28/18k,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
258,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,60.0,08-17-2021,--,Gastrointestinal disorders,Constipation,,1,Unrelated,Unrelated,Probable,surgery,Not a Serious Adverse Event,None,None,
259,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,60.0,08-17-2021,--,Gastrointestinal disorders,Flatulence,,1,Unrelated,Unrelated,Probable,surgery,Not a Serious Adverse Event,None,None,
260,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,61.0,11-21-2021,11-29-2021,Musculoskeletal and connective tissue disorders,Back pain,left sided flank pain,1,Unrelated,Possible,Possible,physical exertion,Not a Serious Adverse Event,None,Symptom,Recovered
261,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,63.0,12-21-2021,--,Investigations,Alkaline phosphatase increased,,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,
262,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,63.0,01-18-2022,--,Investigations,Serum amylase increased,,2,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
263,4013ce1eb4e04dc53415c02629dc6a36,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,08-28-2018,11-06-2018,Vascular disorders,Hot flashes,Intermittent,1,Unlikely,Unlikely,Possible,Prior chemo; 3-hypothyroid,Not a Serious Adverse Event,None,None,Recovered
279,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,06-24-2018,07-24-2018,Musculoskeletal and connective tissue disorders,Arthralgia,Steroid injections indicated on 7/10/18,3,Unrelated,Unrelated,Probable,"Prior therapy, BL",Not a Serious Adverse Event,None,Support,
280,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,10-29-2018,03-05-2019,Gastrointestinal disorders,Hemorrhoidal hemorrhage,Intermittent blood in stool since surgery,1,Unrelated,Unrelated,Probable,Physical straining;,Not a Serious Adverse Event,None,Symptom,Recovered
281,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,10-29-2018,10-29-2018,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",Rsx abd wall mets w/abd wall reconstruction,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Vigorous,Recovered
282,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,10-29-2018,10-29-2018,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",Resection abd wall mets,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Vigorous,Recovered
283,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,11-01-2018,11-26-2018,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unlikely,Possible,"Prior tx, hemorrhoids, stomach ulcer",Not a Serious Adverse Event,None,None,Recovered
284,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,10-30-2018,11-01-2018,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Unlikely,Possible,"Prior tx, surgery, hemorr, stomach ulcer",Not a Serious Adverse Event,None,None,Recovered
285,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,10-30-2018,11-26-2018,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unrelated,Possible,Possible,Diet,Not a Serious Adverse Event,None,None,Recovered
286,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,10-30-2018,11-26-2018,Investigations,Lymphocyte count decreased,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
287,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,11-26-2018,12-06-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 11/27/18 and 11/29/18,3,Unlikely,Possible,Possible,"Palliative surg, hemorr, stomach ulcer",Hospitalized,Regimen Interrupted,Support,Recovered
288,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,11-26-2018,11-27-2018,Metabolism and nutrition disorders,Hyperkalemia,IV Dextrose and insulin indication,1,Unlikely,Unlikely,Probable,Dietary,Not a Serious Adverse Event,None,Support,Recovered
289,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,11-26-2018,10-29-2019,Psychiatric disorders,Insomnia,Secondary to pruritus-temazepam indicated,1,Unrelated,Unrelated,Possible,Generalized itching,Not a Serious Adverse Event,None,Symptom,Recovered
290,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,11-26-2018,10-29-2019,Skin and subcutaneous tissue disorders,Pruritus,"Refractory itching limiting sleep; oral hydroxyzine indicated; tx held for weeks 39, 45, and 51",2,Possible,Unlikely,Probable,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
291,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,11-26-2018,02-05-2019,Investigations,Weight loss,,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
292,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,13.0,11-28-2018,--,Gastrointestinal disorders,Gastric ulcer,Fundus and antral peptic ulcers,2,Unrelated,Unrelated,Possible,NSAID use,Not a Serious Adverse Event,None,Symptom,
293,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,16.0,01-10-2019,02-05-2019,Infections and infestations,Rash pustular,Eruption of shingles causing patient to miss scheduled Week 33 clinic visit on 1/22/19,2,Unrelated,Unrelated,Probable,Viral infection,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
294,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,17.0,02-04-2019,02-19-2019,Investigations,Lymphocyte count decreased,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
295,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,18.0,02-05-2019,07-09-2019,Metabolism and nutrition disorders,Anorexia,Low appetite; nutritional supplement indicated,2,Unlikely,Unlikely,Probable,Post-surgical deconditioning,Not a Serious Adverse Event,None,Symptom,Recovered
296,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,18.0,02-05-2019,02-19-2019,Investigations,Weight loss,Nutritional supplement indicated-started taking Benecalorie,2,Unrelated,Unrelated,Probable,Anorexia,Not a Serious Adverse Event,None,Symptom,Recovered
297,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,19.0,02-19-2019,03-05-2019,Blood and lymphatic system disorders,Anemia,Clinically significant at 2/19/19 d/t requirement for IV iron repletion; 2 doses IV iron indicated,2,Unlikely,Unlikely,Possible,Prior tx or iron deficiency,Not a Serious Adverse Event,None,Support,Recovered
298,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,19.0,02-19-2019,05-28-2019,Investigations,Weight loss,Taking Benecalor supplement,1,Unlikely,Unlikely,Probable,Anorexia,Not a Serious Adverse Event,None,Symptom,Recovered
299,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,22.0,04-15-2019,05-28-2019,Investigations,Lymphocyte count decreased,,2,Unrelated,Possible,Probable,Prior therapy,Not a Serious Adverse Event,None,None,Recovered
300,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,33.0,09-15-2019,12-10-2019,Skin and subcutaneous tissue disorders,Rash acneiform,,1,Unlikely,Unlikely,Possible,infection,Not a Serious Adverse Event,None,Symptom,Recovered
301,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,37.0,10-29-2019,--,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unlikely,Probable,Baseline,Not a Serious Adverse Event,None,Symptom,
302,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,08-04-2018,08-21-2018,Nervous system disorders,Dizziness,Intermittent; required withholding of study drug per patient choice,1,Unlikely,Possible,Possible,Physical exertion,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
303,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,07-25-2018,08-07-2018,Nervous system disorders,Headache,"Morning HA's s/p infusion, resolving after 2 weeks",1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
304,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,07-25-2018,04-16-2019,Skin and subcutaneous tissue disorders,Rash acneiform,Developed on face/chest after last tx; intermittent; topical cream indicated,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
305,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,40.0,01-01-2020,--,"Respiratory, thoracic and mediastinal disorders",Cough,,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
306,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,08-21-2018,09-18-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 8/21/18,2,Unlikely,Unlikely,Possible,"Prior tx, hemorrhoids, stomach ulcer",Not a Serious Adverse Event,None,Support,Recovered
307,8cef60952b35498cb9fe41077e327d0f,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,10-02-2018,10-30-2018,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unlikely,Possible,"Prior tx, hemorrhoids, stomach ulcer",Not a Serious Adverse Event,None,None,Recovered
308,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,1.0,07-01-2018,07-17-2018,Gastrointestinal disorders,Dyspepsia,Upset stomach; no intervention indicated,1,Unrelated,Unrelated,Possible,Viral infection,Not a Serious Adverse Event,None,None,Recovered
309,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,1.0,07-01-2018,07-17-2018,Gastrointestinal disorders,Nausea,Zofran indicated,1,Unrelated,Unrelated,Possible,Viral infection,Not a Serious Adverse Event,None,Symptom,Recovered
310,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,1.0,06-26-2018,07-17-2018,Infections and infestations,Upper respiratory infection,"Fevers, chills, productive cough white/yellow phlegm",2,Unlikely,Unlikely,Possible,Infection,Not a Serious Adverse Event,None,Symptom,Recovered
311,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,1.0,07-01-2018,07-17-2018,Gastrointestinal disorders,Vomiting,Zofran indicated,2,Unrelated,Unrelated,Possible,Viral infection,Not a Serious Adverse Event,None,Symptom,Recovered
312,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,10.0,11-05-2018,01-29-2019,Musculoskeletal and connective tissue disorders,Pain in extremity,Secondary to re-fx R foot,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
313,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,11.0,11-06-2018,01-29-2019,"Injury, poisoning and procedural complications",Fracture,Confirmed oblique fx 3rd metatarsal R foot; boot immobilizer indicated,2,Unrelated,Unrelated,Possible,Med Hs of Osteopenia/Osteoporosis,Not a Serious Adverse Event,None,Support,Recovered
314,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,12.0,11-19-2018,01-29-2019,Musculoskeletal and connective tissue disorders,Pain in extremity,L thigh pain,1,Unrelated,Unrelated,Possible,Gait with fx,Not a Serious Adverse Event,None,Symptom,Recovered
315,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,15.0,01-09-2019,01-29-2019,Gastrointestinal disorders,Nausea,Nauseous 3-4 times daily since starting ABX; Zofran IVP indicated,1,Unrelated,Unrelated,Definite,Antibiotic,Not a Serious Adverse Event,None,Support,Recovered
316,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,15.0,01-04-2019,04-09-2019,Skin and subcutaneous tissue disorders,Pruritus,Tretinoin cream indicated for itching,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
317,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,15.0,01-09-2019,01-29-2019,Infections and infestations,Skin infection,Draining lesions over LEs w/o evidence of abscess formation-empirical ABX indicated,2,Unlikely,Unlikely,Probable,Infective process foliculitis,Not a Serious Adverse Event,None,Symptom,Recovered
318,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,18.0,02-25-2019,03-12-2019,Infections and infestations,Urinary tract infection,C/O burning sensation when urinating; UA+-Macrobid indicated,2,Unlikely,Unlikely,Probable,Infective process,Not a Serious Adverse Event,None,Symptom,Recovered
319,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,19.0,03-11-2019,03-12-2019,General disorders and administration site conditions,Non-cardiac chest pain,Mid-epigastric pain which comes and goes and lasts for a few seconds,1,Unlikely,Unrelated,Probable,GI reflux r/t gastritis,Not a Serious Adverse Event,None,None,Recovered
320,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-15-2018,07-15-2018,Gastrointestinal disorders,Anal hemorrhage,3-4 episodes of BRBPR,1,Possible,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
321,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-04-2018,04-09-2019,Musculoskeletal and connective tissue disorders,Back pain,,3,Unrelated,Possible,Possible,Med Hx,Not a Serious Adverse Event,None,Symptom,Recovered
322,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-16-2018,--,Gastrointestinal disorders,Constipation,Intermittent; associated w/hard stools,1,Unrelated,Unrelated,Possible,Pain med use,Not a Serious Adverse Event,None,Symptom,
323,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-19-2018,--,Gastrointestinal disorders,Gastritis,As determined by biopsy on 7/19/19; pantoprazole indicated,2,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,Symptom,
324,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-04-2018,09-26-2018,Musculoskeletal and connective tissue disorders,Muscle weakness lower limb,Worsening proximal LE weakness; most noticed when standing up from sitting position,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
325,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-04-2018,09-26-2018,Musculoskeletal and connective tissue disorders,Muscle weakness upper limb,Worsening UE weakness; notice when holding items,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
326,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-17-2018,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","Keratoacanthomas, b/l arms, chest, back, neck per Derm dx; study drug held beg 10/23/18",2,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
327,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-14-2018,07-15-2018,Nervous system disorders,"Nervous system disorders - Other, specify","Withdrawal sys: tremulousness, fever, chills since stoppage of MS Contin",1,Unrelated,Unrelated,Possible,Pain med,Not a Serious Adverse Event,None,Symptom,Recovered
328,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-03-2018,08-14-2018,Infections and infestations,Papulopustular rash,Inflammatory SC nodule R axilla,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
329,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,07-03-2018,07-17-2018,Skin and subcutaneous tissue disorders,Rash acneiform,Right & left forearms,1,Possible,Unlikely,,"B/L arms, chest, back, and neck",Not a Serious Adverse Event,None,Symptom,Recovered
330,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,23.0,04-24-2019,04-28-2019,General disorders and administration site conditions,Flu like symptoms,,1,Unlikely,Unlikely,Probable,Infection,Not a Serious Adverse Event,None,None,Recovered
331,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,23.0,05-02-2019,05-07-2019,"Injury, poisoning and procedural complications",Wound dehiscence,,1,Unlikely,Unlikely,Possible,Chronic leg edema,Not a Serious Adverse Event,None,Symptom,Recovered
332,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,27.0,06-18-2019,06-18-2019,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",L VAT rsx pulm nodule w/R thoracotomy and pulm metastasectomy including superior segmentectomy RLL,3,Unrelated,Definite,,,Hospitalized,Therapy Discontinued,Support,Recovered
333,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,29.0,07-16-2019,--,Skin and subcutaneous tissue disorders,Hyperhidrosis,,1,Unlikely,Unlikely,Possible,"post-menopausal ,Duloxetine dose",Not a Serious Adverse Event,None,None,
334,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,07-28-2018,04-01-2019,Gastrointestinal disorders,Anal hemorrhage,"Intermittently, ~2x weekly",1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
335,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,07-25-2018,08-27-2019,Vascular disorders,Lymphedema,,2,Unlikely,Unlikely,Possible,BL lymphedema,Not a Serious Adverse Event,None,None,Recovered
336,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,07-29-2018,07-31-2018,Musculoskeletal and connective tissue disorders,Pain in extremity,R foot painful-unable to walk; required ER visit and X-Ray,2,Unrelated,Unrelated,Possible,Med Hx,Not a Serious Adverse Event,None,Symptom,Recovered
337,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,31.0,08-20-2019,--,General disorders and administration site conditions,Pain,,1,Unrelated,Unlikely,Probable,"surgical site, post op",Not a Serious Adverse Event,None,None,
338,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,32.0,10-01-2019,10-08-2019,General disorders and administration site conditions,Flu like symptoms,,2,Unrelated,Unlikely,Probable,infection,Not a Serious Adverse Event,None,Symptom,Recovered
339,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,33.0,10-20-2019,11-01-2019,Infections and infestations,Bronchial infection,,2,Unrelated,Unlikely,Probable,infection,Not a Serious Adverse Event,None,Symptom,Recovered
340,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,34.0,11-01-2019,02-11-2020,"Respiratory, thoracic and mediastinal disorders",Cough,,1,Unrelated,Unlikely,Probable,infection,Not a Serious Adverse Event,None,None,Recovered
341,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,07-31-2018,09-18-2018,Musculoskeletal and connective tissue disorders,Pain in extremity,R foot pay improved w/out meds,1,Unrelated,Unrelated,Possible,Med Hx,Not a Serious Adverse Event,None,None,Recovered
342,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,08-13-2018,11-19-2019,Skin and subcutaneous tissue disorders,Rash acneiform,Bilateral forearms; per Derm dx Lichen Spinulosus,1,Possible,Unlikely,Possible,R/t sun exposure;  Lichen Spinulosus,Not a Serious Adverse Event,None,Symptom,Recovered
343,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,08-14-2018,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Relieved  w/ rest,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
344,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,08-14-2018,09-23-2018,General disorders and administration site conditions,Fatigue,Declining PS-ECOG 3-(in bed> half the day),1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
345,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,08-14-2018,--,Nervous system disorders,Headache,Intermittent and ongoing; relieved w/opioid analgesic,1,Unlikely,Unlikely,Possible,BL pain/anxiety,Not a Serious Adverse Event,None,Symptom,
346,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,08-14-2018,08-28-2018,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
347,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,08-28-2018,01-04-2019,Skin and subcutaneous tissue disorders,Pruritus,,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
348,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,6.0,09-04-2018,12--2018,Gastrointestinal disorders,Fecal incontinence,"Intermittent, occasional",1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
349,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,6.0,09-03-2018,01-29-2019,Musculoskeletal and connective tissue disorders,Muscle cramp,Intermittent leg muscle spasms,2,Unlikely,Unlikely,Possible,PN and pain BL,Not a Serious Adverse Event,None,Symptom,Recovered
350,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,6.0,09-04-2018,09-19-2018,Renal and urinary disorders,Urinary frequency,Increased frequency of urination,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
351,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-23-2018,09-26-2018,Metabolism and nutrition disorders,Anorexia,,2,Unrelated,Unlikely,Probable,Prior XRT and esophagitis,Not a Serious Adverse Event,None,Symptom,Recovered
352,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-17-2018,09-21-2018,Gastrointestinal disorders,Dysphagia,Early difficulty swallowing; globus sensation,1,Unrelated,Unlikely,Possible,Prior XRT,Not a Serious Adverse Event,None,None,Recovered
353,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-23-2018,10-02-2018,General disorders and administration site conditions,Fatigue,,2,Unrelated,Unlikely,Probable,Prior XRT and exophagitis,Not a Serious Adverse Event,None,None,Recovered
354,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-19-2018,10-23-2018,"Injury, poisoning and procedural complications",Fracture,R 3rd metatarsal R foot,2,Unrelated,Unrelated,Possible,Unk trauma R foot,Not a Serious Adverse Event,None,Symptom,Recovered
355,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-18-2018,10-23-2018,General disorders and administration site conditions,Gait disturbance,Antalgic gait; discharged w/immobilizing boot and forearm crutches,2,Unrelated,Unrelated,Possible,R 3rd metatarsal fx w/assoc discomfort,Not a Serious Adverse Event,None,Symptom,Recovered
356,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-17-2018,09-26-2018,Investigations,Lymphocyte count decreased,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
357,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-15-2018,09-16-2018,Gastrointestinal disorders,Nausea,Single episode of nausea on weekend,1,Unrelated,Unrelated,Possible,Overeating,Not a Serious Adverse Event,None,None,Recovered
358,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-15-2018,09-16-2018,Musculoskeletal and connective tissue disorders,Neck pain,Significant R-sided neck pain; Tylenol given,1,Unrelated,Unrelated,Possible,MSK strain,Not a Serious Adverse Event,None,Symptom,Recovered
359,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-18-2018,09-25-2018,Musculoskeletal and connective tissue disorders,Pain in extremity,R foot pain w/weight bearingincreasing,2,Unrelated,Unrelated,Possible,Possible unk trauma R foot,Not a Serious Adverse Event,None,Symptom,Recovered
360,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-15-2018,09-16-2018,Gastrointestinal disorders,Vomiting,Single episode of vomiting on weekend,1,Unrelated,Unrelated,Possible,Overeating,Not a Serious Adverse Event,None,None,Recovered
361,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,09-24-2018,09-27-2018,Gastrointestinal disorders,Vomiting,,3,Unrelated,Unrelated,Definite,Esophagitis,Hospitalized,Regimen Interrupted,Support,Recovered
362,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,8.0,09-25-2018,09-27-2018,Metabolism and nutrition disorders,Dehydration,,2,Unrelated,Unrelated,Definite,Esophagitis,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
363,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,8.0,09-25-2018,09-27-2018,Gastrointestinal disorders,Esophagitis,,3,Unrelated,Unrelated,Definite,Radiation therapy,Hospitalized,Regimen Interrupted,Symptom,Recovered
364,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,8.0,09-25-2018,09-27-2018,Gastrointestinal disorders,Nausea,,3,Unrelated,Unrelated,Definite,Esophagitis,Hospitalized,Regimen Interrupted,Support,Recovered
365,76a31fecc63b4452993209c2b6e75de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,9.0,10-09-2018,10-22-2018,Investigations,Lymphocyte count decreased,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
422,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,08-16-2018,08-29-2018,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,Possible,Keto diet,Not a Serious Adverse Event,None,None,Recovered
423,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,08-20-2018,--,Skin and subcutaneous tissue disorders,Rash acneiform,Torso (mult acne-like lesions on shoulders & back) new redness on face began 10/23/18,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,
424,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-29-2018,08-29-2018,Gastrointestinal disorders,Diarrhea,Watery diarrhea twice on C2D2,2,Possible,Unlikely,Possible,GI illness,Not a Serious Adverse Event,None,None,Recovered
425,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-29-2018,09-11-2018,Nervous system disorders,Dizziness,Intermittent,1,Possible,Possible,Probable,Infection,Not a Serious Adverse Event,None,None,Recovered
426,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-29-2018,09-25-2018,General disorders and administration site conditions,Fatigue,,2,Possible,Possible,Possible,Keto diet,Not a Serious Adverse Event,None,None,Recovered
427,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-30-2018,08-31-2018,Gastrointestinal disorders,Nausea,,1,Possible,Unlikely,Possible,GI illness,Not a Serious Adverse Event,None,None,Recovered
428,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,09-25-2018,--,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,Possible,Keto diet; 3-Hypothyroid,Not a Serious Adverse Event,None,None,
429,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,09-11-2018,--,Gastrointestinal disorders,"Gastrointestinal disorders - Other, specify",Hyperpigmentation of tongue,1,Unlikely,Unlikely,Possible,Prior XRT changes,Not a Serious Adverse Event,None,None,
430,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,10-16-2018,--,Musculoskeletal and connective tissue disorders,Muscle cramp,,1,Unlikely,Unlikely,Possible,Diet or patient activity,Not a Serious Adverse Event,None,None,
431,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,11-05-2018,--,Vascular disorders,Thromboembolic event,Thrombus in L atrium as per 11/5/18 CT; Lovenox indicated,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,Symptom,
432,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,11-19-2018,--,"Respiratory, thoracic and mediastinal disorders",Pleural effusion,Dose adjustment of Lovenox-LMWH dose indicated,2,Unlikely,Possible,Possible,Lovenox,Not a Serious Adverse Event,None,Symptom,
433,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,11-12-2018,12-05-2018,"Respiratory, thoracic and mediastinal disorders","Respiratory, thoracic and mediastinal disorders - Other, specify",Intermittent hemoptysis; Lovenox dose adjustment indicated-LMWH dose initiated,2,Unlikely,Possible,Possible,Lovenox,Not a Serious Adverse Event,None,Symptom,
434,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,11-17-2018,11-17-2018,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,Pain radiating from RUQ to R shoulder and clavicular-acrommial joint; took 2 Tylenol ES w/relief,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,Symptom,Recovered
435,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,11-29-2018,12-02-2018,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Subjective feeling of abn air flow and resp sounds; CXR indicated,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
436,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,11-24-2018,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","Per DERM, described as clinically a Keratocanthoma",1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,
437,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,11-20-2018,--,Skin and subcutaneous tissue disorders,Rash maculo-papular,Lesions on L chest wall-bx on 12/4/18=lichen planus,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,
438,c6d12120838563dcd1a1241d48adab62,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,12-24-2018,12-31-2018,General disorders and administration site conditions,Flu like symptoms,,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
439,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,09-21-2018,01-31-2019,Gastrointestinal disorders,Ascites,Patient began to retain fluids in abd starting 3D after infusion w/a 4 lb weight gain; started Lasix,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
440,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,09-21-2018,04-02-2019,General disorders and administration site conditions,Edema limbs,B/L lower extremities; started Lasix,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,
441,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,09-19-2018,09-22-2018,General disorders and administration site conditions,Fatigue,Profound fatigue s/p Wk 1 infusion; sleeping 20 hrs/day,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
442,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,09-18-2018,--,Metabolism and nutrition disorders,Hyperglycemia,,1,Unrelated,Unrelated,Probable,Baseline + steroid use,Not a Serious Adverse Event,None,Symptom,
443,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,-1.0,09--2018,10-16-2018,Gastrointestinal disorders,Vomiting,Intermittent; increase in BL nausea causing pt to vomit 2x/day,1,Unlikely,Unlikely,Possible,Nausea,Not a Serious Adverse Event,None,Symptom,Recovered
444,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,10.0,01-31-2019,04-16-2019,Gastrointestinal disorders,Ascites,"Lasix,OT/PT indicated",1,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
445,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,10.0,01-23-2019,04-16-2019,Investigations,Weight loss,,1,Unlikely,Unlikely,Probable,Fluid retention decrease and diet,Not a Serious Adverse Event,None,None,Recovered
446,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,11.0,02-05-2019,05-31-2019,Metabolism and nutrition disorders,Anorexia,Intermittent,1,Unlikely,Unlikely,Probable,Current health status,Not a Serious Adverse Event,None,None,
447,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,11.0,02-06-2019,03-12-2019,Nervous system disorders,Concentration impairment,Mild concentration impairment,1,Unrelated,Possible,Probable,Lymphedema,Not a Serious Adverse Event,None,None,Recovered
448,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,11.0,02-10-2019,04-09-2019,Gastrointestinal disorders,Diarrhea,,1,Unlikely,Unlikely,Probable,Mechanical procedure-colonoscopy,Not a Serious Adverse Event,None,None,Recovered
449,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,11.0,02-05-2019,02-19-2019,"Injury, poisoning and procedural complications",Fall,2 episodes only; PT advised pt to use a cane & toilet stool,1,Unlikely,Unlikely,Definite,Weakness b/l lower extremities,Not a Serious Adverse Event,None,None,Recovered
450,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,11.0,02-06-2019,--,General disorders and administration site conditions,Pain,New-onset b/l shin pain,1,Unrelated,Unrelated,Probable,Lymphedema and muscle weakness,Not a Serious Adverse Event,None,Symptom,
451,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,02-19-2019,12-12-2019,Nervous system disorders,Dizziness,"Intermittent, when eyes closed",1,Unlikely,Unlikely,Possible,When eyes are closed-reason unk,Not a Serious Adverse Event,None,None,Recovered
452,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,02-19-2019,--,Gastrointestinal disorders,Gastroesophageal reflux disease,Protonix indicated,2,Unlikely,Unlikely,Probable,GI upset r/t mult medications,Not a Serious Adverse Event,None,Symptom,
453,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,02-19-2019,04--2019,General disorders and administration site conditions,Pain,"R groin pain, intermittent",1,Unrelated,Unrelated,Possible,Fibroids,Not a Serious Adverse Event,None,None,Recovered
454,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,13.0,03-05-2019,03-12-2019,"Injury, poisoning and procedural complications",Fall,Intermittent- ~1 x weekly,1,Unrelated,Unrelated,Probable,Lymphedema and muscle weakness,Not a Serious Adverse Event,None,None,Recovered
455,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,15.0,04-12-2019,06-11-2019,Gastrointestinal disorders,Diarrhea,,1,Unlikely,Unlikely,Probable,Mechanical proc-colonoscopy,Not a Serious Adverse Event,None,None,Recovered
456,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,15.0,04-09-2019,04-11-2019,Gastrointestinal disorders,Diarrhea,,2,Unlikely,Unlikely,Probable,Mechanical proc colonoscopy,Not a Serious Adverse Event,None,None,Recovered
457,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,15.0,04-02-2019,09-03-2019,General disorders and administration site conditions,Edema limbs,Edema B/L legs requiring ongoing OT/PT and Lasix therapy,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
458,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,15.0,04-09-2019,04-09-2019,Gastrointestinal disorders,Vomiting,,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
459,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,16.0,04-16-2019,04-30-2019,Investigations,Weight loss,,2,Unlikely,Unlikely,Probable,Fluid retention decrease & diet,Not a Serious Adverse Event,None,None,Recovered
460,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,17.0,04-30-2019,05-31-2019,Investigations,Weight loss,,1,Unlikely,Unlikely,Probable,Fluid retention decrease & diet,Not a Serious Adverse Event,None,None,Recovered
461,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,18.0,05-14-2019,05-31-2019,Investigations,Lymphocyte count decreased,,3,Unrelated,Unrelated,Possible,baseline,Not a Serious Adverse Event,None,None,Recovered
462,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,19.0,05-31-2019,06-11-2019,Investigations,Lymphocyte count decreased,,4,Unrelated,Unrelated,Probable,Baseline,Not a Serious Adverse Event,None,None,Recovered
463,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,19.0,06-01-2019,--,Gastrointestinal disorders,Oral pain,all teeth,1,Unrelated,Unrelated,Possible,steroid,Not a Serious Adverse Event,None,None,
464,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,19.0,05-31-2019,07-09-2019,Investigations,Weight loss,,2,Unlikely,Unlikely,Probable,Fluid retention decr & diet,Not a Serious Adverse Event,None,None,Recovered
465,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,10-02-2018,12--2018,"Respiratory, thoracic and mediastinal disorders",Cough,Irritative tickle/cough w/o phlegm or wheezing,1,Unrelated,Unrelated,Probable,Ascites; 3-Anemia,Not a Serious Adverse Event,None,None,Recovered
466,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,10-02-2018,--,Renal and urinary disorders,Urinary frequency,,1,Unlikely,Unlikely,Probable,Diabetes,Not a Serious Adverse Event,None,None,
467,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,20.0,06-11-2019,06-25-2019,Investigations,Lymphocyte count decreased,,3,Unrelated,Unrelated,Probable,baseline,Not a Serious Adverse Event,None,None,Recovered
468,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,07-09-2019,11-12-2019,Skin and subcutaneous tissue disorders,Alopecia,,1,Unrelated,Unrelated,Possible,Age-related changes,Not a Serious Adverse Event,None,None,Recovered
469,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,07-09-2019,09-18-2019,Gastrointestinal disorders,Diarrhea,,1,Unlikely,Unlikely,Probable,"Per pt, prev CS procedure",Not a Serious Adverse Event,None,None,Recovered
470,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,07-09-2019,--,Nervous system disorders,Headache,,1,Unrelated,Unrelated,Possible,Tension,Not a Serious Adverse Event,None,None,
471,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,07-09-2019,07-23-2019,Investigations,Lymphocyte count decreased,,3,Unrelated,Unrelated,Probable,Baseline,Not a Serious Adverse Event,None,None,
472,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,07-09-2019,08-06-2019,Investigations,Weight loss,,1,Unlikely,Unlikely,Possible,Fluid retention decr & diet,Not a Serious Adverse Event,None,None,Recovered
473,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,24.0,08-06-2019,09-03-2019,Investigations,Lymphocyte count decreased,,3,Unrelated,Unrelated,Probable,baseline,Not a Serious Adverse Event,None,None,Recovered
474,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,24.0,08-06-2019,11-12-2019,Investigations,Weight loss,,2,Unlikely,Unlikely,Possible,Fluid retention decr & diet,Not a Serious Adverse Event,None,None,Recovered
475,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,25.0,08-25-2019,--,General disorders and administration site conditions,Fatigue,,2,Unrelated,Possible,Possible,deconditioning,Not a Serious Adverse Event,None,None,
476,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,28.0,10-16-2019,10-20-2020,Gastrointestinal disorders,Diarrhea,,1,Unlikely,Unlikely,Possible,previous colonoscopy procedure,Not a Serious Adverse Event,None,None,Recovered
477,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,28.0,10-16-2019,--,Vascular disorders,Hot flashes,,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,None,
478,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,28.0,10-16-2019,--,Ear and labyrinth disorders,Tinnitus,,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,None,
479,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,10-16-2018,10-29-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 10/16/18 at NIH and on 10/24/18 per home oncologist,3,Possible,Possible,Possible,Internal bleeding,Hospitalized,Regimen Interrupted,Support,Recovered
480,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,10-16-2018,12--2018,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,2,Unlikely,Unlikely,Possible,Ascites,Not a Serious Adverse Event,None,None,Recovered
481,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,10-16-2018,10-29-2018,Investigations,Lymphocyte count decreased,,3,Unrelated,Unrelated,Possible,Seasonal allergies,Not a Serious Adverse Event,None,None,Recovered
482,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,10-16-2018,04-02-2019,Cardiac disorders,Palpitations,Racing heart w/exertion; intermittent,1,Unrelated,Unrelated,Possible,Ascites,Not a Serious Adverse Event,None,None,Recovered
483,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,10-29-2018,11-13-2018,Blood and lymphatic system disorders,Anemia,Secondary to duodenal bleed-transfusion indicated on 11/2/18 at NIH,2,Possible,Possible,Possible,Internal bleeding,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
484,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,11-12-2018,01-07-2019,Eye disorders,Blurred vision,Cloudy vision x 4 weeks,2,Unlikely,Unlikely,Probable,Diabetes,Not a Serious Adverse Event,None,None,Recovered
485,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,11-02-2018,03-05-2019,Gastrointestinal disorders,Upper gastrointestinal hemorrhage,,3,Probable,Unlikely,Definite,Med Hx,Important Medical Event,Regimen Interrupted,None,Recovered
486,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,12--2018,12--2018,"Injury, poisoning and procedural complications",Fall,"Fall w/scalp laceration, closure w/sutures in ER",2,Unrelated,Unrelated,Possible,Pain from leg edema,Not a Serious Adverse Event,None,Support,Recovered
487,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,12--2018,--,Musculoskeletal and connective tissue disorders,Muscle weakness lower limb,Weakness b/l thighs/hips; PT initiated,2,Unlikely,Unlikely,Possible,"Med hx, plexop vs diab amyotro, myopathy",Not a Serious Adverse Event,None,Support,
488,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,12--2018,--,General disorders and administration site conditions,Pain,"B/L knees s/p recent fall, R.L; difficulty w/ambulation d/t pain; knee brace indicated",2,Unrelated,Unrelated,Definite,Trauma,Not a Serious Adverse Event,None,Symptom,
489,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,7.0,12-10-2018,02-19-2019,Musculoskeletal and connective tissue disorders,Muscle weakness upper limb,RUE + drop arm test weakness w/shoulder abduction; R chest port removed on 2/11/19,2,Unrelated,Unrelated,Possible,Med hx pain in shoulder,Not a Serious Adverse Event,None,Support,Recovered
490,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,8.0,12-26-2018,02-19-2019,General disorders and administration site conditions,Pain,R shoulder pain > BL w/limited ROM; R rotator cuff injury; R chest port removed 2/11/19,2,Unrelated,Unrelated,Probable,Baseline and prior port placement,Not a Serious Adverse Event,None,Support,Recovered
491,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,01-07-2019,03-12-2019,Psychiatric disorders,Insomnia,,1,Unlikely,Unlikely,Probable,Pain d/t edema,Not a Serious Adverse Event,None,None,Recovered
492,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,01-07-2019,--,Nervous system disorders,Paresthesia,Slight fluctuating numbness and constant tingling in legs,1,Unlikely,Unlikely,Probable,"Neurology issues, weakness",Not a Serious Adverse Event,None,None,
493,91f21fa70ee3bc8bbea83a1282f266cf,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,01-07-2019,10-01-2019,Eye disorders,Retinopathy,"Symptomatic, causing blurred vision",2,Unlikely,Unlikely,Definite,Diabetes,Not a Serious Adverse Event,None,None,Recovered
494,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,1.0,09-26-2018,--,Musculoskeletal and connective tissue disorders,Back pain,"New onset lower back pain, 4/10",2,Unrelated,Possible,Possible,BL/Med Hx,Not a Serious Adverse Event,None,None,
495,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-24-2018,10-25-2018,Gastrointestinal disorders,Abdominal pain,,3,Unrelated,Probable,Probable,Procedural,Not a Serious Adverse Event,None,Support,Recovered
496,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-25-2018,--,Gastrointestinal disorders,Abdominal pain,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,Symptom,
497,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,10-24-2018,Investigations,Alanine aminotransferase increased,,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,Recovered
498,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-24-2018,10-28-2018,Investigations,Alanine aminotransferase increased,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
499,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,--,Investigations,Alkaline phosphatase increased,,2,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,
500,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-24-2018,10-25-2018,Blood and lymphatic system disorders,Anemia,,2,Possible,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
501,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,--,Metabolism and nutrition disorders,Anorexia,Dronabinol indicated,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,Symptom,
502,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,10-24-2018,Investigations,Aspartate aminotransferase increased,,2,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,Recovered
503,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,10-25-2018,Hepatobiliary disorders,Bile duct stenosis,Stricture common bile duct; s/p stent placement at UMD med center on 10/25/18,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Vigorous,Recovered
504,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-27-2018,--,Investigations,Blood bilirubin increased,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,
505,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,10-27-2018,Investigations,Blood bilirubin increased,,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,Recovered
506,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,--,Hepatobiliary disorders,"Hepatobiliary disorders - Other, specify",Hepatic duct stenosis,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Vigorous,
507,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-27-2018,10-28-2018,Metabolism and nutrition disorders,Hyponatremia,Intermittent,2,Unlikely,Possible,Possible,Anorexia,Not a Serious Adverse Event,None,None,Recovered
508,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-29-2018,--,Metabolism and nutrition disorders,Hyponatremia,Intermittent,2,Unlikely,Possible,Possible,Anorexia,Not a Serious Adverse Event,None,None,
509,d869dac0cc532b7676d237c1ac5a5f4e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,3.0,10-23-2018,--,General disorders and administration site conditions,Non-cardiac chest pain,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
554,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-26-2018,11-07-2018,Gastrointestinal disorders,Fecal incontinence,Overflow stool incontinence,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
555,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-16-2018,--,Nervous system disorders,Headache,,1,Unrelated,Unlikely,Possible,Stress,Not a Serious Adverse Event,None,Symptom,
556,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-16-2018,11-07-2018,Gastrointestinal disorders,Nausea,Mild nausea,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
557,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-29-2018,10-29-2018,Gastrointestinal disorders,Vomiting,x1 episode when travelling to NIH,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
558,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-09-2018,11-14-2018,Gastrointestinal disorders,Abdominal pain,Recurrent pain,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
559,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,11-06-2018,Gastrointestinal disorders,Abdominal pain,"L-sided burning, severe pain-IV morphine indicated",3,Unrelated,Definite,,,Hospitalized,None,Support,Recovered
560,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-31-2018,11-02-2018,Gastrointestinal disorders,Abdominal pain,L-sided burning,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
561,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,--,Investigations,Alkaline phosphatase increased,Intermittent,2,Unrelated,Possible,Possible,Baseline,Not a Serious Adverse Event,None,None,
562,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-07-2018,11-18-2018,Blood and lymphatic system disorders,Anemia,,3,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
563,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-30-2018,11-07-2018,Blood and lymphatic system disorders,Anemia,Transfusions indicated on 11/2/18 and 11/3/18,2,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,Support,Recovered
564,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-31-2018,--,Metabolism and nutrition disorders,Anorexia,Intermittent,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,
565,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,--,Psychiatric disorders,Anxiety,Intermittent; oral and IV meds indicated,2,Unrelated,Unlikely,Probable,Current medical status,Not a Serious Adverse Event,None,Support,
566,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,--,Gastrointestinal disorders,Ascites,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,
567,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,11--2018,Cardiac disorders,Atrial fibrillation,Metoprolol and IVFs indicated,2,Unrelated,Unlikely,Probable,Med hx,Not a Serious Adverse Event,None,Support,Recovered
568,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,11--2018,Cardiac disorders,Atrial flutter,Metoprolol indicated,2,Unrelated,Unlikely,Probable,Med hx,Not a Serious Adverse Event,None,Support,Recovered
569,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,--,Gastrointestinal disorders,Constipation,Assoc w/overflow stool incontinence-bowel regimen initiated; intermittent,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,
570,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,11-07-2018,Metabolism and nutrition disorders,Dehydration,Volume depletion w/assoc tachycardia-IVFs indicated,2,Unrelated,Possible,Possible,Volume depletion,Not a Serious Adverse Event,None,Support,Recovered
571,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,11-07-2018,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
572,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-11-2018,--,General disorders and administration site conditions,Fever,Intermittent; Tylenol indicated,1,Unrelated,Definite,Possible,"Tumors, DP",Hospitalized,Regimen Interrupted,Symptom,
573,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-01-2018,11-04-2018,General disorders and administration site conditions,Fever,Interm.; IV Tylenol indicated upon admission and prn,1,Unrelated,Definite,Possible,Increasing necrotic liver mets,Hospitalized,None,Support,Recovered
574,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-31-2018,11-07-2018,Gastrointestinal disorders,Flatulence,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
575,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-30-2018,11-02-2018,Metabolism and nutrition disorders,Hypercalcemia,2L NS and IV Zometa on 10/30/18,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Support,Recovered
576,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-05-2018,12-18-2018,Metabolism and nutrition disorders,Hypoalbuminemia,Intermittent,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
577,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-07-2018,11-13-2018,Metabolism and nutrition disorders,Hypophosphatemia,Daily PO phos repletion x 7 days,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
578,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,11-07-2018,Vascular disorders,Hypotension,IVFs indicated,2,Unrelated,Possible,Probable,Volume depletion,Not a Serious Adverse Event,None,Support,Recovered
579,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-30-2018,12-20-2018,Investigations,Lymphocyte count decreased,,2,Unrelated,Unlikely,Probable,Baseline,Not a Serious Adverse Event,None,None,Recovered
580,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-02-2018,11-28-2018,Vascular disorders,Thromboembolic event,New thrombosis L portal vein-Lovenox indicated beg 11/7/18,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,Symptom,Recovered
581,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-14-2018,12-07-2018,Gastrointestinal disorders,Abdominal pain,Emergent care indicated; admitted to MSKCC,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Support,Recovered
582,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2018,12-02-2018,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
583,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-14-2018,12-09-2018,Psychiatric disorders,Confusion,,1,Unrelated,Definite,Definite,Pain medications,Not a Serious Adverse Event,None,None,Recovered
584,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-14-2018,--,General disorders and administration site conditions,Edema limbs,Intermittent; r/t hypoalbuminemia; IV fluids stopped,1,Unrelated,Definite,Possible,Hypoalbuminemia,Not a Serious Adverse Event,None,None,
585,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-21-2018,11-22-2018,Renal and urinary disorders,Hematuria,IVFs indicated on 11/22/18,1,Unrelated,Unlikely,Possible,Renal calculi,Not a Serious Adverse Event,None,Support,Recovered
586,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-15-2018,12-05-2018,Metabolism and nutrition disorders,Hypomagnesemia,Oral and IV repletion indicated,1,Unrelated,Definite,,,Not a Serious Adverse Event,None,Support,Recovered
587,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-23-2018,--,Nervous system disorders,Lethargy,Intermittent; lethargic since nerve block procedure,1,Unrelated,Definite,Probable,Nerve block procedure,Not a Serious Adverse Event,None,None,
588,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-14-2018,--,Gastrointestinal disorders,Nausea,Intermittent; related to DP; Zofran indicated,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
589,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-20-2018,--,"Respiratory, thoracic and mediastinal disorders",Pleural effusion,Small b/l pleural effusions,1,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,
590,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-14-2018,12-07-2018,Gastrointestinal disorders,Vomiting,Zofran indicated,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
591,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-02-2018,12-04-2018,Blood and lymphatic system disorders,Anemia,,3,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
592,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-04-2018,12-17-2018,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
593,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-09-2018,12-15-2018,Psychiatric disorders,Confusion,Intermittent; IV hydration and olanzapine indicated;  IT pump settings adjusted down on 12/12/18,2,Unrelated,Definite,Probable,Pain meds; 3-IT pump,Not a Serious Adverse Event,None,Support,Recovered
594,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-07-2018,12-19-2018,Gastrointestinal disorders,Rectal hemorrhage,2 episodes of BRBPR on TP and in loose BMs,1,Unrelated,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
595,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-05-2018,12-24-2018,Renal and urinary disorders,Urinary retention,Catheterization performed q8h,2,Unrelated,Probable,Probable,Intrathecal pump,Not a Serious Adverse Event,None,Support,Recovered
596,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-15-2018,12-24-2018,Gastrointestinal disorders,Abdominal pain,,3,Unrelated,Probable,,,Hospitalized,Regimen Interrupted,Symptom,Recovered
597,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-18-2018,12-20-2018,Psychiatric disorders,Agitation,Combative and agitated in setting of perceived neglect to CP; IV Haldol + Lorazepam indicated,2,Unrelated,Possible,Probable,Pain meds,Not a Serious Adverse Event,None,Support,Recovered
598,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-23-2018,--,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,
599,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-17-2018,12-18-2018,Blood and lymphatic system disorders,Anemia,,3,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
600,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-18-2018,12-22-2018,Blood and lymphatic system disorders,Anemia,,2,Unrelated,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
601,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-22-2018,12-23-2018,Blood and lymphatic system disorders,Anemia,,3,Unrelated,Unlikely,Possible,Baseline,Not a Serious Adverse Event,None,None,Recovered
602,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-15-2018,12-17-2018,Cardiac disorders,Atrial flutter,Asymptomatic-resolved s/p IV Metoprolol; digoxin indicated on 12/15/18; converted to SR after IVFs,2,Unrelated,Unlikely,Probable,Med hx,Not a Serious Adverse Event,None,Support,Recovered
603,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-24-2018,--,Psychiatric disorders,Confusion,Intermittent,1,Unrelated,Definite,Probable,Pain meds,Not a Serious Adverse Event,None,None,
604,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-15-2018,12-24-2018,Psychiatric disorders,Confusion,Intermittent; olanzapine indicated,3,Unrelated,Probable,Probable,Pain med; 3-Intrathecal pump,Hospitalized,Regimen Interrupted,Symptom,Recovered
605,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-18-2018,12-20-2018,Psychiatric disorders,Delirium,Altered mental status with worsening sys on 12/19/18,2,Unrelated,Possible,Definite,"Morphine, hypercal, steroids, urin ret",Not a Serious Adverse Event,None,Support,Recovered
606,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-15-2018,12-24-2018,Nervous system disorders,Depressed level of consciousness,,2,Unrelated,Unlikely,Probable,Pain meds; 3-intrathecal pump,Hospitalized,Regimen Interrupted,None,Recovered
607,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-19-2018,12-20-2018,Gastrointestinal disorders,Diarrhea,Frequent loose BMs-oral loperamide indicated on 12/20/18,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
608,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,01-27-2019,01-27-2019,General disorders and administration site conditions,Disease progression,,5,Unrelated,Definite,,,Death,None,None,Died
609,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-15-2018,--,Psychiatric disorders,Hallucinations,Intermittent,4,Unrelated,Probable,Probable,Pain med; 3-Intrathecal pump; 4-paranoia,Not a Serious Adverse Event,None,Symptom,Recovered
610,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-14-2018,12-15-2018,Metabolism and nutrition disorders,Hypercalcemia,IVFs and Zometa indicated on 12/14/18,3,Unrelated,Probable,,,Not a Serious Adverse Event,None,Support,Recovered
611,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-14-2018,12-15-2018,Metabolism and nutrition disorders,Hypercalcemia,Intermittent; 2L NSS IVFs and IV Zometa indicated on 12/14/18,3,Unrelated,Probable,,,Not a Serious Adverse Event,None,Support,Recovered
612,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-20-2018,--,Investigations,Lymphocyte count decreased,,3,Unrelated,Unlikely,Probable,Baseline,Not a Serious Adverse Event,None,None,
613,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-15-2018,12-16-2018,General disorders and administration site conditions,Non-cardiac chest pain,,1,Unrelated,Probable,Probable,Pleural effusions,Not a Serious Adverse Event,None,None,Recovered
614,69a0d1ccba33f6d40b042ec617177636,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,12-19-2018,--,Psychiatric disorders,Psychosis,New-onset suspiciousness and distrust-paranoia-Haldol indicated,3,Unrelated,Probable,Probable,Pain meds and paranoia; 3-IT pump,Not a Serious Adverse Event,None,Symptom,
615,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,10-26-2018,10-26-2018,General disorders and administration site conditions,Chills,,1,Possible,Unlikely,Possible,Anemia,Not a Serious Adverse Event,None,None,Recovered
616,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,10-26-2018,10-29-2018,Vascular disorders,Hot flashes,Patient experienced 3 days of night sweats,1,Possible,Unlikely,Possible,Anemia,Not a Serious Adverse Event,None,None,Recovered
617,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,-1.0,10--2018,--,Gastrointestinal disorders,Rectal hemorrhage,Intermittent,1,Possible,Unlikely,Definite,Med Hx,Not a Serious Adverse Event,None,None,
618,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-08-2018,12-18-2018,Gastrointestinal disorders,Abdominal pain,Intermittent; occurs prior to having a BM,1,Unlikely,Unlikely,Possible,Stimulant tea,Not a Serious Adverse Event,None,None,Recovered
619,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-06-2018,11-07-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 11/6/18 and 11/7/18,3,Unlikely,Probable,Possible,Baseline,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
620,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-08-2018,--,Metabolism and nutrition disorders,Anorexia,,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,
621,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-06-2018,--,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unlikely,Unlikely,Possible,Lab variation,Not a Serious Adverse Event,None,None,
622,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,11-30-2018,12-03-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 11/30/18,3,Unlikely,Probable,Possible,Baseline,Not a Serious Adverse Event,None,Support,Recovered
623,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,12--2018,--,General disorders and administration site conditions,Edema limbs,"LLE swelling w/assoc discomfort, L>R",1,Unlikely,Possible,Possible,Tumor compression of lymphatics,Not a Serious Adverse Event,None,None,
624,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,12-18-2018,--,Gastrointestinal disorders,Abdominal pain,,2,Unlikely,Unlikely,Possible,Stimulant tea,Not a Serious Adverse Event,None,None,
625,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,12-18-2018,12-31-2018,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 12/21/18,3,Unlikely,Probable,Possible,Baseline,Not a Serious Adverse Event,None,Support,Recovered
626,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,12-18-2018,--,Gastrointestinal disorders,Nausea,,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,
627,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,12-18-2018,--,Renal and urinary disorders,"Renal and urinary disorders - Other, specify",Urinaryhesitancy and sensation of incomplete voiding,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,
628,0a1b939444c4adcb1393c65274a17355,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,,02-13-2019,02-13-2019,General disorders and administration site conditions,Death NOS,,5,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Died
629,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,10-30-2018,11-13-2018,Vascular disorders,Flushing,S/P infusion x 3 days,1,Possible,Unlikely,Possible,Medications,Not a Serious Adverse Event,None,None,Recovered
630,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,10-30-2018,--,Gastrointestinal disorders,Vomiting,Intermittent,1,Unlikely,Unlikely,Probable,BL nausea,Not a Serious Adverse Event,None,Symptom,Recovered
631,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-16-2018,11-26-2018,Gastrointestinal disorders,Abdominal pain,,3,Unrelated,Probable,,,Hospitalized,None,Symptom,Recovered
632,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-21-2018,11-26-2018,Gastrointestinal disorders,Bloating,Symptomatic; decreased oral intake & change in bowel function,2,Unrelated,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
633,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-16-2018,--,Gastrointestinal disorders,Constipation,,2,Unrelated,Unlikely,Probable,Medications,Not a Serious Adverse Event,None,Symptom,
634,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-25-2018,11-26-2018,Metabolism and nutrition disorders,Hypokalemia,,1,Unrelated,Unlikely,Possible,"N/V and anorexia, watery BMs",Not a Serious Adverse Event,None,Symptom,Recovered
635,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-20-2018,11-21-2018,Metabolism and nutrition disorders,Hypokalemia,Oral dose of KCL indicated,1,Unrelated,Unlikely,Possible,N/V and anorexia,Not a Serious Adverse Event,None,Symptom,Recovered
636,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-16-2018,11-23-2018,Gastrointestinal disorders,Nausea,,3,Unrelated,Probable,Probable,Constipation,Not a Serious Adverse Event,None,Symptom,Recovered
637,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-19-2018,11-20-2018,Investigations,Neutrophil count decreased,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
638,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-21-2018,11-23-2018,Investigations,Neutrophil count decreased,,3,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
639,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-25-2018,11-26-2018,Investigations,Neutrophil count decreased,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
640,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-19-2018,12-24-2018,Investigations,Weight loss,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
641,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-21-2018,11-23-2018,Investigations,White blood cell decreased,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
642,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,12--2018,12-11-2018,"Respiratory, thoracic and mediastinal disorders",Cough,Resolved after 1 dose of penicillin (500 mg) w/out medical advice,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
643,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,12-10-2018,12-11-2018,Cardiac disorders,Sinus tachycardia,Coreg administered,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
644,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,12--2018,12-11-2018,"Respiratory, thoracic and mediastinal disorders",Sore throat,Resolved after 1 dose of penicillin (500 mg) w/out medical advice,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
645,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,12-15-2018,--,Skin and subcutaneous tissue disorders,Rash acneiform,"Slight rash to back, legs, trunk",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
646,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,01-05-2019,02-05-2019,Gastrointestinal disorders,Abdominal pain,Required increased pain meds,3,Unlikely,Probable,Probable,Baseline,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
647,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,01-05-2019,--,Musculoskeletal and connective tissue disorders,Back pain,Increased pain meds indicated,3,Unlikely,Probable,Probable,Baseline,Not a Serious Adverse Event,None,Symptom,
648,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,12-31-2018,01-11-2019,"Respiratory, thoracic and mediastinal disorders",Cough,Z-Pak indicated,2,Unrelated,Unrelated,Definite,Infection,Not a Serious Adverse Event,None,Symptom,Recovered
649,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,12-24-2018,--,Endocrine disorders,Hypothyroidism,Synthroid indicated,2,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
650,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,01--2019,01--2019,"Respiratory, thoracic and mediastinal disorders",Sore throat,Severe pain upon swallowing; emergent tx required at local urgent care,2,Unrelated,Unrelated,Possible,Infection,Not a Serious Adverse Event,None,Symptom,Recovered
651,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,01-14-2019,01-15-2019,Skin and subcutaneous tissue disorders,Rash acneiform,,1,Unlikely,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
652,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,01-11-2019,--,Renal and urinary disorders,Urinary retention,Urinary hesitancy sometimes w/urination,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,
653,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-05-2019,02-13-2019,Gastrointestinal disorders,Abdominal pain,Intractable LLQ abdominal pain requiring increased meds,3,Unlikely,Probable,Probable,Baseline,Hospitalized,None,Support,Recovered
654,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-06-2019,02-11-2019,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
655,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-12-2019,--,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unrelated,,,Not a Serious Adverse Event,None,None,
656,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-05-2019,02-13-2019,General disorders and administration site conditions,Fatigue,,2,Unrelated,Unrelated,Probable,Abd pain,Not a Serious Adverse Event,None,None,Recovered
657,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-06-2019,02-08-2019,General disorders and administration site conditions,Fever,Acetaminophen indicated on 2/7/19; IVFs,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
658,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-10-2019,02-11-2019,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
659,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-07-2019,02-11-2019,Metabolism and nutrition disorders,Hypocalcemia,Calcium Carbonate  indicated on 2/10/19,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
660,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-12-2019,--,Metabolism and nutrition disorders,Hypocalcemia,,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,
661,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-07-2019,02-13-2019,Infections and infestations,"Infections and infestations - Other, specify","Diagnosed with Influenza A assoc with malaise, nausea and interm fever; Tamiflu indicated",2,Unrelated,Unrelated,Definite,Infection,Not a Serious Adverse Event,None,Symptom,Recovered
662,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-06-2019,02-07-2019,Investigations,Lymphocyte count decreased,,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
663,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-05-2019,02-13-2019,Gastrointestinal disorders,Nausea,,2,Unrelated,Unrelated,Probable,Abd pain,Not a Serious Adverse Event,None,Support,Recovered
664,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-07-2019,02-08-2019,Investigations,Neutrophil count decreased,Filgrastim indicated on 2/7/19,3,Unrelated,Unrelated,Probable,Prior chemotherapy,Not a Serious Adverse Event,None,Support,Recovered
665,ccecd2b9caceb75e156d158ef7513799,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,02-06-2019,02-06-2019,Investigations,Neutrophil count decreased,,3,Unrelated,Unrelated,Probable,Prior chemotherapy,Not a Serious Adverse Event,None,None,Recovered
666,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,03-19-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Keratoacanthoma lesions as per Dermatology bx results; steroid cream and prednisone indicated,2,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
667,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,03-19-2019,04-09-2019,Skin and subcutaneous tissue disorders,Pruritus,"Intermittent; moisturizers, clobetasol cream, and Sarna cream indicated; Wk 19 tx held",2,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
668,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,04-09-2019,05-14-2019,Skin and subcutaneous tissue disorders,Pruritus,"Moisturizers, clobetasol cream, Sarna cream, steroids & Atarax indicated",3,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
669,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,04-02-2019,06-11-2019,Skin and subcutaneous tissue disorders,Rash acneiform,"KA and Verruca mix; hydrocortisone cream, prednisone indicated",2,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
670,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,14.0,05-14-2019,06-10-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,Probable,Baseline,Not a Serious Adverse Event,None,None,Recovered
671,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,14.0,05-14-2019,06-11-2019,Skin and subcutaneous tissue disorders,Pruritus,"Continues tx w/moisturizers, clobetasol cream, Sarna cream, Atarax, and steroids",2,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
672,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,16.0,06-11-2019,--,Skin and subcutaneous tissue disorders,Pruritus,"Continues hydrocortisone, moisturizers, clobetasol and Sarna cream, steroids + atarax",1,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
673,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,16.0,06-11-2019,--,Skin and subcutaneous tissue disorders,Rash acneiform,"Pruritic rash on back, abd, extremities; KA + verruca mix; continues topical medications",1,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
674,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,17.0,06-25-2019,07-09-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
675,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,18.0,07-22-2019,08-06-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,Probable,Baseline,Not a Serious Adverse Event,None,None,Recovered
676,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,18.0,07-20-2019,07-21-2019,Gastrointestinal disorders,Diarrhea,,1,Unrelated,Unrelated,Probable,Dietary,Not a Serious Adverse Event,None,None,Recovered
677,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,18.0,07-21-2019,07-21-2019,"Injury, poisoning and procedural complications",Fall,Tripped on steps and fell with accompanying pain in arm,1,Unrelated,Unrelated,Definite,Tripping on stairs,Not a Serious Adverse Event,None,None,Recovered
678,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,18.0,07-20-2019,07-21-2019,Gastrointestinal disorders,Vomiting,,1,Unrelated,Unrelated,Probable,Dietary,Not a Serious Adverse Event,None,None,Recovered
679,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-27-2018,04-29-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,Probable,Baseline,Not a Serious Adverse Event,None,None,Recovered
680,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-27-2018,03-19-2019,Skin and subcutaneous tissue disorders,Pruritus,Intermittent; generalized itching; hydrocortisone indicated,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
681,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-27-2018,04-02-2019,Skin and subcutaneous tissue disorders,Rash acneiform,"Pruritic rash on back, abdomen, and extremities-hydrocortisone indicated",1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
682,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,21.0,08-25-2019,--,General disorders and administration site conditions,Gait disturbance,,2,Unrelated,Unrelated,Probable,cerebellar surgery,Not a Serious Adverse Event,None,None,
683,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,21.0,08-30-2019,08-31-2019,Investigations,Lymphocyte count decreased,,2,Unrelated,Unrelated,Probable,BL,Not a Serious Adverse Event,None,None,Recovered
684,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,21.0,08-19-2019,10-28-2019,Nervous system disorders,"Nervous system disorders - Other, specify",balance difficulties,2,Unlikely,Possible,Probable,baseline,Not a Serious Adverse Event,None,None,Recovered
685,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,21.0,08-25-2019,08-31-2019,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",craniotomyy for resection of cerebellar tumors,3,Unrelated,Definite,,,Hospitalized,None,None,Recovered
686,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,22.0,09-25-2019,10-28-2019,"Injury, poisoning and procedural complications",Fall,,2,Unrelated,Unrelated,Definite,craniotomy,Not a Serious Adverse Event,None,None,Recovered
687,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,23.0,09-26-2019,--,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,Probable,BL,Not a Serious Adverse Event,None,None,
688,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,23.0,09-26-2019,10-05-2019,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",radiation therapy for cerebellar tumor,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,Recovered
689,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,24.0,10-21-2019,--,Investigations,Lymphocyte count decreased,,2,Unrelated,Unrelated,Probable,BL,Not a Serious Adverse Event,None,None,
690,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,25.0,10-28-2019,--,"Injury, poisoning and procedural complications",Fall,,3,Unrelated,Unrelated,,,Hospitalized,None,None,
691,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,25.0,10-22-2019,--,Musculoskeletal and connective tissue disorders,Generalized muscle weakness,,1,Unrelated,Possible,Possible,Surgery & deconditioning,Not a Serious Adverse Event,None,None,
692,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,25.0,10-28-2019,10-31-2019,Nervous system disorders,"Nervous system disorders - Other, specify",balance difficulties,3,Unlikely,Possible,Possible,BL,Hospitalized,None,None,Recovered
693,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,26.0,11-11-2019,11-13-2019,Metabolism and nutrition disorders,Hyponatremia,,3,Unrelated,Definite,,,Hospitalized,None,None,Recovered
694,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,26.0,11-13-2019,--,Metabolism and nutrition disorders,Hyponatremia,,1,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,
695,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-22-2018,01-08-2019,Gastrointestinal disorders,Diarrhea,Intermittent; OTC Imodium indicated,2,Possible,Unrelated,Probable,Med Hx and diet,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
696,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-11-2018,--,Gastrointestinal disorders,Hemorrhoidal hemorrhage,Intermittent,1,Unrelated,Unrelated,Probable,Med Hx of hemorrhoids,Not a Serious Adverse Event,None,Symptom,
697,de5479020c2993d8b712e1f8595233c4,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-24-2018,02-19-2019,Gastrointestinal disorders,Abdominal pain,Intermittent B/L abdominal pain,1,Unlikely,Unlikely,Probable,Diet and Med Hx,Not a Serious Adverse Event,None,None,Recovered
698,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,04-22-2019,05-22-2019,"Respiratory, thoracic and mediastinal disorders",Pleural effusion,"New onset, R-sided pleural effusion found on CT scan",1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
699,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,04-23-2019,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,"Increased SOB with minimal exertion, i.e., 1 flight of stairs; steroids and tx hold indicated",2,Possible,Probable,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
700,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,12-18-2018,01-14-2019,Metabolism and nutrition disorders,Hypophosphatemia,Oral repletion indicated-K-PHOS x 4 days,2,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
701,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,12-28-2018,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","Dermal carcinoma with LVI on forehead, mid-back, and abdomen (R lateral and superior chest)",1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,
702,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,01-15-2019,02-12-2019,Skin and subcutaneous tissue disorders,Rash acneiform,"Upper back and neck; erythematous, non-raised, non-pruritic",1,Unlikely,Unlikely,Probable,Prior therapy,Not a Serious Adverse Event,None,None,Recovered
703,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,02-13-2019,--,Nervous system disorders,Headache,Intermittent L-sided HA x ~2 weeks and relieved with NSAIDS prn,1,Unlikely,Possible,Possible,Stress and life issues,Not a Serious Adverse Event,None,Symptom,
704,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,03-11-2019,--,Cardiac disorders,Pericardial effusion,Found incidentally on CT scan,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
705,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,03-12-2019,04-05-2019,"Respiratory, thoracic and mediastinal disorders",Cough,Chronic cough; intermittent; affecting sleep; Mucinex prn indicated,2,Unlikely,Possible,Possible,"Prior XRT, dry mouth/nasal drip",Not a Serious Adverse Event,None,Symptom,Recovered
706,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,04-08-2019,04-08-2019,Gastrointestinal disorders,Oral hemorrhage,,1,Unlikely,Possible,Probable,Baseline cough,Not a Serious Adverse Event,None,None,Recovered
707,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,03-27-2019,--,Cardiac disorders,Supraventricular tachycardia,Intermittent; required tx hold pending evaluation; diltiazem Rx on 4/5/19 indicated for rate control,1,Unlikely,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
708,bf11e3cd44670a1d3c6a93e5801a9aa5,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,,05-22-2019,--,"Respiratory, thoracic and mediastinal disorders",Pleural effusion,Required R lung thoracentesis,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,Support,
709,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,1.0,12-12-2018,12-14-2018,General disorders and administration site conditions,Flu like symptoms,"Cold sys including: muscle aches, sore throat, chills slight worsening of CP and fatigue",1,Unlikely,Unrelated,Probable,Viral etiology,Not a Serious Adverse Event,None,None,Recovered
710,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,10.0,04-18-2019,05-02-2019,Ear and labyrinth disorders,Ear pain,External ear pain/discomfort; resolved with stopping of Acetretin given for pruritis,1,Unrelated,Unrelated,Definite,Acitretin oral medication,Not a Serious Adverse Event,None,Symptom,Recovered
711,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,11.0,05-11-2019,--,Musculoskeletal and connective tissue disorders,Pain in extremity,"Intermittent pain, right leg",1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,
712,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,13.0,06-11-2019,--,Reproductive system and breast disorders,Pelvic pain,Intermittent; crampy,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,Symptom,
713,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,14.0,06-12-2019,06-24-2019,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unlikely,Possible,Iron deficiency,Not a Serious Adverse Event,None,None,Recovered
714,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,15.0,06-25-2019,--,Gastrointestinal disorders,Rectal hemorrhage,Intermittent; small blood streaks when wipes-hematochezia,1,Possible,Unlikely,Probable,Straining,Not a Serious Adverse Event,None,None,
715,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,01-03-2019,02-05-2019,Reproductive system and breast disorders,Pelvic pain,L hip/L-sided pelvic pain x 5 days s/p exercise; pain  meds & Tylenol indicated,2,Unrelated,Definite,Possible,Scarring r/t dis and prior tx fibrosis,Not a Serious Adverse Event,None,Symptom,Recovered
716,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,01-08-2019,02-19-2019,Gastrointestinal disorders,Constipation,Bowel regimen and stool softener indicated,1,Unrelated,Unlikely,Probable,Narcotics pain medication,Not a Serious Adverse Event,None,Symptom,Recovered
717,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,01-09-2019,01-09-2019,Nervous system disorders,Headache,Tylenol indicated,1,Unrelated,Unrelated,Definite,Stress of pelvic pain an interventions,Not a Serious Adverse Event,None,Symptom,Recovered
718,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,01-21-2019,02-05-2019,Gastrointestinal disorders,Rectal hemorrhage,One occurrence on 1/21/19; bowel regimen/stool softener indicated,1,Unrelated,Unlikely,Probable,Constipation and straining w/stool,Not a Serious Adverse Event,None,None,Recovered
719,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,01-22-2019,04-02-2019,Metabolism and nutrition disorders,Anorexia,"Poor appetite; altered, only 2 meals daily; withholding of study drug indicated for safety d/t sys",2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
720,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,01-22-2019,02-05-2019,General disorders and administration site conditions,Fatigue,Study drug held for safety d/t sys,2,Unlikely,Probable,Definite,Increased pain,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
721,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,01-22-2019,02-05-2019,General disorders and administration site conditions,Pain,Increased pain sacral/anal area in setting of BL hx of gr 2 pain to this area; IV pain med indicated,3,Unrelated,Definite,Possible,Scarring r/t dis and prior tx fibrosis,Not a Serious Adverse Event,None,Symptom,Recovered
722,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,01-22-2019,02-16-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,L thigh Keratoses,1,Possible,Unrelated,,Keratoses inflamed,Not a Serious Adverse Event,None,None,Recovered
723,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,02-05-2019,02-19-2019,Reproductive system and breast disorders,Pelvic pain,Pain medication and Tylenol indicated,1,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
724,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,02-05-2019,02-19-2019,Reproductive system and breast disorders,Pelvic pain,Pain medication and Tylenol indicated,1,Unrelated,Definite,Possible,Scarring r/t dis+ and prior tx fibrosis,Not a Serious Adverse Event,None,Symptom,Recovered
725,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,02-16-2019,04-02-2019,Skin and subcutaneous tissue disorders,Pruritus,Medicated cream/ointment indicated,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
726,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,6.0,02-19-2019,--,Skin and subcutaneous tissue disorders,Rash acneiform,"L thigh, abd, UEs-spreading, now wart-like and painful-Tretinoin cream indicated; possible KA",2,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
727,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,6.0,02-19-2019,05-02-2019,Gastrointestinal disorders,Rectal hemorrhage,"Intermittent, small blood streaks when wipes",1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
728,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,03-07-2019,03-19-2019,General disorders and administration site conditions,Edema limbs,L antecubital fossa; unk etiology,1,Unrelated,Unrelated,Possible,Soft tissue trauma,Not a Serious Adverse Event,None,None,Recovered
729,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,03-05-2019,--,Vascular disorders,Thromboembolic event,Tumor thrombus features into IVC and L internal iliac vein-Lovenox indicated,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,Symptom,
730,7d6b3003a0ab29e50e44cc5d6ffb2f39,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,9.0,04-02-2019,--,Skin and subcutaneous tissue disorders,Pruritus,"Increased at night; Claritin indicated; prednisone, hydroxyzine; study drug held 5/2/19, 5/16/19",2,Probable,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
731,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,11.0,04-30-2019,05-01-2019,Musculoskeletal and connective tissue disorders,Rhabdomyolysis,,1,Unlikely,Unlikely,Probable,Exercise and trauma,Not a Serious Adverse Event,None,None,Recovered
732,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,2.0,12-26-2018,01-22-2019,Investigations,Lymphocyte count decreased,,3,Unrelated,Unrelated,Probable,BL Med Hx,Not a Serious Adverse Event,None,None,Recovered
733,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,01-08-2019,01-22-2019,Gastrointestinal disorders,Abdominal pain,Diffuse,1,Unrelated,Unrelated,Definite,Diabetic Ketoacidosis,Not a Serious Adverse Event,None,None,Recovered
734,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,01-08-2019,01-22-2019,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,Possible,Diabetic Ketoacidosis,Not a Serious Adverse Event,None,None,Recovered
735,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,01-11-2019,--,Metabolism and nutrition disorders,Hyperglycemia,Requirement for BG monitoring and diabetic medications,2,Probable,Unlikely,,,Not a Serious Adverse Event,None,Symptom,
736,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,01-08-2019,01-11-2019,Metabolism and nutrition disorders,Hyperglycemia,"Required admission to ICU with insulin drip for mgmt. of HG and presumed DKA, and IV hydration",3,Possible,Unlikely,Probable,BL Med Hx,Hospitalized,Regimen Interrupted,Support,Recovered
737,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,01-08-2019,01-08-2019,Metabolism and nutrition disorders,Hyperkalemia,IVFs indicated to reduce acidity and return electrolyte balance,3,Unrelated,Unrelated,Definite,Diabetic Ketoacidosis,Not a Serious Adverse Event,None,Support,Recovered
738,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,01-08-2019,01-22-2019,General disorders and administration site conditions,Non-cardiac chest pain,,1,Unrelated,Unrelated,Definite,Diabetic Ketoacidosis,Not a Serious Adverse Event,None,None,Recovered
739,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,01-29-2019,--,Gastrointestinal disorders,Dry mouth,Therabreath lozenges prn & dry mouth tooth paste indicated,1,Possible,Unlikely,Probable,"Prior tx, XRT, DM",Not a Serious Adverse Event,None,Symptom,
740,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,6.0,02-26-2019,03-12-2019,Investigations,Alanine aminotransferase increased,Oral steroids indicated beginning on 3/5/19,2,Possible,Unrelated,Possible,Herbal Supplement Turmeric,Not a Serious Adverse Event,None,Symptom,Recovered
741,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,6.0,02-19-2019,02-26-2019,Investigations,Aspartate aminotransferase increased,Lab becomes CS at 2/19/19 when study drug is held,1,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
742,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,6.0,02-26-2019,03-12-2019,Investigations,Aspartate aminotransferase increased,Oral steroids indicated beginning on 3/5/19,2,Possible,Unrelated,Possible,Herbal Supplement Turmeric,Not a Serious Adverse Event,None,Symptom,Recovered
743,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,7.0,03-05-2019,04-01-2019,Investigations,Lymphocyte count decreased,,3,Unlikely,Unrelated,Probable,"BL Med Hx, prior treatments",Not a Serious Adverse Event,None,None,Recovered
744,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,8.0,03-18-2019,--,Investigations,Lymphocyte count decreased,,3,Unrelated,Unrelated,Probable,Baseline Med Hx,Not a Serious Adverse Event,None,None,
745,fc68f402183b853a44935936ce8a3be4,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,9.0,04-15-2019,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Interm  w/mod exertion; Albuterol inhaler +steroids indicated; tx delayed; d/t pericardial effusion,1,Unlikely,Probable,Possible,Hypothyroid-not well controlled on med,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
746,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,12-19-2018,12-31-2018,Musculoskeletal and connective tissue disorders,Muscle cramp,New onset R side/R rib cage area muscle spasms; possible muscle strain; Baclofen indicated,2,Unlikely,Unlikely,Definite,Mechanical muscle strain,Not a Serious Adverse Event,None,Symptom,Recovered
747,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,12-19-2018,12-31-2018,Skin and subcutaneous tissue disorders,Pruritus,"New onset, intermittent pruritus to b/l arms from elbow to wrist",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
748,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,12-19-2018,--,Vascular disorders,Thromboembolic event,RLE DVT; s/p IVC filter; Lovenox indicated,2,Unrelated,Probable,Definite,BL hx of multiple DVT events,Not a Serious Adverse Event,None,Symptom,
749,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,12-31-2018,01-04-2019,Investigations,Alanine aminotransferase increased,AE indication for holding M7824 and stopping Tylenol,2,Possible,Unlikely,Possible,Taking large doses of Tylenol for pain,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
750,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,01-04-2019,01-08-2019,Musculoskeletal and connective tissue disorders,Flank pain,Right-sided,3,Unrelated,Definite,Definite,Hydronephrosis,Hospitalized,None,Symptom,Recovered
751,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,01-09-2019,--,Musculoskeletal and connective tissue disorders,Flank pain,R-sided pain requiring oxycodone as needed,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
752,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,01-09-2019,--,Renal and urinary disorders,Hematuria,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,
753,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,01-04-2019,01-08-2019,Renal and urinary disorders,Hematuria,,3,Unrelated,Definite,Definite,Hydronephrosis,Hospitalized,None,Symptom,Recovered
754,ad0f6d0f06469e9179935afed8931055,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,01-04-2019,01-08-2019,Renal and urinary disorders,Urinary tract obstruction,R percutaneous nephrostomy tube indicated,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Support,
755,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,01-23-2019,02-02-2019,Gastrointestinal disorders,Diarrhea,Loose stools incr 6X over BL; mild cramping,2,Unlikely,Unlikely,Probable,Filgras inj; 3-XRT recall to GI area,Not a Serious Adverse Event,None,None,Recovered
756,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,10.0,05-30-2019,05-30-2019,Reproductive system and breast disorders,Uterine hemorrhage,Mild x1 episode,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
757,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,07-09-2019,07-10-2019,Gastrointestinal disorders,Abdominal pain,Cramping w/diarrhea episodes; Dicyclomine indicated,1,Unrelated,Unlikely,Definite,Neulasta sensitivity rxn,Not a Serious Adverse Event,None,Symptom,Recovered
758,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,07-09-2019,07-10-2019,General disorders and administration site conditions,Chills,x1 episode,1,Unrelated,Unrelated,Definite,Neulasta sensitivity rxn,Not a Serious Adverse Event,None,None,Recovered
759,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,07-09-2019,07-10-2019,Gastrointestinal disorders,Diarrhea,x3 episodes; took Imodium as prescribed,1,Unrelated,Unlikely,Definite,Neulasta sensitivity rxn,Not a Serious Adverse Event,None,Symptom,Recovered
760,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,07-01-2019,10-01-2019,Nervous system disorders,Dizziness,Intermittent; positional,1,Unlikely,Unlikely,Possible,"Sun and heat exposure, positioning",Not a Serious Adverse Event,None,None,Recovered
761,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,07-02-2019,10-01-2019,Musculoskeletal and connective tissue disorders,Muscle cramp,"Intermittent, L calf",1,Unlikely,Possible,Possible,"Positioning, sitting on garden stool",Not a Serious Adverse Event,None,None,Recovered
762,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,07-09-2019,07-10-2019,Gastrointestinal disorders,Nausea,Zofran indicated,1,Unrelated,Unrelated,Definite,Neulasta sensitivity rxn,Not a Serious Adverse Event,None,Symptom,Recovered
763,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,06-25-2019,10-15-2019,Reproductive system and breast disorders,Uterine hemorrhage,"Scan, intermittent with wiping",1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
764,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,07-09-2019,07-10-2019,Gastrointestinal disorders,Vomiting,Zofran indicated,1,Unrelated,Unrelated,Definite,Neulasta sensitivity rxn,Not a Serious Adverse Event,None,Symptom,Recovered
765,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,14.0,07-23-2019,09-03-2019,General disorders and administration site conditions,Fatigue,,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
766,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,15.0,08-06-2019,--,Gastrointestinal disorders,Rectal hemorrhage,intermittent with stool/wiping,1,Probable,Unlikely,,,Not a Serious Adverse Event,None,None,
767,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,17.0,09-03-2019,12-10-2019,General disorders and administration site conditions,Fatigue,,2,Possible,Unlikely,Probable,MDS,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
768,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,18.0,09-17-2019,11-12-2019,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Unlikely,Definite,"MDS,Acitretin medication",Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
769,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,18.0,09-29-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",MDS,2,Unrelated,Unlikely,Definite,prior pelvic radiation & chemotherpay,Not a Serious Adverse Event,None,Support,
770,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,02-13-2019,03-01-2019,Renal and urinary disorders,Bladder spasm,Intermittent; Pyridium indicated,2,Unlikely,Unlikely,Probable,Radiation cystitis,Not a Serious Adverse Event,None,Symptom,Recovered
771,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,02-09-2019,03-01-2019,Renal and urinary disorders,Cystitis noninfective,Radiation-induced cystitis,1,Unlikely,Unlikely,Definite,Prior pelvic radiation treatments,Not a Serious Adverse Event,None,None,Recovered
772,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,02-07-2019,07-23-2019,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
773,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,02-09-2019,03-01-2019,Renal and urinary disorders,Hematuria,Pink-tinged urine; negative urine culture,1,Possible,Unlikely,Probable,Radiation cystitis,Not a Serious Adverse Event,None,None,Recovered
774,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,20.0,10-15-2019,01-07-2020,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unrelated,Unlikely,Definite,anemia,Not a Serious Adverse Event,None,None,Recovered
775,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,11-12-2019,11-26-2019,Blood and lymphatic system disorders,Anemia,,1,Unlikely,Unlikely,Probable,"MDS diagnosis,Acitretin medication",Not a Serious Adverse Event,None,None,Recovered
776,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,23.0,11-26-2019,01-06-2020,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unlikely,Unlikely,"MDS diagnosis,Acitretin medication",Not a Serious Adverse Event,None,None,Recovered
777,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,24.0,01-06-2020,04-21-2020,Blood and lymphatic system disorders,Anemia,,1,Unrelated,Unlikely,Possible,MDS,Not a Serious Adverse Event,None,None,
778,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,24.0,12-10-2019,09-21-2021,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,Probable,MDS/Anemia,Not a Serious Adverse Event,None,None,Recovered
779,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,24.0,04-07-2020,07-14-2020,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","Keratoacanthoma,site left upper eyelid",1,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
780,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,24.0,04-21-2020,07-14-2020,Investigations,Neutrophil count decreased,,4,Unrelated,Unlikely,Definite,MDS affecting WBC cell line,Not a Serious Adverse Event,None,None,Recovered
781,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,24.0,01-07-2020,04-21-2020,Skin and subcutaneous tissue disorders,Rash maculo-papular,,1,Unrelated,Unrelated,Possible,Contact Dermatitis,Not a Serious Adverse Event,None,Symptom,Recovered
782,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,26.0,07-14-2020,12-14-2021,Gastrointestinal disorders,Dysphagia,,2,Unrelated,Unrelated,Probable,R/T Esophageal ring,Not a Serious Adverse Event,None,None,Recovered
783,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,26.0,07-14-2020,10-06-2020,Investigations,Neutrophil count decreased,,3,Unrelated,Unlikely,Definite,MDS affecting WBC cell line,Not a Serious Adverse Event,None,None,Recovered
784,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,27.0,10-06-2020,01-05-2021,Investigations,Neutrophil count decreased,,4,Unrelated,Unlikely,Definite,MDS affecting WBC cell line,Not a Serious Adverse Event,None,None,Recovered
785,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,27.0,10-06-2020,01-05-2021,Skin and subcutaneous tissue disorders,Rash maculo-papular,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
786,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,28.0,01-05-2021,08-09-2022,Investigations,White blood cell decreased,,3,Unrelated,Unrelated,Definite,MDS,Not a Serious Adverse Event,None,None,Recovered
787,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,29.0,03-30-2021,08-09-2022,Investigations,Neutrophil count decreased,,4,Unrelated,Unrelated,Definite,MDS diagnosis,Not a Serious Adverse Event,None,None,Recovered
788,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,02-19-2019,03-19-2019,Blood and lymphatic system disorders,Anemia,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
789,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,03-02-2019,03-02-2019,Gastrointestinal disorders,Diarrhea,x1 episode with quick resolution,1,Unlikely,Unrelated,Probable,Food intake,Not a Serious Adverse Event,None,None,Recovered
790,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,02-19-2019,04-02-2019,Gastrointestinal disorders,Gingival pain,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
791,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,03-04-2019,03-19-2019,Investigations,Neutrophil count decreased,Returned to baseline Gr 3 at 3/19/19,2,Unlikely,Unrelated,Definite,BL hx Leukopenia r/t prior XRT,Not a Serious Adverse Event,None,None,Recovered
792,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,02-19-2019,03-04-2019,Investigations,Neutrophil count decreased,,3,Unlikely,Unrelated,Definite,BL hx of Leukopenia r/t XRT,Not a Serious Adverse Event,None,None,
793,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,02-19-2019,10-15-2019,Gastrointestinal disorders,Oral hemorrhage,"Gingival bleed with flossing, mild-no clots",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
794,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,30.0,08-30-2021,12-14-2021,Infections and infestations,Urinary tract infection,,2,Unrelated,Unrelated,Definite,Bacterial infection,Not a Serious Adverse Event,None,Symptom,Recovered
795,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,31.0,09-21-2021,12-14-2021,General disorders and administration site conditions,Fatigue,,2,Unrelated,Unrelated,Probable,UTI & treatment,Not a Serious Adverse Event,None,None,Recovered
796,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,34.0,08-09-2022,--,Investigations,Neutrophil count decreased,,3,Unrelated,Unrelated,Definite,MDS,Not a Serious Adverse Event,None,None,
797,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,34.0,08-09-2022,--,Investigations,White blood cell decreased,,2,Unrelated,Unrelated,Definite,MDS,Not a Serious Adverse Event,None,None,
798,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,03-08-2019,03-10-2019,Renal and urinary disorders,Hematuria,Pink-tinged urine x 2 days Mirabegron prn indicated on the 2 days of event,1,Possible,Unlikely,Possible,Recent cystitis diagnosis,Not a Serious Adverse Event,None,Symptom,Recovered
799,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,03-16-2019,05-28-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Benign Keratoacanthomas back of neck and R clavicle-DERM consult and monitoring,1,Probable,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
800,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,5.0,03-19-2019,04-02-2019,Blood and lymphatic system disorders,Anemia,Taking B12 and Folate supplementation,2,Possible,Unrelated,Possible,Hx r/t prior pelvic XRT,Not a Serious Adverse Event,None,None,Recovered
801,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,5.0,03-22-2019,05-28-2019,Renal and urinary disorders,Hematuria,Intermittent pink-tinged spotting on urinary incontinence pads,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
802,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,04-02-2019,04-15-2019,Blood and lymphatic system disorders,Anemia,Taking B12 and Folate supplementation,1,Possible,Unlikely,Probable,Prior pelvic XRT and chemo,Not a Serious Adverse Event,None,Symptom,Recovered
803,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,04-15-2019,08-06-2019,Blood and lymphatic system disorders,Anemia,Taking B12 and Folate supplementation,2,Possible,Unlikely,Probable,Prior pelvic XRT & chemotherapy,Not a Serious Adverse Event,None,Symptom,Recovered
804,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,04-02-2019,04-02-2019,General disorders and administration site conditions,Chills,,1,Unrelated,Unrelated,Probable,Neulasta,Not a Serious Adverse Event,None,None,Recovered
805,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,04-03-2019,04-05-2019,Gastrointestinal disorders,Diarrhea,"Loose, soft stools w/urgency and abd cramping 4-5/10 in severity requiring Imodium on 2nd day",1,Unlikely,Unrelated,Probable,Baseline,Not a Serious Adverse Event,None,Symptom,Recovered
806,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,04-02-2019,05-14-2019,Skin and subcutaneous tissue disorders,Dry skin,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
807,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,04-03-2019,04-30-2019,Vascular disorders,Hot flashes,Intermittent,1,Unlikely,Unlikely,Possible,Neulasta,Not a Serious Adverse Event,None,None,Recovered
808,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,04-02-2019,04-15-2019,Investigations,Neutrophil count decreased,Lowest value since start of study and baseline requiring Hematology consult,3,Unlikely,Unlikely,Definite,Prior pelvic XRT and chemo,Not a Serious Adverse Event,None,Support,Recovered
809,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,8.0,04-30-2019,04-21-2020,Nervous system disorders,Memory impairment,CT Brain performed 5/28/19-negative,1,Unrelated,Unlikely,Possible,Age-related changes,Not a Serious Adverse Event,None,None,Recovered
810,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,8.0,04-30-2019,05-28-2019,Musculoskeletal and connective tissue disorders,Myalgia,Ligament injury; Tramadol and cyclobenzaprine indicated for muscle pain,2,Unrelated,Unlikely,Definite,R hip ligament injury,Not a Serious Adverse Event,None,Symptom,
811,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,05-14-2019,11-26-2019,Skin and subcutaneous tissue disorders,Dry skin,Generalized; Aquaphor cream indicated,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
812,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,05-28-2019,10-29-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","Keratoacanthomas; liquid nitrogen to lesions on nose, R knee; neck +R chest lesions resolved",2,Probable,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
813,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,05-28-2019,10-15-2019,Skin and subcutaneous tissue disorders,Pruritus,DERM prescribed skin creams for itching,2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
814,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,05-28-2019,10-29-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,"Upper arms, torso, legs; areas of rash increased; DERM Rx skin creams for itching",2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
815,a24ee1ece206989032e3494ea3ee1061,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,05-14-2019,05-28-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,Mild dermatitis per DERM assessment; OTC steroid cream recommended,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
816,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,02-20-2019,04-24-2019,Musculoskeletal and connective tissue disorders,Back pain,Lower back; sacral insufficiency fx and Vertebral insufficiency at L3-L5; requires intervention,2,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Not a Serious Adverse Event,None,Symptom,Recovered
817,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,03-04-2019,04-24-2019,Musculoskeletal and connective tissue disorders,Back pain,Diagnosed with sacral fx requiring surgery,3,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
818,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,03-04-2019,04-03-2019,"Injury, poisoning and procedural complications",Fracture,Sacral insuf/Vert insuf L3-L5 requiring Sacralplasty/vertebroplasty 4/3/19,3,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
819,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,02-19-2019,03-15-2019,Gastrointestinal disorders,Rectal hemorrhage,Hematochezia,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
820,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,5.0,04-10-2019,--,Musculoskeletal and connective tissue disorders,Back pain,Limiting ADLs and self care; possible occult pelvic fx,3,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
821,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,5.0,04-10-2019,--,General disorders and administration site conditions,Pain,Left groin,3,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
822,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,04-24-2019,--,Musculoskeletal and connective tissue disorders,Back pain,lumbar sacral,1,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Not a Serious Adverse Event,None,None,
823,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,05-02-2019,--,Infections and infestations,Bacteremia,,2,Unrelated,Unrelated,Probable,Cutaneous skin ulcer,Not a Serious Adverse Event,None,None,
824,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,05-20-2019,05-20-2019,General disorders and administration site conditions,Death NOS,,5,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Died
825,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,04-30-2019,--,General disorders and administration site conditions,Fever,"Blood cultures collected, was + for s. aureus probably related to cutaneous ulcer",1,Unrelated,Unrelated,Definite,Bacteremia,Not a Serious Adverse Event,None,None,
826,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,04-30-2019,--,"Injury, poisoning and procedural complications",Fracture,Pelvis; unable to move; requires hospitalization,3,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Hospitalized,Regimen Interrupted,Support,
827,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,04-24-2019,04-30-2019,"Injury, poisoning and procedural complications",Fracture,Left pubic body,2,Unrelated,Unlikely,Definite,Degenerative Osteoporosis,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
828,03b2e85588ad5649532819daf87797a7,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,04-30-2019,--,Infections and infestations,Skin infection,posterior cutaneous ulcer,3,Unrelated,Unrelated,Definite,Due to immobility,Not a Serious Adverse Event,None,Support,
829,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,02-13-2019,--,Vascular disorders,Hot flashes,Effexor indicated,2,Unrelated,Unrelated,Probable,Hormonal changes,Not a Serious Adverse Event,None,Symptom,
830,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,02-13-2019,02-26-2019,Musculoskeletal and connective tissue disorders,Pain in extremity,Increase in R leg pain from BL; fentanyl patch and oxycodone indicated,2,Unlikely,Possible,Possible,Piriformis Syndrome vs neuropathy,Not a Serious Adverse Event,None,Symptom,Recovered
831,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,02-12-2019,02-15-2019,Skin and subcutaneous tissue disorders,Rash acneiform,,1,Unrelated,Unrelated,Possible,irritant vs. lovenox reactio,Not a Serious Adverse Event,None,None,Recovered
832,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,03-11-2019,03-11-2019,Gastrointestinal disorders,Abdominal pain,,1,Unlikely,Unlikely,Possible,Diarrhea/GI upset,Not a Serious Adverse Event,None,None,Recovered
833,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,02-26-2019,04-01-2019,Blood and lymphatic system disorders,Anemia,"Symptomatic as of 3/12/19 visit; transfusion on 3/13/19,  iron studies, and GI consult indicated",2,Unlikely,Probable,Probable,"Prior XRT, chemotherapy, or Lovenox",Not a Serious Adverse Event,None,Support,Recovered
834,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,03-11-2019,03-11-2019,Gastrointestinal disorders,Diarrhea,x 1 episode,1,Unlikely,Unlikely,Possible,GI upset,Not a Serious Adverse Event,None,None,Recovered
835,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,03-05-2019,04-02-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,Dyspnea requiring withholding of Week 5 dose,2,Unlikely,Possible,Probable,Anemia,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
836,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,03-05-2019,04-02-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,SOB likely sym of increasing anemia;study drug held; transfusion on 3/13/19,2,Unlikely,Possible,Probable,Anemia,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
837,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,03-11-2019,--,General disorders and administration site conditions,Fatigue,Week 5 dose held,2,Unlikely,Possible,Probable,Anemia; 3-Narcotics,Not a Serious Adverse Event,Regimen Interrupted,None,
838,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,03-11-2019,03-11-2019,Gastrointestinal disorders,Nausea,x 2 episodes; prn antiemetic indicated,1,Unlikely,Unlikely,Possible,Narcotic dosing/Fentanyl/GI upset,Not a Serious Adverse Event,None,Symptom,Recovered
839,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,03-11-2019,03-11-2019,Gastrointestinal disorders,Vomiting,x 2 episodes; prn antiemetic indicated,1,Unlikely,Unlikely,Possible,Narcotics/FentanyL/GI upset,Not a Serious Adverse Event,None,Symptom,
840,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,03-24-2019,03-29-2019,Gastrointestinal disorders,Constipation,No BM in 3 days; has discomfort; bowel regimen started,2,Unrelated,Possible,Probable,Narcotics medication regimen,Not a Serious Adverse Event,None,Symptom,Recovered
841,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,03-12-2019,03-25-2019,Metabolism and nutrition disorders,Hypokalemia,Oral supplementation indicated,2,Unlikely,Unlikely,Probable,"Electrolyte imbalance, diet",Not a Serious Adverse Event,None,Symptom,Recovered
842,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,03-12-2019,03-25-2019,Metabolism and nutrition disorders,Hypokalemia,Oral supplementation indicated,2,Unrelated,Unlikely,Probable,"Electrolyte imbalance, diet",Not a Serious Adverse Event,None,Symptom,Recovered
843,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,03-25-2019,03-30-2019,Investigations,Lymphocyte count decreased,,2,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
844,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,03-25-2019,03-30-2019,Investigations,Lymphocyte count decreased,,2,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
845,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,03-25-2019,--,Renal and urinary disorders,"Renal and urinary disorders - Other, specify",Bacteriuria as per urine culture collected per Urology Consult; negative for infection,1,Unrelated,Possible,Probable,R Urinary obstruction/hydronephrosis,Not a Serious Adverse Event,None,None,
846,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,03-25-2019,--,Renal and urinary disorders,Urinary tract obstruction,New dx of R-sided hydronephrosis seen on CT scan,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Support,
847,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-26-2019,04-02-2019,Gastrointestinal disorders,Abdominal pain,Lower region; r/t new R-sided hydronephrosis; Fentanyl patch and oxycodone indicated,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
848,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-26-2019,04-02-2019,Gastrointestinal disorders,Abdominal pain,Lower abdomen,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
849,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-02-2019,04-08-2019,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Probable,Probable,"Prior chemo/XRT, Lovenox",Not a Serious Adverse Event,None,None,Recovered
850,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-01-2019,04-02-2019,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Probable,Probable,"Prior XRT, chemotherapy, and Lovenox",Not a Serious Adverse Event,None,Support,Recovered
851,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-08-2019,04-18-2019,Blood and lymphatic system disorders,Anemia,Transfusion indicated on 4/10/19,3,Unlikely,Probable,Probable,Prior chemo/XRT or Lovenox; 3-Gemzar,Not a Serious Adverse Event,None,Support,Recovered
852,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-02-2019,--,Musculoskeletal and connective tissue disorders,Back pain,Lower; tx w/narcotics regimen and alt therapies,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
853,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-26-2019,03-27-2019,Musculoskeletal and connective tissue disorders,Back pain,Low back r/t new R-sided hydronephrosis; Fentanyl patch and oxycodone indicated,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
854,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-27-2019,04-02-2019,Musculoskeletal and connective tissue disorders,Back pain,"Low back and L flank; med change indicated, P&P consult",3,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
855,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-02-2019,--,"Respiratory, thoracic and mediastinal disorders",Cough,Intermittent,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
856,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-07-2019,--,General disorders and administration site conditions,Edema limbs,,2,Unrelated,Possible,Definite,DVT R leg,Not a Serious Adverse Event,None,None,
857,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-01-2019,04-07-2019,"Injury, poisoning and procedural complications",Fall,x 2 episodes in 1 week; slipped on floor in socks,1,Unrelated,Unlikely,Definite,Mechanical-slipped on floor in socks,Not a Serious Adverse Event,None,None,Recovered
858,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-01-2019,04-01-2019,General disorders and administration site conditions,Fever,"Low grade, not a reaction; Tylenol prn indicated",1,Unrelated,Unlikely,Possible,Post blood transfusion,Not a Serious Adverse Event,None,Symptom,Recovered
859,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-01-2019,--,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unrelated,Possible,Probable,"Vomiting, compromised nutrition",Not a Serious Adverse Event,None,None,
860,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-29-2019,04-01-2019,Metabolism and nutrition disorders,Hypokalemia,,3,Unlikely,Unlikely,Definite,"Vomiting, electrolyte loss",Not a Serious Adverse Event,None,Symptom,Recovered
861,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-02-2019,--,Psychiatric disorders,Insomnia,Ativan prn indicated,2,Unrelated,Probable,Definite,Pain,Not a Serious Adverse Event,None,Symptom,
862,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,04-01-2019,--,Gastrointestinal disorders,Mucositis oral,Tongue ulcers and gingival inflammation; Week 9 tx held,2,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
863,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-27-2019,04-01-2019,Gastrointestinal disorders,Mucositis oral,"Tongue, not interfering w/eating or drinking; Magic Mouth Wash order to use prn",1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
864,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-26-2019,03-29-2019,Gastrointestinal disorders,Nausea,Mild and intermittent; takes antiemetics prn after taking oral narcotics pain meds,1,Unlikely,Possible,Definite,Oral narcotics pain meds,Not a Serious Adverse Event,None,Symptom,Recovered
865,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-29-2019,04-02-2019,Gastrointestinal disorders,Nausea,Intractable nausea in setting of recent change in oral opioid regimen; IV Zofran indicated,3,Unlikely,Possible,Definite,Narcotics regimen,Hospitalized,None,Support,Recovered
866,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,03-29-2019,04-02-2019,Gastrointestinal disorders,Vomiting,Intractable vomiting in setting of recent change in oral opioid regimen; IV Zofran indicated,3,Unlikely,Possible,Definite,Narcotics regimen,Hospitalized,None,Support,Recovered
867,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,04-18-2019,--,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Probable,Probable,"Prior XRT/chemo, Lovenox",Hospitalized,None,Support,
868,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,04-18-2019,--,Skin and subcutaneous tissue disorders,Bullous dermatitis,Rash over <5% of body; urgent care visit and steroids indicated,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
869,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,04-18-2019,04-19-2019,General disorders and administration site conditions,Fever,,3,Unlikely,Possible,Probable,Lung infection,Not a Serious Adverse Event,None,Symptom,Recovered
870,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,04-16-2019,--,Infections and infestations,Lung infection,,2,Unlikely,Possible,Probable,Opportunistic infection,Not a Serious Adverse Event,None,Symptom,
871,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,04-09-2019,--,Vascular disorders,Thromboembolic event,Right leg; Lovenox dose adjustment indicated,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,Symptom,
872,6cc9a1944d2e3ac159dc4a4dd2277176,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,,06-01-2019,06-01-2019,General disorders and administration site conditions,Death NOS,,5,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Died
873,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,04-22-2019,04-24-2019,Gastrointestinal disorders,Nausea,,2,Unrelated,Possible,Probable,Constipation,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
874,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,04-19-2019,04-22-2019,Gastrointestinal disorders,Nausea,,1,Unrelated,Unlikely,Possible,Constipation,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
875,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,04-19-2019,05-01-2019,Infections and infestations,Urinary tract infection,7-day course of Bactrim indicated,2,Unrelated,Possible,Definite,Bacteriuria,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
876,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,04-19-2019,04-22-2019,Gastrointestinal disorders,Vomiting,Intermittent,1,Unrelated,Unlikely,Possible,Constipation,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
877,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,04-22-2019,04-24-2019,Gastrointestinal disorders,Vomiting,,2,Unrelated,Possible,Probable,Constipation,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
878,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-25-2019,--,Blood and lymphatic system disorders,Anemia,Transfusion indicated,3,Unrelated,Possible,Probable,Prior chemo/XRT; 3-dlutional d/t hydra,Not a Serious Adverse Event,Regimen Interrupted,Support,
879,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-29-2019,--,Musculoskeletal and connective tissue disorders,Bone pain,R groin to knee; bone mets dx on 5/1/19 scan; palliative XRT indicated,2,Unrelated,Definite,,,Not a Serious Adverse Event,Therapy Discontinued,Support,
880,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,05-03-2019,--,Gastrointestinal disorders,Colonic obstruction,Dx on 5/3/19 Flex sigmoidoscopy,3,Unrelated,Definite,,,Not a Serious Adverse Event,Therapy Discontinued,None,
881,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-24-2019,04-29-2019,Gastrointestinal disorders,Constipation,GI Ileus dx on 4/24/19,3,Unrelated,Probable,Possible,Opioid regimen; 4-Hypercalcemia,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
882,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,05-01-2019,05-07-2019,Gastrointestinal disorders,Diarrhea,,2,Unrelated,Unlikely,Definite,"Tx for Ileus, LX,  Methylnaltrexone",Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
883,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,05-03-2019,--,Gastrointestinal disorders,Duodenal obstruction,Dx on 5/3/19 UGI & Endoscopy; PEG tube placed 5/7/19 for feeding,3,Unrelated,Definite,,,Not a Serious Adverse Event,Therapy Discontinued,None,
884,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-25-2019,04-29-2019,Nervous system disorders,Extrapyramidal disorder,Required change of narcotics' regimen,1,Unrelated,Unrelated,Definite,Opioid regimen,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
885,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-25-2019,04-29-2019,Psychiatric disorders,Hallucinations,Occurring especially with sleep/resting; req change of narcotics' regimen,1,Unrelated,Unrelated,Definite,Opioid regimen,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
886,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-24-2019,04-26-2019,Metabolism and nutrition disorders,Hypercalcemia,"Req hospital admission for supportive care, IV Zometa ,and fluids",2,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Support,Recovered
887,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-29-2019,--,Metabolism and nutrition disorders,Hypocalcemia,IV hydration indicated; Ca replacement on 5/1/19,1,Unrelated,Definite,Possible,Nutritional status,Not a Serious Adverse Event,Regimen Interrupted,Support,
888,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,05-05-2019,05-05-2019,Metabolism and nutrition disorders,Hypokalemia,KPhos supplementation indicated,1,Unrelated,Unlikely,Probable,Electrolyte imbalance/nutritional status,Not a Serious Adverse Event,Therapy Discontinued,Support,Recovered
889,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-27-2019,04-28-2019,Metabolism and nutrition disorders,Hypokalemia,Supplementation indicated,1,Unrelated,Unlikely,Probable,Electrolyte imbalance/nutritional status,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
890,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-26-2019,05-08-2019,Metabolism and nutrition disorders,Hypophosphatemia,Supplementation indicated,2,Unrelated,Unlikely,Probable,Electrolyte imbalance/nutritional status,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
891,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-25-2019,04-26-2019,Metabolism and nutrition disorders,Hypophosphatemia,Supplementation indicated,1,Unrelated,Unlikely,Probable,Electro imbalance d/t nutritional status,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
892,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-24-2019,04-29-2019,Gastrointestinal disorders,Ileus,Req hospital admission for eval and supp care; dx on 4/24/19 after reviewing outside 4/22/19 CT,2,Unrelated,Probable,Probable,Hypercalcemia; 3-Opioid regimen,Hospitalized,Regimen Interrupted,Symptom,Recovered
893,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-24-2019,05-09-2019,Gastrointestinal disorders,Nausea,Symptomatic GI Ileus diagnosed on 4/24/19,3,Unrelated,Unlikely,Probable,"Obstipation/Ileus, hypercalcemia",Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
894,f93819c38f7ca8f77469ee9f53fce1de,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,04-24-2019,05-09-2019,Gastrointestinal disorders,Vomiting,,3,Unrelated,Unlikely,Probable,"Obstipation/Ileus, hypercalcemia",Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
895,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,05-28-2019,06-03-2019,"Respiratory, thoracic and mediastinal disorders",Cough,"Dry, intermittent cough resolved by day 7",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
896,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,05-28-2019,06-03-2019,"Injury, poisoning and procedural complications",Infusion related reaction,"Intermittent throat itching, resolved by day 7",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
897,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,05-29-2019,05-30-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,Red rash to anterior mid-chest area; self-limiting and resolved by day 3 w/out intervention,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
898,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,10.0,10-08-2019,10-29-2019,Nervous system disorders,Facial nerve disorder,left lower jaw twitching,1,Possible,Unrelated,Probable,Recent Bell's Palsy diagnosis,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
899,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,11-06-2019,11-26-2019,Gastrointestinal disorders,Rectal hemorrhage,,1,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
900,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,13.0,11-12-2019,01-07-2020,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
901,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,13.0,11-12-2019,12-10-2019,Nervous system disorders,Facial nerve disorder,numbness to mouth and lips,1,Possible,Unrelated,Probable,numbness to mouth and lips,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
902,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,13.0,11-18-2019,11-26-2019,Gastrointestinal disorders,Mucositis oral,,2,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
903,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,13.0,11-12-2019,01-07-2020,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
904,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,14.0,11-26-2019,02-04-2020,Skin and subcutaneous tissue disorders,Rash maculo-papular,Lichenoid Dermatitis,2,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
905,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,16.0,12-24-2019,01-07-2020,Gastrointestinal disorders,Rectal hemorrhage,,1,Possible,Unrelated,Possible,hist of hemorroids,Not a Serious Adverse Event,None,None,Recovered
906,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,18.0,01-21-2020,01-24-2020,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",Left Psoas Mass Resection,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,Recovered
907,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,21.0,03-16-2020,--,Endocrine disorders,Hypothyroidism,,2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
908,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,03-17-2020,05-12-2020,Gastrointestinal disorders,Constipation,,1,Unrelated,Unrelated,Possible,Diet changes,Not a Serious Adverse Event,None,None,Recovered
909,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,22.0,03-17-2020,05-12-2020,Skin and subcutaneous tissue disorders,Pruritus,"upper back, intermittent",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
910,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,27.0,11-10-2020,--,Eye disorders,"Eye disorders - Other, specify","peripheral visual fields altered left eye, r/t brain lesion",2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,
911,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,27.0,09-15-2020,10-28-2020,Gastrointestinal disorders,Nausea,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Support,Recovered
912,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,27.0,10-23-2020,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Brain lesion,3,Unrelated,Definite,,,Not a Serious Adverse Event,None,Support,
913,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,27.0,09-15-2020,10-28-2020,Gastrointestinal disorders,Vomiting,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Support,Recovered
914,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,07-05-2019,02-04-2020,Gastrointestinal disorders,Abdominal pain,Intermittent cramping lower L side,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
915,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,06-29-2019,09-03-2019,Gastrointestinal disorders,Hemorrhoidal hemorrhage,Intermittent with wiping post BM; OTC Preparation H prn indicated,1,Possible,Unrelated,Probable,Prior hemorrhoid hx,Not a Serious Adverse Event,None,Symptom,Recovered
916,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,06-29-2019,03-17-2020,Gastrointestinal disorders,Oral hemorrhage,Intermittent gingival bleeding with brushing,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
917,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,07-06-2019,09-03-2019,Skin and subcutaneous tissue disorders,Pruritus,B/L lower extremities and upper arms; Benadryl and topical HC indicated,1,Probable,Unrelated,Unlikely,Mosquito bites,Not a Serious Adverse Event,None,Symptom,Recovered
918,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,07-09-2019,01-07-2020,"Respiratory, thoracic and mediastinal disorders",Cough,"Dry, intermittent",1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
919,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,07-12-2019,08-06-2019,Gastrointestinal disorders,Mucositis oral,Lesion on lateral tongue w/interm bleeding; Dexamethasone mouth rinse indicated,2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
920,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,5.0,08-01-2019,05-12-2020,Gastrointestinal disorders,Nausea,Intermittent,1,Unlikely,Unlikely,Possible,Appetite change/Mood,Not a Serious Adverse Event,None,None,Recovered
921,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,08-06-2019,12-24-2019,Metabolism and nutrition disorders,Anorexia,5-lb weight loss from BL; taking CBD oil as appetite stimulant,2,Unlikely,Unlikely,Probable,"Mood, coping, and BL hx",Not a Serious Adverse Event,None,None,Recovered
922,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,08-06-2019,11-12-2019,Gastrointestinal disorders,Constipation,Intermittent,1,Unlikely,Unlikely,Possible,"Diet, meds",Not a Serious Adverse Event,None,None,Recovered
923,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,08-10-2019,09-17-2019,Nervous system disorders,Facial muscle weakness,L-sided; oral steroids indicated,2,Probable,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
924,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,6.0,08-06-2019,11-26-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,"On b/l lower and upper extreme, scattered; top HC indicated",1,Possible,Unrelated,Possible,Insect bite/dermatitis,Not a Serious Adverse Event,None,Symptom,Recovered
925,64f5309673cbf36a4298a56da2b87048,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,9.0,09-17-2019,05-12-2020,Nervous system disorders,Concentration impairment,,1,Unrelated,Unlikely,Probable,depression,Not a Serious Adverse Event,None,None,Recovered
926,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,14.0,01-07-2020,02-18-2020,Investigations,Lymphocyte count decreased,,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
927,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,14.0,01-07-2020,03-02-2020,Investigations,White blood cell decreased,,2,Unlikely,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
928,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,15.0,01-24-2020,--,Nervous system disorders,Dizziness,,2,Unlikely,Possible,Possible,cardiac med. hx,Not a Serious Adverse Event,None,None,
929,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,15.0,01-22-2020,01-24-2020,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",TAVR aortic valve replacement,3,Unrelated,Unrelated,Definite,cardiac medical history,Hospitalized,Regimen Interrupted,None,Recovered
930,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,16.0,02-04-2020,03-31-2020,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Possible,Probable,S/P TAVR surgery,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
931,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,17.0,02-18-2020,--,Musculoskeletal and connective tissue disorders,Arthralgia,,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,None,
932,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-09-2019,08-05-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Unrelated,Probable,Baseline,Not a Serious Adverse Event,None,None,Recovered
933,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-09-2019,08-20-2019,"Respiratory, thoracic and mediastinal disorders",Epistaxis,Intermittent when blowing nose,1,Possible,Unrelated,Possible,Anticoagulant,Not a Serious Adverse Event,None,None,Recovered
934,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-09-2019,08-20-2019,Gastrointestinal disorders,Flatulence,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
935,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-09-2019,07-23-2019,Skin and subcutaneous tissue disorders,Pruritus,,2,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
936,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-09-2019,12-10-2019,Skin and subcutaneous tissue disorders,Rash acneiform,Topical steroid continues+ Acitretin,1,Possible,Unrelated,Possible,BL exacerbation,Not a Serious Adverse Event,None,Symptom,Recovered
937,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-05-2019,08-20-2019,Blood and lymphatic system disorders,Anemia,,3,Possible,Unlikely,Possible,"epistaxis, psoriatic lesions",Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
938,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-06-2019,01-24-2020,Cardiac disorders,Palpitations,,1,Unlikely,Possible,Possible,cardiac med. hx,Not a Serious Adverse Event,None,None,Recovered
939,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-06-2019,10-15-2019,Skin and subcutaneous tissue disorders,Pruritus,,2,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
940,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,08-20-2019,09-16-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Unrelated,Probable,BL,Not a Serious Adverse Event,None,Support,Recovered
941,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,08-20-2019,09-03-2019,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unlikely,Possible,anticoagulants,Not a Serious Adverse Event,None,None,Recovered
942,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-06-2019,10-01-2019,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unlikely,Possible,anticoagulants,Not a Serious Adverse Event,None,None,Recovered
943,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,09-16-2019,10-15-2019,Blood and lymphatic system disorders,Anemia,,3,Possible,Unlikely,Possible,"anticoagulant, epistaxis",Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
944,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,09-16-2019,10-01-2019,Investigations,Lymphocyte count decreased,,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
945,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,09-17-2019,09-17-2019,Nervous system disorders,Presyncope,,2,Unlikely,Possible,Possible,a-fib med. hx,Not a Serious Adverse Event,None,None,Recovered
946,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,09-20-2019,09-22-2019,Nervous system disorders,Presyncope,,2,Unlikely,Possible,Possible,Med Hist atrial Fibrillation,Hospitalized,None,None,Recovered
947,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,09-17-2019,10-15-2019,Skin and subcutaneous tissue disorders,Rash acneiform,Bilateral arms,1,Possible,Unrelated,Possible,contact allergy,Not a Serious Adverse Event,None,None,Recovered
948,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,10-01-2019,10-15-2019,Gastrointestinal disorders,Oral hemorrhage,,2,Possible,Unlikely,Possible,anticoagulants,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
949,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,10-15-2019,11-12-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Unlikely,Possible,anticoagulant,Not a Serious Adverse Event,None,Support,Recovered
950,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,10-15-2019,12-10-2019,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unlikely,Possible,anticoagulants,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
951,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,10-15-2019,02-18-2020,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
952,f089e1b909605b0d39ac54cc18f05758,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,,03-04-2021,--,Hepatobiliary disorders,"Hepatobiliary disorders - Other, specify",Nodular Regenerative Hyperplasia,1,Definite,Unrelated,,,Important Medical Event,None,Support,
953,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,1.0,07-17-2019,--,Metabolism and nutrition disorders,Anorexia,,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,
954,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,1.0,07-17-2019,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,New-onset hypoxia requiring 2L NC w/in past week,2,Unrelated,Possible,Probable,Anemia,Not a Serious Adverse Event,None,Symptom,
955,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,1.0,07-17-2019,--,General disorders and administration site conditions,Fatigue,,2,Possible,Possible,Probable,Anemia,Not a Serious Adverse Event,None,None,
956,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,1.0,07-09-2019,--,Metabolism and nutrition disorders,Hypomagnesemia,Oral supplement indicated,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
957,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,1.0,07-17-2019,--,"Respiratory, thoracic and mediastinal disorders",Hypoxia,O2 2L NC indicated,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,Symptom,
958,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,1.0,07-10-2019,08-06-2019,Reproductive system and breast disorders,Vaginal hemorrhage,,2,Unrelated,Definite,Possible,Prior therapy,Hospitalized,Regimen Interrupted,None,Recovered
959,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-23-2019,07-24-2019,Blood and lymphatic system disorders,Anemia,Symptomatic; transfusion indicated,3,Unrelated,Probable,Probable,Vaginal bleeding,Hospitalized,Regimen Interrupted,Support,Recovered
960,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-24-2019,--,Blood and lymphatic system disorders,Anemia,Transfusion indicated,2,Unrelated,Probable,Probable,Vaginal bleeding,Not a Serious Adverse Event,None,Support,
961,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-23-2019,--,Metabolism and nutrition disorders,Dehydration,IVFs indicated,2,Unrelated,Unrelated,Probable,Anorexia,Not a Serious Adverse Event,None,Support,
962,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,08-06-2019,08-09-2019,General disorders and administration site conditions,"General disorders and administration site conditions - Other, specify",Mucosal Bleeding (Vaginal hemorrhage),3,Unlikely,Probable,Unlikely,Prior therapies,Hospitalized,None,Support,Recovered
963,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-23-2019,--,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unrelated,,Probable,Anorexia,Not a Serious Adverse Event,None,None,
964,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-23-2019,07-24-2019,Metabolism and nutrition disorders,Hypokalemia,Oral supplement indicated,1,Unrelated,Unrelated,Probable,Dehydration + anorexia,Not a Serious Adverse Event,None,Symptom,Recovered
965,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-23-2019,07-23-2019,Metabolism and nutrition disorders,Hyponatremia,,2,Unrelated,Unrelated,Probable,Dehydration,Not a Serious Adverse Event,None,None,Recovered
966,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-24-2019,07-25-2019,Infections and infestations,Lung infection,Possible CAP,3,Unlikely,Unrelated,Probable,Infection,Not a Serious Adverse Event,None,Support,Recovered
967,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-25-2019,--,Infections and infestations,Lung infection,Possible CAP; oral ABX indicated,2,Unrelated,Unlikely,Probable,Infection,Not a Serious Adverse Event,None,Symptom,
968,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-25-2019,--,Investigations,Lymphocyte count decreased,,2,Unrelated,Possible,Probable,Prior therapies,Not a Serious Adverse Event,None,None,
969,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-23-2019,07-24-2019,Investigations,Lymphocyte count decreased,,2,Unrelated,Unrelated,Probable,Prior therapy,Not a Serious Adverse Event,None,None,Recovered
970,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,2.0,07-23-2019,--,Cardiac disorders,Sinus tachycardia,,1,Unrelated,Unrelated,Probable,Dehydration & anorexia,Not a Serious Adverse Event,None,None,
971,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,,08-19-2019,08-19-2019,General disorders and administration site conditions,Death NOS,,5,Unrelated,Definite,,,Hospitalized,None,None,Died
972,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,,08-15-2019,08-19-2019,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",surgery to stabilize leg bone metastasis,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,Recovered
973,fd204329b6f420abfec04e8269fee41e,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,INSUFFICIENT SAMPLE FOR DIAGNOSIS,,08-19-2019,08-19-2019,Vascular disorders,Thromboembolic event,,5,Unrelated,Possible,Possible,surgical procedure,Not a Serious Adverse Event,None,None,Died
974,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-23-2019,--,Investigations,Creatinine increased,,1,Unlikely,Unlikely,Possible,Oral hydration status,Not a Serious Adverse Event,None,None,
975,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-09-2019,07-12-2019,General disorders and administration site conditions,Non-cardiac chest pain,Intermittent tightness; EKG demonstrated no change from BL and cardiac enzymes WNL,1,Unlikely,Definite,,,Not a Serious Adverse Event,None,None,Recovered
976,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-12-2019,12-12-2019,Infections and infestations,Papulopustular rash,"On arms, torso, and scalp, <10% of BSA;  DERM consult and topical and oral meds indicated",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
977,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-12-2019,01-21-2020,Skin and subcutaneous tissue disorders,Pruritus,"Mild itching; DERM consult, topical and oral meds indicated",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
978,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,11-14-2019,11-24-2019,"Respiratory, thoracic and mediastinal disorders",Cough,,2,Unlikely,Possible,Probable,Prior Bronchiectasis & COPD hx,Not a Serious Adverse Event,None,Symptom,Recovered
979,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,11-14-2019,11-24-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,2,Unlikely,Possible,Probable,Prior Bronchiectasis & COPD hx,Not a Serious Adverse Event,None,None,Recovered
980,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,11-16-2019,01-21-2020,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,,2,Unrelated,Definite,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
981,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,11-26-2019,11-27-2019,Cardiac disorders,Atrial fibrillation,,2,Unrelated,Unrelated,Definite,med hist,Hospitalized,Regimen Interrupted,None,Recovered
982,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,11-26-2019,11-27-2019,Cardiac disorders,Atrial flutter,,2,Unrelated,Unrelated,Definite,med hist,Hospitalized,Regimen Interrupted,None,Recovered
983,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-11-2019,12-24-2019,Gastrointestinal disorders,Constipation,,2,Unrelated,Unrelated,Probable,Narcotic/Opioid pain regimen,Not a Serious Adverse Event,None,Symptom,Recovered
984,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-20-2019,12-24-2019,Metabolism and nutrition disorders,Dehydration,,2,Unrelated,Possible,Probable,Radiation treatment,Not a Serious Adverse Event,None,Symptom,Recovered
985,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-17-2019,12-17-2019,Nervous system disorders,Dizziness,,1,Unrelated,Unrelated,Probable,Orthostatic Hypotension,Not a Serious Adverse Event,None,None,Recovered
986,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-17-2019,12-18-2019,Vascular disorders,Hypotension,orthostatic,2,Unlikely,Unrelated,Probable,"Cardizem medication, hold if BP  low",Not a Serious Adverse Event,None,Symptom,Recovered
987,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-11-2019,12-11-2019,"Injury, poisoning and procedural complications",Infusion related reaction,,2,Probable,Unrelated,,,Not a Serious Adverse Event,Therapy Discontinued,None,Recovered
988,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-19-2019,12-24-2019,Gastrointestinal disorders,Nausea,,1,Unrelated,Unlikely,Probable,Radiation treatment,Not a Serious Adverse Event,None,None,Recovered
989,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-12-2019,03-03-2020,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Keratoacanthomas,2,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
990,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-18-2019,--,Musculoskeletal and connective tissue disorders,Pain in extremity,"right hip, radiates down leg",2,Unrelated,Unlikely,Definite,Degenerative Joint Disease,Not a Serious Adverse Event,None,None,
991,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,13.0,01-06-2020,01-21-2020,Metabolism and nutrition disorders,Anorexia,,2,Unrelated,Possible,Probable,Radiation Therapy,Not a Serious Adverse Event,None,Symptom,Recovered
992,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,13.0,01-06-2020,01-21-2020,General disorders and administration site conditions,Fatigue,,2,Unrelated,Possible,Probable,Radiation Therapy,Not a Serious Adverse Event,None,Symptom,Recovered
993,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,15.0,01-21-2020,03-03-2020,Gastrointestinal disorders,Constipation,,1,Unrelated,Unrelated,Probable,"Medications, diet",Not a Serious Adverse Event,None,Symptom,Recovered
994,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,17.0,03-02-2020,--,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Possible,Possible,Radiation therapy,Not a Serious Adverse Event,None,Support,
995,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,18.0,03-03-2020,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Keratoacanthomas (left shoulder),1,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,
996,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-04-2019,08-14-2019,"Respiratory, thoracic and mediastinal disorders",Cough,Intermittent and dry; mainly in mornings,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
997,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-14-2019,09-15-2019,"Respiratory, thoracic and mediastinal disorders",Cough,,2,Unlikely,Possible,Possible,Unknown etiology,Not a Serious Adverse Event,None,Symptom,Recovered
998,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-06-2019,12-12-2019,Infections and infestations,Herpes simplex reactivation,"New onset, vesicular rash, cluster at L shoulder base; bx positive for HSV-2",1,Unlikely,Unlikely,Possible,HSV Zoster hx,Not a Serious Adverse Event,None,None,Recovered
999,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-14-2019,09-05-2019,"Respiratory, thoracic and mediastinal disorders",Postnasal drip,,2,Unlikely,Unlikely,Possible,prior radiation,Not a Serious Adverse Event,None,Symptom,Recovered
1000,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,09-05-2019,10-16-2019,Metabolism and nutrition disorders,Dehydration,,2,Unlikely,Unlikely,Possible,Decrease oral fluid,Not a Serious Adverse Event,None,Support,Recovered
1001,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-09-2019,09-12-2019,Infections and infestations,Bronchial infection,,2,Unlikely,Unlikely,Definite,Infectious process,Not a Serious Adverse Event,None,Symptom,Recovered
1002,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-12-2019,09-16-2019,Infections and infestations,Bronchial infection,,3,Unlikely,Definite,Definite,Infectious process,Hospitalized,Regimen Interrupted,Symptom,Recovered
1003,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-16-2019,10-01-2019,Infections and infestations,Bronchial infection,,2,Unlikely,Definite,Definite,Infectious process,Not a Serious Adverse Event,None,Symptom,Recovered
1004,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-16-2019,10-01-2019,"Respiratory, thoracic and mediastinal disorders",Cough,,3,Unlikely,Unlikely,Definite,Acute Bronchitis,Not a Serious Adverse Event,None,Symptom,Recovered
1005,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-12-2019,09-16-2019,"Respiratory, thoracic and mediastinal disorders",Cough,ntractable,3,Unlikely,Unlikely,Definite,Acute Bronchitis,Hospitalized,Regimen Interrupted,Symptom,Recovered
1006,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-16-2019,10-01-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unlikely,Unlikely,Definite,Acute Bronchitis,Not a Serious Adverse Event,None,None,Recovered
1007,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,09-12-2019,09-16-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,2,Unlikely,Unlikely,Definite,"Acute Bronchitis, cough",Hospitalized,Regimen Interrupted,Symptom,Recovered
1008,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,09-26-2019,10-16-2019,Musculoskeletal and connective tissue disorders,Chest wall pain,right lateral,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1009,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,10-21-2019,11-12-2019,Infections and infestations,Bronchial infection,,2,Unlikely,Unlikely,Definite,Bronchiectasis,Not a Serious Adverse Event,None,Symptom,Recovered
1010,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,10-29-2019,12-12-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Keratoacanthomas,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1011,ee21ede823037fd3671f67a68376422a,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,11-12-2019,11-26-2019,Musculoskeletal and connective tissue disorders,Chest wall pain,,1,Unrelated,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
1012,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-19-2019,07-29-2019,Metabolism and nutrition disorders,Anorexia,"Unable to tolerate any foods, liquids, or meds; IV hydration indicated",2,Unlikely,Unrelated,Probable,"N/V, altered oral intake",Not a Serious Adverse Event,None,Support,Recovered
1013,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-23-2019,07-29-2019,Metabolism and nutrition disorders,Dehydration,IVFs IV Normal Saline indicated,2,Unlikely,Unlikely,Definite,N/V,Not a Serious Adverse Event,None,Support,Recovered
1014,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-19-2019,07-29-2019,Gastrointestinal disorders,Nausea,"Nausea refractory to antiemetics; IVF hydration and IV antiemetic, including oral, indicated",2,Unlikely,Possible,Definite,BL hx ong nausea,Not a Serious Adverse Event,None,Support,Recovered
1015,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-25-2019,07-30-2019,Musculoskeletal and connective tissue disorders,Pain in extremity,Radiates from LB; BL hx of LBP; Lyrica indicated; Cauda Equina compression found,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
1016,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,07-19-2019,07-29-2019,Gastrointestinal disorders,Vomiting,"Refractory vomiting requiring IV hydration and IV antiemetic, including oral and rectal",2,Unlikely,Possible,Probable,BL Hx of ongoing nausea,Not a Serious Adverse Event,None,Support,Recovered
1017,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-05-2019,08-12-2019,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Unlikely,Possible,Dilutional r/t hospitalization,Not a Serious Adverse Event,None,None,Recovered
1018,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-29-2019,08-12-2019,Metabolism and nutrition disorders,Anorexia,,1,Unlikely,Unrelated,Definite,Altered nutrition r/t N/V episodes,Not a Serious Adverse Event,None,None,Recovered
1019,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-06-2019,08-14-2019,Gastrointestinal disorders,Constipation,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
1020,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-29-2019,08-22-2019,Musculoskeletal and connective tissue disorders,Muscle weakness lower limb,R lower limb on exam; MRI lumbar sacral spine ordered,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1021,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-01-2019,--,Musculoskeletal and connective tissue disorders,Pain in extremity,"left knee pain,radiation therapy planned",3,Unrelated,Definite,,,Not a Serious Adverse Event,Regimen Interrupted,Support,
1022,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-30-2019,08-22-2019,Nervous system disorders,Paresthesia,right lower extremity,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1023,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-01-2019,--,Nervous system disorders,Paresthesia,"left lower extremity,radiation therapy planned",2,Unrelated,Definite,,,Not a Serious Adverse Event,Regimen Interrupted,Support,
1024,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-06-2019,08-27-2019,Cardiac disorders,Sinus tachycardia,,1,Unrelated,Unlikely,Possible,Hydration status and medications,Not a Serious Adverse Event,None,None,Recovered
1025,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,07-29-2019,08-06-2019,Nervous system disorders,Spinal cord compression,"partial, L2-L4, right side extremity affected",3,Unrelated,Definite,,,Hospitalized,None,Support,Recovered
1026,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,08-10-2019,08-28-2019,Gastrointestinal disorders,Vomiting,,1,Unrelated,Unlikely,Possible,"medications, steroids, Neurontin",Not a Serious Adverse Event,None,None,Recovered
1027,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-22-2019,--,Metabolism and nutrition disorders,Anorexia,,3,Unrelated,Possible,Probable,"Lack of appetite, fatigue",Not a Serious Adverse Event,None,None,
1028,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-12-2019,08-22-2019,Metabolism and nutrition disorders,Anorexia,,2,Unrelated,Possible,Probable,"Lack of appetite, constipation",Not a Serious Adverse Event,None,None,Recovered
1029,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-12-2019,--,Metabolism and nutrition disorders,Dehydration,,2,Unrelated,Possible,Probable,Altered nutritional status,Not a Serious Adverse Event,None,Symptom,
1030,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-27-2019,08-28-2019,General disorders and administration site conditions,Fatigue,asthenia,3,Unlikely,Definite,Possible,anorexia,Hospitalized,Regimen Interrupted,None,Recovered
1031,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-12-2019,08-27-2019,General disorders and administration site conditions,Fatigue,,2,Unrelated,Probable,Possible,"Deconditioned, recent surgery",Not a Serious Adverse Event,None,None,Recovered
1032,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-12-2019,08-13-2019,Metabolism and nutrition disorders,Hypercalcemia,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1033,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-12-2019,08-13-2019,Metabolism and nutrition disorders,Hyperphosphatemia,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1034,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-22-2019,08-27-2019,Metabolism and nutrition disorders,Hyponatremia,,2,Unrelated,Possible,Definite,Altered nutritional status,Not a Serious Adverse Event,None,None,Recovered
1035,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-22-2019,--,Investigations,Lymphocyte count decreased,,3,Unlikely,Possible,Possible,R/T radiation treatment,Not a Serious Adverse Event,None,None,
1036,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-27-2019,08-28-2019,Cardiac disorders,Sinus tachycardia,,2,Unlikely,Definite,,,Hospitalized,Regimen Interrupted,None,
1037,7820df7c75ff9301d2adc15aa337db34,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,08-12-2019,--,Investigations,Weight loss,,2,Unlikely,Possible,Probable,"Anorexia, fatigue, deconditioning",Not a Serious Adverse Event,None,None,
1038,465c8bdb1a94aa4ec6e2ac2b230c1caa,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,08-12-2019,--,General disorders and administration site conditions,Fatigue,,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
1039,465c8bdb1a94aa4ec6e2ac2b230c1caa,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,08-12-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,,3,Unlikely,Probable,,,Not a Serious Adverse Event,None,Symptom,
1040,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,08-07-2019,08-09-2019,Gastrointestinal disorders,Diarrhea,,1,Possible,Unlikely,Possible,Antibiotics,Not a Serious Adverse Event,None,None,Recovered
1041,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,08-19-2019,03-17-2020,Renal and urinary disorders,Hematuria,Intermittent tiny clots;  urine pink,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1042,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,08-19-2019,03-17-2020,Gastrointestinal disorders,Oral hemorrhage,Gingival bleeding with brush/floss,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1043,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,08-09-2019,12-24-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,B/L forearms-not itchy,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1044,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,10.0,12-13-2019,12-14-2019,General disorders and administration site conditions,Fever,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,
1045,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,11.0,12-24-2019,03-17-2020,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Keratoacanthomas,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1046,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,11.0,12-24-2019,03-17-2020,Skin and subcutaneous tissue disorders,Rash acneiform,follicular dyskeratosis,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1047,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,11.0,12-24-2019,03-17-2020,Skin and subcutaneous tissue disorders,"Skin and subcutaneous tissue disorders - Other, specify",seborrheic dermatitis,1,Unlikely,Unrelated,Possible,Prior existing skin condition,Not a Serious Adverse Event,None,None,Recovered
1048,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,01-18-2020,01-28-2020,Gastrointestinal disorders,Abdominal pain,,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1049,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,01-18-2020,01-19-2020,General disorders and administration site conditions,Fever,,2,Unrelated,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
1050,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,01-18-2020,01-19-2020,Gastrointestinal disorders,Nausea,,1,Unrelated,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1051,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,01-21-2020,01-28-2020,Hepatobiliary disorders,Cholecystitis,,3,Unrelated,Probable,,,Hospitalized,Regimen Interrupted,None,Recovered
1052,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,01-24-2020,03-17-2020,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1053,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,01-22-2020,03-17-2020,Investigations,Lymphocyte count decreased,,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1054,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,01-21-2020,01-28-2020,"Respiratory, thoracic and mediastinal disorders",Pneumothorax,,2,Unrelated,Unlikely,Probable,History of pulmonary blebs/artifacts,Hospitalized,Regimen Interrupted,Symptom,Recovered
1055,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,02-17-2020,03-17-2020,General disorders and administration site conditions,Fever,,2,Unrelated,Probable,,,Hospitalized,Regimen Interrupted,Symptom,Recovered
1056,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,02-17-2020,02-25-2020,Infections and infestations,Urinary tract infection,,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Symptom,Recovered
1057,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,02-17-2020,02-25-2020,Renal and urinary disorders,Urinary tract obstruction,,3,Unrelated,Definite,,,Hospitalized,None,Symptom,Recovered
1058,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,08-20-2019,09-20-2019,Investigations,Alanine aminotransferase increased,Withholding Week #3 dose indicated,2,Possible,Probable,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
1059,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,08-20-2019,09-16-2019,Investigations,Aspartate aminotransferase increased,,1,Possible,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1060,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,08-20-2019,--,"Respiratory, thoracic and mediastinal disorders",Epistaxis,x1 episode; onset upon blowing nose,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1061,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,08-22-2019,08-23-2019,General disorders and administration site conditions,Fever,Biliary Drains (hx complications with),2,Unrelated,Unlikely,Definite,Biliary Drains (hx complications with),Not a Serious Adverse Event,None,Symptom,Recovered
1062,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,08-23-2019,10-15-2019,General disorders and administration site conditions,Pain,biliary drain insert sites,1,Unrelated,Unlikely,Definite,Biliary Drain insertion sites,Not a Serious Adverse Event,None,None,Recovered
1063,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,08-31-2019,10-15-2019,Gastrointestinal disorders,Rectal hemorrhage,intermittent with wiping after BM,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1064,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-16-2019,10-28-2019,Investigations,Alkaline phosphatase increased,,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1065,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-16-2019,09-20-2019,Investigations,Aspartate aminotransferase increased,,2,Possible,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1066,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-17-2019,09-20-2019,Metabolism and nutrition disorders,Dehydration,,3,Unrelated,Possible,,,Hospitalized,Regimen Interrupted,Support,Recovered
1067,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-16-2019,09-25-2019,Investigations,Lipase increased,,2,Unlikely,Unlikely,Possible,Right biliary drain reflux,Not a Serious Adverse Event,None,None,Recovered
1068,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-16-2019,09-20-2019,Investigations,Serum amylase increased,,1,Unlikely,Unlikely,Possible,Right biliary drain reflux,Not a Serious Adverse Event,None,None,Recovered
1069,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-17-2019,09-20-2019,Cardiac disorders,Sinus tachycardia,,1,Unrelated,Unlikely,Definite,dehydration,Not a Serious Adverse Event,None,Support,Recovered
1070,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-16-2019,02-17-2020,Renal and urinary disorders,Urinary tract obstruction,Right,3,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1071,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-03-2019,--,Renal and urinary disorders,Urinary urgency,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,
1072,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,09-17-2019,10-29-2019,Investigations,Weight loss,,2,Unrelated,Possible,Probable,"Altered nutr, mechan / R bil drain",Not a Serious Adverse Event,None,None,Recovered
1073,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,09-20-2019,09-30-2019,Investigations,Alanine aminotransferase increased,,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1074,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,09-19-2019,03-17-2020,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,,,Not a Serious Adverse Event,None,Support,Recovered
1075,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,09-20-2019,09-25-2019,Investigations,Aspartate aminotransferase increased,,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1076,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,09-25-2019,10-28-2019,Investigations,Lipase increased,,1,Unlikely,Unlikely,Possible,Right Biliary drain,Not a Serious Adverse Event,None,None,Recovered
1077,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,09-25-2019,01-21-2020,Investigations,Lipase increased,,1,Unlikely,Unlikely,Possible,Right Biliary drain,Not a Serious Adverse Event,None,None,Recovered
1078,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,09-20-2019,01-22-2020,Investigations,Lymphocyte count decreased,,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1079,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,09-20-2019,09-25-2019,Investigations,Serum amylase increased,,3,Unlikely,Unlikely,Possible,Right biliary drain reflux,Not a Serious Adverse Event,None,None,Recovered
1080,08b7f8ae708607415cb6d91315044748,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,9.0,12-08-2019,03-17-2020,Gastrointestinal disorders,Hemorrhoidal hemorrhage,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1081,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,08-15-2019,10-08-2019,Musculoskeletal and connective tissue disorders,Arthralgia,,2,Possible,Unlikely,Possible,baseline symptom,Not a Serious Adverse Event,None,Symptom,Recovered
1082,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,08-15-2019,--,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1083,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,08-15-2019,05-05-2020,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1084,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,08-15-2019,08-18-2019,Reproductive system and breast disorders,Vaginal hemorrhage,,1,Possible,Possible,Possible,baseline,Not a Serious Adverse Event,None,None,Recovered
1085,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,12.0,01-17-2020,01-18-2020,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",surgical de-bulking condyloma,3,Unrelated,Probable,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
1086,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,13.0,01-28-2020,02-11-2020,Endocrine disorders,Hypothyroidism,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1087,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,13.0,01-28-2020,02-11-2020,Investigations,Lymphocyte count decreased,,2,Unrelated,Unrelated,Probable,BL,Not a Serious Adverse Event,None,None,Recovered
1088,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,14.0,02-11-2020,--,Endocrine disorders,Hypothyroidism,,2,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
1089,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,15.0,03-02-2020,05-05-2020,Musculoskeletal and connective tissue disorders,Arthralgia,,2,Possible,Unlikely,Possible,BL,Not a Serious Adverse Event,None,Symptom,Recovered
1090,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,16.0,03-10-2020,--,Investigations,Weight loss,,1,Unlikely,Possible,Probable,surgical healing,Not a Serious Adverse Event,None,None,
1091,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,08-28-2019,03-10-2020,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1092,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,20.0,05-05-2020,--,Musculoskeletal and connective tissue disorders,Arthralgia,,1,Possible,Unlikely,Possible,BL,Not a Serious Adverse Event,None,None,
1093,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,09-24-2019,11-05-2019,Reproductive system and breast disorders,Perineal pain,,1,Unrelated,Unrelated,Possible,surgical site scar tissue irritation,Not a Serious Adverse Event,None,None,Recovered
1094,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,09-24-2019,11-25-2019,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unlikely,Possible,psoriasis flare,Not a Serious Adverse Event,None,None,Recovered
1095,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,5.0,10-08-2019,10-22-2019,Infections and infestations,Bronchial infection,,2,Unlikely,Unlikely,Probable,infection,Not a Serious Adverse Event,None,Symptom,Recovered
1096,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,5.0,10-08-2019,10-22-2019,Gastrointestinal disorders,Mucositis oral,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1097,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,7.0,11-06-2019,11-11-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,2,Possible,Unlikely,Possible,asthma exacerbation,Not a Serious Adverse Event,None,Symptom,Recovered
1098,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,7.0,11-17-2019,12-17-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,2,Possible,Unlikely,Possible,asthma exacerbation,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
1099,ebac4f67360c91e7bd8c6e10ba775fcd,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,7.0,11-05-2019,--,Reproductive system and breast disorders,Perineal pain,,2,Unrelated,Unlikely,Possible,surgical site scar tissue irritation,Not a Serious Adverse Event,None,None,
1100,13f0c302e519fabfdec53ebec86a164f,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,09-02-2019,10-04-2019,Nervous system disorders,Extrapyramidal disorder,,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1101,13f0c302e519fabfdec53ebec86a164f,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,09-04-2019,11-01-2019,Renal and urinary disorders,Hematuria,,2,Possible,Unrelated,Possible,"trauma, infection,med history",Not a Serious Adverse Event,None,None,Recovered
1102,13f0c302e519fabfdec53ebec86a164f,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,08-25-2019,09-04-2019,Renal and urinary disorders,Hematuria,,3,Possible,Possible,Possible,"trauma, infection",Not a Serious Adverse Event,None,Support,Recovered
1103,13f0c302e519fabfdec53ebec86a164f,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,-1.0,08-20-2019,08-21-2019,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",Nephrostomy tube exchange trauma,3,Unrelated,Unrelated,,,Hospitalized,None,None,Recovered
1104,13f0c302e519fabfdec53ebec86a164f,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,10-04-2019,10-04-2019,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Unrelated,Probable,"anticoagulant,baseline",Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
1105,13f0c302e519fabfdec53ebec86a164f,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,10-15-2019,--,Musculoskeletal and connective tissue disorders,Back pain,,2,Unrelated,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
1106,13f0c302e519fabfdec53ebec86a164f,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,6.0,11-01-2019,--,Reproductive system and breast disorders,Pelvic pain,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
1107,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-30-2019,--,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
1108,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-28-2019,08-29-2019,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1109,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-29-2019,08-30-2019,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Probable,,,Not a Serious Adverse Event,None,Symptom,Recovered
1110,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-27-2019,--,Metabolism and nutrition disorders,Anorexia,,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,
1111,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-26-2019,09-03-2019,Nervous system disorders,Dizziness,,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1112,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-26-2019,09-03-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1113,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-27-2019,09-03-2019,General disorders and administration site conditions,Fever,,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1114,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-26-2019,09-08-2019,Musculoskeletal and connective tissue disorders,Generalized muscle weakness,,3,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1115,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-27-2019,08-28-2019,Metabolism and nutrition disorders,Hypokalemia,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
1116,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-24-2019,--,Gastrointestinal disorders,Nausea,,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,Symptom,
1117,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,1.0,08-27-2019,09-03-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,Abdominal pain,3,Unrelated,Definite,,,Hospitalized,None,Symptom,Recovered
1118,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-12-2019,09-13-2019,Cardiac disorders,Atrial fibrillation,,2,Unrelated,Probable,Definite,Electrolyte Imbalance,Not a Serious Adverse Event,None,Symptom,Recovered
1119,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-08-2019,09-11-2019,Psychiatric disorders,Confusion,,2,Unrelated,Probable,Definite,Hypercalcemia and electrolyte Imbalance,Hospitalized,None,None,Recovered
1120,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-09-2019,09-13-2019,Investigations,Electrocardiogram QT corrected interval prolonged,,3,Unrelated,Probable,Definite,Electrolyte Imbalance,Not a Serious Adverse Event,None,Symptom,Recovered
1121,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-08-2019,--,General disorders and administration site conditions,Fatigue,,3,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
1122,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-08-2019,09-11-2019,Metabolism and nutrition disorders,Hypercalcemia,,4,Unrelated,Definite,,,Hospitalized,None,Support,Recovered
1123,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-14-2019,09-18-2019,Metabolism and nutrition disorders,Hypocalcemia,,1,Unrelated,Probable,Definite,Electrolyte Imbalanced,Not a Serious Adverse Event,None,None,Recovered
1124,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-22-2019,09-22-2019,Metabolism and nutrition disorders,Hypokalemia,,3,Unrelated,Probable,Definite,Electrolyte Imbalance,Not a Serious Adverse Event,None,Symptom,Recovered
1125,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-08-2019,09-11-2019,Metabolism and nutrition disorders,Hypokalemia,,2,Unrelated,Probable,Definite,Electrolyte Imbalance,Not a Serious Adverse Event,None,Symptom,Recovered
1126,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-08-2019,--,Metabolism and nutrition disorders,Hypomagnesemia,,1,Unrelated,Probable,Definite,Electrolyte Imbalance,Not a Serious Adverse Event,None,Symptom,Recovered
1127,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-14-2019,--,Metabolism and nutrition disorders,Hyponatremia,,2,Unrelated,Probable,Definite,Electrolyte Imbalance,Not a Serious Adverse Event,None,Symptom,Recovered
1128,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-14-2019,09-17-2019,Metabolism and nutrition disorders,Hypophosphatemia,,2,Unrelated,Probable,Definite,Electrolyte Imbalance,Not a Serious Adverse Event,None,Symptom,Recovered
1129,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-08-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",brain metastasis,3,Unrelated,Definite,,,Hospitalized,None,None,
1130,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-08-2019,--,Skin and subcutaneous tissue disorders,Skin ulceration,,3,Unrelated,Definite,,,Hospitalized,None,Symptom,
1131,880d1b0ab2e5e4946585422e8ce11ac4,6,Patients determined  to be HPV negative  after enrolling  will be taken  off p,NEGATIVE,2.0,09-03-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,ight abdomen,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
1132,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,1.0,09-04-2019,11-12-2019,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,Possible,viral infection/allergy,Not a Serious Adverse Event,None,None,Recovered
1133,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,13.0,02-18-2020,--,Investigations,Weight gain,,1,Unrelated,Unrelated,Probable,steroid use,Not a Serious Adverse Event,None,None,
1134,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,14.0,03-09-2020,--,"Respiratory, thoracic and mediastinal disorders",Cough,,2,Possible,Unlikely,Possible,allergy or viral; reactive airway dx,Not a Serious Adverse Event,None,Symptom,
1135,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,14.0,03-09-2020,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Possible,Unlikely,Possible,allergy or viral; reactive airway dx,Not a Serious Adverse Event,None,None,
1136,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,2.0,09-17-2019,09-17-2019,"Injury, poisoning and procedural complications",Infusion related reaction,,2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Support,Recovered
1137,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,2.0,09-24-2019,02-18-2020,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1138,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,10-03-2019,02-18-2020,"Respiratory, thoracic and mediastinal disorders",Cough,,1,Unrelated,Unrelated,Possible,allergy or viral,Not a Serious Adverse Event,None,None,Recovered
1139,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,10-08-2019,10-10-2019,Gastrointestinal disorders,Mucositis oral,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1140,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,10-15-2019,--,"Respiratory, thoracic and mediastinal disorders",Allergic rhinitis,,2,Unrelated,Unrelated,Probable,allergy,Not a Serious Adverse Event,None,Symptom,
1141,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,10-15-2019,--,Skin and subcutaneous tissue disorders,Rash acneiform,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1142,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,10-15-2019,12-10-2019,Gastrointestinal disorders,Rectal pain,,1,Unrelated,Unrelated,Possible,baseline,Not a Serious Adverse Event,None,Symptom,Recovered
1143,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,6.0,11-12-2019,01-21-2020,Eye disorders,Blurred vision,,1,Unlikely,Unrelated,Possible,fatigue,Not a Serious Adverse Event,None,None,Recovered
1144,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,8.0,12-21-2019,12-31-2019,Skin and subcutaneous tissue disorders,Pruritus,,2,Unlikely,Unrelated,Probable,probable antibiotic reaction,Not a Serious Adverse Event,None,None,Recovered
1145,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,8.0,12-21-2019,12-31-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,,2,Unlikely,Unrelated,Probable,probable antibiotic reaction,Not a Serious Adverse Event,None,None,Recovered
1146,55af5e66a032ff37979476659764d59a,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,9.0,12-27-2019,12-31-2019,Nervous system disorders,Headache,,1,Unlikely,Unrelated,Probable,probable sinus irritation,Not a Serious Adverse Event,None,None,Recovered
1147,0a6d8ed57bad6cc2158c1a3100d01de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,09-25-2019,12-31-2019,Gastrointestinal disorders,Oral hemorrhage,gingival bleeding,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1148,0a6d8ed57bad6cc2158c1a3100d01de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,10-22-2019,--,Gastrointestinal disorders,Rectal pain,pelvic pain,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,
1149,0a6d8ed57bad6cc2158c1a3100d01de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,11-05-2019,12-31-2019,"Injury, poisoning and procedural complications",Intestinal stoma site bleeding,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1150,0a6d8ed57bad6cc2158c1a3100d01de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,11-05-2019,--,Skin and subcutaneous tissue disorders,Rash maculo-papular,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1151,0a6d8ed57bad6cc2158c1a3100d01de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,6.0,11-25-2019,--,Gastrointestinal disorders,Constipation,,1,Unrelated,Possible,Probable,probable narcotic pain regimen,Not a Serious Adverse Event,None,Symptom,
1152,0a6d8ed57bad6cc2158c1a3100d01de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,6.0,11-19-2019,--,General disorders and administration site conditions,Fatigue,,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
1153,0a6d8ed57bad6cc2158c1a3100d01de7,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,7.0,12-17-2019,12-31-2019,Blood and lymphatic system disorders,Anemia,,2,Possible,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1154,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,02-04-2020,--,Cardiac disorders,Pericardial effusion,,3,Unlikely,Possible,Possible,possible URI,Not a Serious Adverse Event,Regimen Interrupted,None,
1155,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,03-03-2020,07-21-2020,Investigations,Lipase increased,,3,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1156,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-16-2019,12-10-2019,Gastrointestinal disorders,Constipation,,2,Unlikely,Unlikely,Possible,diet,Not a Serious Adverse Event,None,Symptom,Recovered
1157,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-21-2019,10-22-2019,General disorders and administration site conditions,Flu like symptoms,,1,Unlikely,Unrelated,Possible,infection,Not a Serious Adverse Event,None,None,Recovered
1158,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-16-2019,06-23-2020,Surgical and medical procedures,"Surgical and medical procedures - Other, specify",inguinal hernia,1,Unlikely,Unlikely,Possible,inguinal hernia,Not a Serious Adverse Event,None,None,Recovered
1159,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,24.0,10-20-2020,--,Gastrointestinal disorders,Gastroesophageal reflux disease,,2,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
1160,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,25.0,01-05-2021,01-06-2021,Gastrointestinal disorders,Oral hemorrhage,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1161,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,11-12-2019,05-26-2020,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1162,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,11-12-2019,11-26-2019,Investigations,Lipase increased,,3,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1163,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,11-26-2019,02-18-2020,Investigations,Weight loss,swallowing issues,1,Possible,Unlikely,Possible,dietary changes,Not a Serious Adverse Event,None,None,Recovered
1164,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,12-26-2019,12-28-2019,Gastrointestinal disorders,Diarrhea,,1,Possible,Unlikely,Possible,holiday diet,Not a Serious Adverse Event,None,None,Recovered
1165,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,12-24-2019,05-26-2020,"Respiratory, thoracic and mediastinal disorders",Epistaxis,intermittent,1,Possible,Unlikely,Possible,winter weather/mucosal drying,Not a Serious Adverse Event,None,None,
1166,c3bb03af386a687b8eef3303f7886bda,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,02-01-2020,02-18-2020,Infections and infestations,Upper respiratory infection,,2,Unrelated,Unrelated,Definite,viral infection,Not a Serious Adverse Event,None,None,Recovered
1167,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-28-2019,--,Investigations,Alkaline phosphatase increased,,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,
1168,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-28-2019,11-18-2019,Investigations,Aspartate aminotransferase increased,,2,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1169,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-28-2019,--,Metabolism and nutrition disorders,Dehydration,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,
1170,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-21-2019,11-12-2019,General disorders and administration site conditions,Fatigue,,1,Unlikely,Probable,Possible,Dehydration,Not a Serious Adverse Event,None,None,Recovered
1171,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-25-2019,10-28-2019,Skin and subcutaneous tissue disorders,Pruritus,2 episodes,2,Unlikely,Unrelated,Definite,Oxycodone pain medication,Not a Serious Adverse Event,None,None,Recovered
1172,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-28-2019,--,Gastrointestinal disorders,Rectal hemorrhage,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1173,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,10-28-2019,10-31-2019,Cardiac disorders,Sinus tachycardia,,1,Unlikely,Unlikely,Possible,Dehydration,Not a Serious Adverse Event,None,None,Recovered
1174,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-31-2019,--,Gastrointestinal disorders,Abdominal pain,distention,2,Unrelated,Definite,,,Hospitalized,None,None,
1175,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-04-2019,11-07-2019,Blood and lymphatic system disorders,Anemia,,2,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1176,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-05-2019,--,Gastrointestinal disorders,Ascites,,2,Unlikely,Definite,,,Not a Serious Adverse Event,None,None,
1177,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-31-2019,11-12-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1178,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-06-2019,--,Gastrointestinal disorders,Gastritis,,2,Unrelated,Unlikely,Definite,GI erosion,Not a Serious Adverse Event,None,None,
1179,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,10-31-2019,11-07-2019,Cardiac disorders,Sinus tachycardia,,2,Unrelated,Possible,Possible,Dehydration,Hospitalized,None,None,Recovered
1180,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Renal and urinary disorders,Acute kidney injury,,3,Unrelated,Definite,,,Hospitalized,None,None,
1181,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,11-22-2019,Renal and urinary disorders,Acute kidney injury,,3,Unrelated,Probable,Definite,Metabolic Abnormalities,Hospitalized,Regimen Interrupted,None,Recovered
1182,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Blood and lymphatic system disorders,Anemia,,3,Unlikely,Possible,,,Not a Serious Adverse Event,None,Support,
1183,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Investigations,Aspartate aminotransferase increased,,3,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,
1184,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,11-20-2019,Investigations,Creatinine increased,,2,Unrelated,Probable,Definite,Metabolic Abnormalities,Not a Serious Adverse Event,None,None,Recovered
1185,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-12-2019,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,
1186,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,General disorders and administration site conditions,Fatigue,,3,Unlikely,Definite,,,Hospitalized,Regimen Interrupted,None,
1187,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,General disorders and administration site conditions,Fatigue,,3,Unrelated,Definite,,,Hospitalized,None,None,
1188,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-12-2019,11-18-2019,General disorders and administration site conditions,Fatigue,,2,Unlikely,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1189,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-20-2019,11-21-2019,Metabolism and nutrition disorders,Hyperkalemia,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,Support,
1190,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Metabolism and nutrition disorders,Hyperkalemia,,3,Unrelated,Probable,Definite,Acute Kidney Injury/Metabolic Abn,Not a Serious Adverse Event,None,None,
1191,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Metabolism and nutrition disorders,Hyperkalemia,,3,Unrelated,Definite,,,Hospitalized,None,None,
1192,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,11-20-2019,Metabolism and nutrition disorders,Hyperphosphatemia,,2,Unrelated,Possible,Definite,Metabolic Abnormalities,Not a Serious Adverse Event,None,None,Recovered
1193,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Metabolism and nutrition disorders,Hyperphosphatemia,,2,Unrelated,Probable,Definite,metabolic abnormalities,Not a Serious Adverse Event,None,None,
1194,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Metabolism and nutrition disorders,Hyperuricemia,,3,Unrelated,Probable,Probable,Metabolic Abnormalities,Not a Serious Adverse Event,None,Support,
1195,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-20-2019,--,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unrelated,Probable,Probable,Metabolic Abnormalities,Not a Serious Adverse Event,None,None,
1196,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,--,Metabolism and nutrition disorders,Hyponatremia,,3,Unrelated,Probable,,,Not a Serious Adverse Event,None,Support,
1197,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-12-2019,11-18-2019,Metabolism and nutrition disorders,Hyponatremia,,2,Unlikely,Possible,Probable,Electrolyte Imbalance,Not a Serious Adverse Event,None,Support,Recovered
1198,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,11-18-2019,11-20-2019,Investigations,INR increased,,3,Unrelated,Possible,Probable,Eliquis,Not a Serious Adverse Event,None,None,Recovered
1199,6193a1dd3825671d9e5ea9f02d0f0fb0,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-02-2019,12-02-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","Neoplasm, Malignant, Metastatic Rectal Cancer",5,Unrelated,Definite,,,Death,Regimen Interrupted,None,Died
1200,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,2.0,11-12-2019,--,Skin and subcutaneous tissue disorders,Rash acneiform,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1201,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,11-19-2019,12-09-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,2,Possible,Possible,,,Not a Serious Adverse Event,Therapy Discontinued,Symptom,Recovered
1202,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,11-19-2019,--,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1203,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,11-19-2019,12-03-2019,Metabolism and nutrition disorders,Hypoalbuminemia,,2,Unlikely,Unlikely,Possible,diet,Not a Serious Adverse Event,None,None,Recovered
1204,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,12-09-2019,--,Cardiac disorders,Atrial fibrillation,,3,Unlikely,Possible,Possible,infection,Hospitalized,None,Symptom,
1205,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,12-09-2019,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,3,Unlikely,Possible,Possible,infection,Hospitalized,None,Symptom,
1206,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,12-03-2019,--,Endocrine disorders,Hypothyroidism,,2,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
1207,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,12-18-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",disease progression HNSCC,5,Unrelated,Definite,,,Important Medical Event,None,None,Died
1208,c460e2e9af240ce9cf71067e48620eeb,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,4.0,12-09-2019,--,"Respiratory, thoracic and mediastinal disorders",Pleural effusion,,1,Unrelated,Possible,Possible,infection,Not a Serious Adverse Event,None,None,
1209,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,11-10-2019,--,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1210,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,11-10-2019,--,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1211,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,11-05-2019,--,Nervous system disorders,Headache,,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,None,
1212,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,11-06-2019,--,"Respiratory, thoracic and mediastinal disorders",Nasal congestion,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,
1213,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-19-2019,--,Gastrointestinal disorders,Dry mouth,,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,None,
1214,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,11-19-2019,--,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,
1215,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-09-2019,12-14-2019,Investigations,Alanine aminotransferase increased,,4,Unrelated,Definite,Probable,baseline,Not a Serious Adverse Event,None,None,Recovered
1216,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-14-2019,12-17-2019,Investigations,Alanine aminotransferase increased,,3,Unrelated,Definite,Probable,baseline,Not a Serious Adverse Event,None,None,Recovered
1217,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-07-2019,12-17-2019,Investigations,Alkaline phosphatase increased,,2,Unrelated,Definite,Probable,baseline,Not a Serious Adverse Event,None,None,Recovered
1218,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-07-2019,12-09-2019,Blood and lymphatic system disorders,Anemia,,3,Possible,Definite,,,Hospitalized,Regimen Interrupted,Support,Recovered
1219,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-10-2019,--,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,None,
1220,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-09-2019,12-14-2019,Investigations,Aspartate aminotransferase increased,,4,Unrelated,Definite,Probable,baseline,Not a Serious Adverse Event,None,None,Recovered
1221,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-14-2019,--,Investigations,Aspartate aminotransferase increased,,2,Unrelated,Definite,Probable,baseline,Not a Serious Adverse Event,None,None,
1222,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-03-2019,--,General disorders and administration site conditions,Chills,,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,
1223,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-10-2019,--,Gastrointestinal disorders,Constipation,,2,Unrelated,Possible,Probable,surgical embolization procedure,Not a Serious Adverse Event,None,Symptom,
1224,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-03-2019,12-14-2019,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unrelated,Possible,Possible,Hx Ashtma,Not a Serious Adverse Event,None,None,Recovered
1225,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-14-2019,--,"Respiratory, thoracic and mediastinal disorders",Pleural effusion,,1,Unrelated,Possible,Probable,surgical embolization procedure,Not a Serious Adverse Event,None,None,
1226,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-10-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor hemorrhage,right hepatic mass lesion,1,Possible,Probable,,,Not a Serious Adverse Event,None,None,
1227,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-07-2019,12-10-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor hemorrhage,right hepatic mass lesion,3,Possible,Probable,,,Hospitalized,Regimen Interrupted,None,Recovered
1228,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-07-2019,12-10-2019,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,RUQ/Abdominal,3,Unlikely,Definite,Possible,bleed in right hepatic mass,Not a Serious Adverse Event,None,None,Recovered
1229,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,12-10-2019,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,RUQ/Abdominal,2,Unlikely,Definite,Possible,Intralesional bleed,Not a Serious Adverse Event,None,None,
1230,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-17-2019,--,Investigations,Alanine aminotransferase increased,,2,Unrelated,Definite,Probable,baseline,Not a Serious Adverse Event,None,None,
1231,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-17-2019,--,Investigations,Alkaline phosphatase increased,,3,Unrelated,Definite,Probable,baseline,Not a Serious Adverse Event,None,None,
1232,6670265bba3f83c1294410a268d3e503,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,12-17-2019,--,Investigations,Blood bilirubin increased,,2,Unrelated,Possible,Probable,surgical embolization procedure,Not a Serious Adverse Event,None,None,
1233,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,11-07-2019,11-07-2019,Gastrointestinal disorders,Diarrhea,,1,Unlikely,Unrelated,Probable,"Dietary/Food, GI irritation",Not a Serious Adverse Event,None,None,Recovered
1234,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,04-07-2020,05-21-2020,Skin and subcutaneous tissue disorders,Rash acneiform,"face, macular-papular arms, legs",2,Probable,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
1235,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,13.0,04-30-2020,04-30-2020,"Respiratory, thoracic and mediastinal disorders",Epistaxis,one episode,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1236,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,05-13-2020,06-02-2020,"Respiratory, thoracic and mediastinal disorders",Epistaxis,intermittent,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1237,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,05-13-2020,05-26-2020,Musculoskeletal and connective tissue disorders,Myalgia,"intermittent, bilateral calf",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1238,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,05-26-2020,--,Endocrine disorders,Adrenal insufficiency,,2,Probable,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
1239,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,15.0,05-21-2020,07-14-2020,Skin and subcutaneous tissue disorders,Rash acneiform,face,1,Probable,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
1240,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,16.0,06-02-2020,06-16-2020,"Respiratory, thoracic and mediastinal disorders",Cough,,1,Unrelated,Unrelated,Possible,Suspicious for possible COVID-19 inf,Not a Serious Adverse Event,None,None,Recovered
1241,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,16.0,06-02-2020,06-16-2020,Nervous system disorders,Dysgeusia,,1,Unrelated,Unrelated,Possible,Suspicious for possible COVID-19 inf,Not a Serious Adverse Event,None,None,Recovered
1242,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,16.0,06-02-2020,06-16-2020,General disorders and administration site conditions,Fever,,1,Unrelated,Unrelated,Possible,Suspicious for possible COVID-19 inf,Not a Serious Adverse Event,None,None,Recovered
1243,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,16.0,06-02-2020,06-16-2020,Nervous system disorders,Headache,,1,Unrelated,Unrelated,Possible,Suspicious for possible COVID-19 inf,Not a Serious Adverse Event,None,None,Recovered
1244,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,11-24-2019,12-01-2019,General disorders and administration site conditions,Flu like symptoms,cold,1,Unrelated,Unrelated,Probable,viral,Not a Serious Adverse Event,None,None,Recovered
1245,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,12-01-2019,12-31-2019,Skin and subcutaneous tissue disorders,Rash maculo-papular,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1246,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,20.0,08-01-2020,--,Nervous system disorders,Anosmia,,1,Unrelated,Unrelated,Probable,Residual of COVID-19 infection,Not a Serious Adverse Event,None,None,
1247,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,12-17-2019,01-28-2020,Endocrine disorders,Hyperthyroidism,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1248,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,12-31-2019,01-28-2020,General disorders and administration site conditions,Edema limbs,bilateral ankles,1,Unrelated,Possible,Possible,impaired lymphatic drainage,Not a Serious Adverse Event,None,None,Recovered
1249,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,01-09-2020,04-07-2020,Skin and subcutaneous tissue disorders,Rash acneiform,"face, ears",1,Possible,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
1250,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,7.0,01-28-2020,--,Endocrine disorders,Hypothyroidism,,2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,
1251,ba8df459b1548c0aca86fbc2a802490a,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,7.0,01-30-2020,03-24-2020,Skin and subcutaneous tissue disorders,Rash acneiform,"keratotic papules, arms, thighs,upper back",2,Probable,Unrelated,,,Not a Serious Adverse Event,None,Symptom,Recovered
1252,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,1.0,12-02-2019,12-17-2019,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1253,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,2.0,12-03-2019,--,Investigations,Lymphocyte count decreased,,2,Unlikely,Possible,Possible,prior chemo/radiation tx,Not a Serious Adverse Event,None,None,
1254,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,12-17-2019,--,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,2,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,
1255,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,12-30-2019,--,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1256,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,3.0,12-24-2019,12-30-2019,General disorders and administration site conditions,Fatigue,,2,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1257,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,6.0,01-28-2020,--,Investigations,Alanine aminotransferase increased,,1,Unlikely,Unlikely,Probable,alcohol and supplementation use,Not a Serious Adverse Event,None,None,
1258,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,6.0,01-28-2020,--,Investigations,Aspartate aminotransferase increased,,2,Unlikely,Unlikely,Probable,alcohol and supplementation use,Not a Serious Adverse Event,None,None,
1259,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,8.0,02-25-2020,--,Psychiatric disorders,Libido decreased,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1260,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,9.0,03-15-2020,03-17-2020,Nervous system disorders,Headache,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1261,aa49b14fb81ff7e0f080562cff98ee13,3,Subjects  with P16+ oropharyngeal  cancer naive to checkpoint inhibition,POSITIVE,9.0,03-15-2020,03-17-2020,"Respiratory, thoracic and mediastinal disorders",Rhinorrhea,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1262,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,12-05-2019,--,Gastrointestinal disorders,Constipation,,2,Unrelated,Possible,Probable,narcotic regimen,Not a Serious Adverse Event,None,Symptom,
1263,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,1.0,12-03-2019,12-10-2019,Infections and infestations,Nail infection,nail injection,1,Unrelated,Unrelated,Definite,"bacterial/nail trauma, pt bites nails",Not a Serious Adverse Event,None,None,Recovered
1264,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,12-10-2019,12-24-2019,Skin and subcutaneous tissue disorders,Pruritus,diffuse,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1265,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,2.0,12-18-2019,12-31-2019,Gastrointestinal disorders,Rectal hemorrhage,,2,Possible,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
1266,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-24-2019,01-18-2020,Gastrointestinal disorders,Abdominal pain,cramping,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1267,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-24-2019,12-26-2019,Blood and lymphatic system disorders,Anemia,,3,Possible,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,Support,Recovered
1268,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-26-2019,12-27-2019,Hepatobiliary disorders,Bile duct stenosis,,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Support,Recovered
1269,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-24-2019,01-18-2020,Gastrointestinal disorders,Bloating,,1,Unrelated,Possible,Probable,constipation,Not a Serious Adverse Event,None,None,Recovered
1270,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-24-2019,12-26-2019,Investigations,Blood bilirubin increased,,2,Unlikely,Probable,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
1271,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-26-2019,12-27-2019,Investigations,Blood bilirubin increased,,3,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1272,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-27-2019,12-29-2019,Investigations,Blood bilirubin increased,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1273,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-29-2019,01-07-2020,Investigations,Blood bilirubin increased,,1,Unrelated,Definite,,,Not a Serious Adverse Event,None,None,Recovered
1274,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-31-2019,--,Skin and subcutaneous tissue disorders,Erythroderma,rash mid abdomen,1,Unlikely,Unrelated,,,Not a Serious Adverse Event,None,None,
1275,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-24-2019,01-28-2020,General disorders and administration site conditions,Fatigue,,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1276,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-26-2019,12-27-2019,Investigations,Lymphocyte count decreased,,3,Unlikely,Possible,Probable,prior chemo and radiation,Not a Serious Adverse Event,None,None,Recovered
1277,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,3.0,12-31-2019,01-13-2020,Gastrointestinal disorders,Rectal hemorrhage,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1278,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-18-2020,--,Gastrointestinal disorders,Abdominal distension,,3,Unrelated,Probable,,,Not a Serious Adverse Event,Regimen Interrupted,None,
1279,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-18-2020,--,Gastrointestinal disorders,Abdominal pain,,3,Unrelated,Probable,,,Not a Serious Adverse Event,Regimen Interrupted,None,
1280,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-13-2020,--,Blood and lymphatic system disorders,Anemia,,3,Possible,Possible,,,Not a Serious Adverse Event,None,Support,
1281,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,--,Metabolism and nutrition disorders,Anorexia,,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,Symptom,
1282,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-25-2020,--,Gastrointestinal disorders,Ascites,,2,Possible,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
1283,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-16-2020,01-18-2020,Gastrointestinal disorders,Ascites,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1284,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-18-2020,01-25-2020,Gastrointestinal disorders,Ascites,,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Symptom,Recovered
1285,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-18-2020,01-25-2020,Hepatobiliary disorders,Cholecystitis,,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Symptom,Recovered
1286,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-25-2020,01-30-2020,Gastrointestinal disorders,Diarrhea,,2,Unrelated,Unlikely,Probable,IV antibiotics,Not a Serious Adverse Event,None,None,Recovered
1287,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-13-2020,--,"Respiratory, thoracic and mediastinal disorders",Dyspnea,,1,Unlikely,Possible,Probable,anemia,Not a Serious Adverse Event,None,None,
1288,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-13-2020,--,General disorders and administration site conditions,Edema limbs,bilateral ankles,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,
1289,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,--,General disorders and administration site conditions,Fatigue,,3,Unrelated,Probable,Possible,decondition recent hospit,Not a Serious Adverse Event,None,None,
1290,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-18-2020,--,General disorders and administration site conditions,Fever,,1,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,
1291,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,02-15-2020,Infections and infestations,Fungemia,,2,Unrelated,Unrelated,,,Hospitalized,Regimen Interrupted,None,Recovered
1292,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,02-02-2020,02-15-2020,Hepatobiliary disorders,"Hepatobiliary disorders - Other, specify",left hepatic lobe abscesses,3,Unrelated,Probable,,,Hospitalized,Regimen Interrupted,None,Recovered
1293,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,02-09-2020,Metabolism and nutrition disorders,Hypoalbuminemia,,3,Unrelated,Definite,,,Not a Serious Adverse Event,None,Symptom,Recovered
1294,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,--,Metabolism and nutrition disorders,Hypocalcemia,,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,Symptom,
1295,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,01-29-2020,Metabolism and nutrition disorders,Hypokalemia,,4,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,Support,Recovered
1296,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,01-30-2020,Metabolism and nutrition disorders,Hyponatremia,,2,Unrelated,Probable,,,Not a Serious Adverse Event,None,Support,Recovered
1297,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-07-2020,--,Investigations,Lymphocyte count decreased,,3,Unlikely,Probable,Possible,prior chemo/radiation,Not a Serious Adverse Event,None,None,
1298,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-31-2020,--,General disorders and administration site conditions,Pain,epigastric-LUQ,2,Unrelated,Possible,,,Not a Serious Adverse Event,None,None,
1299,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,02-02-2020,--,Hepatobiliary disorders,Portal vein thrombosis,,3,Unrelated,Probable,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
1300,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-28-2020,02-15-2020,Hepatobiliary disorders,Portal vein thrombosis,,3,Unrelated,Unrelated,,,Hospitalized,Regimen Interrupted,None,Recovered
1301,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-13-2020,--,Gastrointestinal disorders,Rectal hemorrhage,,2,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1302,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-18-2020,01-25-2020,Infections and infestations,Sepsis,,3,Unrelated,Definite,,,Hospitalized,Regimen Interrupted,None,Recovered
1303,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-13-2020,--,Cardiac disorders,Sinus tachycardia,,1,Unlikely,Possible,Probable,anemia,Not a Serious Adverse Event,None,None,
1304,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,4.0,01-29-2020,--,Reproductive system and breast disorders,Vaginal hemorrhage,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1305,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,02-09-2020,--,Metabolism and nutrition disorders,Hypoalbuminemia,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,Symptom,
1306,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,02-10-2020,02-12-2020,Metabolism and nutrition disorders,Hypokalemia,,3,Unrelated,Probable,Probable,Ascites,Not a Serious Adverse Event,None,Symptom,Recovered
1307,5afd3991622b7c89cbca6bb4fd725221,4,"Subjects  with other rare  HPV associated  tumors (e.g. squamous  cell rectal,",POSITIVE,,02-09-2020,02-11-2020,Metabolism and nutrition disorders,Hyponatremia,,3,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1308,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,12-23-2019,--,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,
1309,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,12-20-2019,03-10-2020,Reproductive system and breast disorders,Vaginal hemorrhage,,1,Possible,Possible,Possible,past radiation tx,Not a Serious Adverse Event,None,None,Recovered
1310,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,01-03-2020,--,"Respiratory, thoracic and mediastinal disorders",Cough,,2,Possible,Possible,Probable,allergies,Not a Serious Adverse Event,None,None,
1311,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,01-05-2020,02-11-2020,Skin and subcutaneous tissue disorders,Pruritus,,1,Possible,Unlikely,Possible,allergies,Not a Serious Adverse Event,None,None,Recovered
1312,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,4.0,01-28-2020,--,Skin and subcutaneous tissue disorders,Rash acneiform,torso (front & back) bilateral legs,1,Probable,Unlikely,,,Not a Serious Adverse Event,None,Symptom,
1313,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,02-20-2020,02-26-2020,Renal and urinary disorders,Hematuria,,1,Possible,Unlikely,,,Not a Serious Adverse Event,Therapy Discontinued,None,Recovered
1314,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,02-11-2020,--,Skin and subcutaneous tissue disorders,Pruritus,,2,Probable,Unrelated,Possible,allergies & winter skin,Not a Serious Adverse Event,None,None,
1315,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,03-01-2020,03-02-2020,Blood and lymphatic system disorders,Anemia,,3,Probable,Unlikely,,,Not a Serious Adverse Event,None,Support,Recovered
1316,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,03-02-2020,03-10-2020,Blood and lymphatic system disorders,Anemia,,2,Probable,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1317,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,02-26-2020,03-01-2020,Blood and lymphatic system disorders,Anemia,,2,Probable,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1318,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,03-05-2020,--,Renal and urinary disorders,Bladder spasm,,2,Unlikely,Possible,,,Not a Serious Adverse Event,Dose Reduced,Symptom,
1319,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,02-25-2020,03-10-2020,Gastrointestinal disorders,Dysphagia,,1,Unlikely,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1320,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,02-26-2020,03-05-2020,Renal and urinary disorders,Hematuria,,3,Unrelated,Definite,Possible,new primary bladder malignancy,Hospitalized,Regimen Interrupted,None,Recovered
1321,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,03-05-2020,--,Infections and infestations,Nail infection,,1,Unlikely,Unlikely,Definite,opportunistic fungal infection,Not a Serious Adverse Event,None,Symptom,
1322,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,02-26-2020,03-05-2020,Renal and urinary disorders,Urinary tract obstruction,,2,Probable,Unlikely,Definite,blood clots secondary to drug,Not a Serious Adverse Event,None,None,Recovered
1323,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,03-05-2020,03-25-2020,Renal and urinary disorders,Urinary urgency,,1,Unlikely,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1324,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,03-10-2020,--,Gastrointestinal disorders,Dysphagia,,2,Unlikely,Probable,Probable,mediastinal mass,Not a Serious Adverse Event,Regimen Interrupted,None,
1325,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,7.0,03-21-2020,--,Infections and infestations,Urinary tract infection,,2,Unlikely,Unlikely,Probable,prior hospital procedures,Not a Serious Adverse Event,None,Symptom,
1326,df5d99e7acc6945774fa3fcc9ca6f4a2,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,03-25-2020,03-25-2020,"Injury, poisoning and procedural complications",Fall,,2,Unrelated,Unlikely,Definite,mechanical fall-slipped in shower,Not a Serious Adverse Event,None,None,Recovered
1327,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,2.0,02-12-2020,--,Skin and subcutaneous tissue disorders,Rash acneiform,tx: dermatology - cryoablation,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,
1328,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,03-02-2020,04-15-2020,Investigations,Alanine aminotransferase increased,,3,Probable,Possible,Definite,myositis,Not a Serious Adverse Event,None,None,Recovered
1329,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,02-18-2020,03-05-2020,Blood and lymphatic system disorders,Anemia,,2,Possible,Possible,,,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
1330,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,03-02-2020,03-06-2020,Investigations,Aspartate aminotransferase increased,,3,Probable,Unlikely,Definite,myositis,Not a Serious Adverse Event,None,None,Recovered
1331,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,03-02-2020,03-10-2020,Investigations,CPK increased,,4,Probable,Unlikely,Definite,myositis & myocarditis,Not a Serious Adverse Event,None,None,Recovered
1332,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,02-26-2020,02-26-2020,Gastrointestinal disorders,Diarrhea,,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1333,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,02-18-2020,02-19-2020,General disorders and administration site conditions,Edema limbs,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1334,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,02-18-2020,02-25-2020,Gastrointestinal disorders,Flatulence,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1335,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,3.0,02-18-2020,03-03-2020,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1336,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,03-06-2020,04-15-2020,Investigations,Aspartate aminotransferase increased,,2,Probable,Possible,Definite,myositis,Not a Serious Adverse Event,None,None,Recovered
1337,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,03-03-2020,03-03-2020,Investigations,Cardiac troponin I increased,,3,Probable,Unlikely,Definite,myositis & myocarditis,Not a Serious Adverse Event,None,None,Recovered
1338,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,03-10-2020,03-24-2020,Investigations,CPK increased,,3,Probable,Unlikely,Definite,myositis & myocarditis,Not a Serious Adverse Event,None,None,Recovered
1339,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,03-03-2020,--,General disorders and administration site conditions,Edema face,,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,
1340,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,03-10-2020,--,General disorders and administration site conditions,Fatigue,,1,Probable,Possible,Definite,myositis & myocarditis,Not a Serious Adverse Event,None,None,
1341,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,03-03-2020,04-14-2020,Cardiac disorders,Myocarditis,,3,Probable,Unlikely,,,Hospitalized,Regimen Interrupted,Support,Recovered
1342,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,4.0,03-03-2020,05-24-2020,Musculoskeletal and connective tissue disorders,Myositis,,2,Probable,Unlikely,,,Hospitalized,Regimen Interrupted,None,Recovered
1343,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,03-24-2020,04-20-2020,Investigations,CPK increased,,2,Probable,Unlikely,Definite,myositis & myocarditis,Not a Serious Adverse Event,None,None,Recovered
1344,b162d352bbfe7f1ac571c079f3a91f96,1,Subjects with anal cancer whose disease is naive to checkpoint inhibition,POSITIVE,5.0,03-17-2020,04-14-2020,Cardiac disorders,Myocarditis,,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,Support,Recovered
1345,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,03-18-2020,06-09-2020,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1346,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,1.0,03-18-2020,07-07-2020,Gastrointestinal disorders,Oral hemorrhage,,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1347,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,10.0,08-17-2020,--,Investigations,Weight loss,,2,Unrelated,Unlikely,Probable,neck radiation therapy,Not a Serious Adverse Event,None,None,
1348,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,09-01-2020,--,Nervous system disorders,Dysgeusia,,1,Unrelated,Unlikely,Probable,radiation therapy,Not a Serious Adverse Event,None,None,
1349,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,09-01-2020,01-05-2021,Gastrointestinal disorders,Dysphagia,,1,Unrelated,Possible,Definite,esophagitis,Not a Serious Adverse Event,None,None,Recovered
1350,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,11.0,09-01-2020,01-05-2021,Gastrointestinal disorders,Esophagitis,,1,Unrelated,Unlikely,Definite,neck radiation therapy,Not a Serious Adverse Event,None,None,Recovered
1351,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,12-01-2020,01-05-2021,Investigations,Lymphocyte count decreased,,2,Unrelated,Possible,Possible,prior chemoradiation therapies,Not a Serious Adverse Event,None,None,Recovered
1352,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,12.0,01-05-2021,--,Investigations,Lymphocyte count decreased,,3,Unrelated,Possible,Possible,prior chemoradiation therapies,Not a Serious Adverse Event,None,None,
1353,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,04-07-2020,04-28-2020,Gastrointestinal disorders,Mucositis oral,Left tonsil lesion,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,Recovered
1354,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,2.0,03-31-2020,09-01-2020,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Tumor pain,L post-auricular / upper posterior triangle nodes; tender to palpation,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,Symptom,Recovered
1355,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,04-14-2020,09-01-2020,Skin and subcutaneous tissue disorders,Dry skin,Forehead,1,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1356,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,3.0,04-14-2020,--,General disorders and administration site conditions,Fatigue,,1,Possible,Possible,,,Not a Serious Adverse Event,None,None,
1357,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,5.0,05-12-2020,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",Skin papilloma,wart on left anterior nose,1,Unlikely,Unlikely,,,Not a Serious Adverse Event,None,None,
1358,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,6.0,05-26-2020,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","KERATOACANTHOMA,right forearm",1,Possible,Unlikely,,,Not a Serious Adverse Event,Regimen Interrupted,Support,
1359,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,07-07-2020,--,Gastrointestinal disorders,Dry mouth,,1,Unrelated,Unlikely,Probable,Radiation therapy,Not a Serious Adverse Event,None,None,
1360,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,07-07-2020,09-01-2020,Gastrointestinal disorders,Dysphagia,,2,Unrelated,Possible,Definite,Esophagitis,Not a Serious Adverse Event,None,Symptom,Recovered
1361,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,07-07-2020,09-01-2020,Gastrointestinal disorders,Esophagitis,,2,Unrelated,Unlikely,Definite,Radiation therapy,Not a Serious Adverse Event,None,Symptom,Recovered
1362,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,8.0,07-07-2020,08-17-2020,Investigations,Weight loss,,1,Unrelated,Unlikely,Probable,radiation therapy,Not a Serious Adverse Event,None,None,Recovered
1363,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,07-21-2020,09-01-2020,"Injury, poisoning and procedural complications",Dermatitis radiation,Base of neck,2,Unrelated,Unrelated,Probable,radiation therapy,Not a Serious Adverse Event,None,None,Recovered
1364,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,07-21-2020,09-01-2020,Nervous system disorders,Dysgeusia,Altered taste,1,Unrelated,Unlikely,Probable,radiation therapy & dry mouth,Not a Serious Adverse Event,None,None,Recovered
1365,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,07-21-2020,09-01-2020,Gastrointestinal disorders,Nausea,,1,Unrelated,Unlikely,Probable,radiation therapy,Not a Serious Adverse Event,None,None,Recovered
1366,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,07-21-2020,09-01-2020,Infections and infestations,Skin infection,left hand lesion,2,Unrelated,Unlikely,Probable,Staff aureus infection per dermatology,Not a Serious Adverse Event,None,Symptom,Recovered
1367,99e34b12538569b3b9f4452ab6ead054,5,Subjects  with any HPV associated  cancer whose disease  is refractory to chec,POSITIVE,9.0,07-21-2020,09-01-2020,Gastrointestinal disorders,Vomiting,,1,Unrelated,Unlikely,Probable,radiation therapy,Not a Serious Adverse Event,None,None,Recovered
1368,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,03-31-2020,04-07-2020,Renal and urinary disorders,"Renal and urinary disorders - Other, specify","Renal and urinary disorder, intermittent",2,Unrelated,Possible,,,Not a Serious Adverse Event,None,Symptom,Recovered
1369,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,04-07-2020,--,Gastrointestinal disorders,Dysphagia,,1,Possible,Definite,Definite,S/p palliative radiation,Not a Serious Adverse Event,None,None,
1370,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,04-07-2020,--,Gastrointestinal disorders,Nausea,,1,Possible,Definite,Definite,Post-tussive,Not a Serious Adverse Event,None,None,
1371,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,04-07-2020,04-21-2020,Gastrointestinal disorders,Vomiting,,1,Possible,Definite,Definite,Post-tussive,Not a Serious Adverse Event,None,None,Recovered
1372,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,04-21-2020,--,Metabolism and nutrition disorders,Anorexia,,2,Possible,Probable,,,Not a Serious Adverse Event,None,None,
1373,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,04-21-2020,--,General disorders and administration site conditions,Fatigue,,2,Probable,Probable,,,Not a Serious Adverse Event,None,None,
1374,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,04-21-2020,--,Metabolism and nutrition disorders,Hypokalemia,,2,Possible,Possible,Possible,Post-tussive vomiting,Not a Serious Adverse Event,None,Support,
1375,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,05-01-2020,--,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify",Brain Metastasis,3,Unrelated,Definite,,,Hospitalized,None,None,
1376,95a25c446c0420eb661d768b5d097f1b,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,04-21-2020,--,"Respiratory, thoracic and mediastinal disorders",Pneumonitis,,2,Probable,Possible,Possible,s/p palliative radiation,Not a Serious Adverse Event,Regimen Interrupted,Symptom,
1377,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,04-20-2020,--,Blood and lymphatic system disorders,Anemia,,2,Possible,Unlikely,,,Not a Serious Adverse Event,None,None,
1378,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,04-16-2020,04-29-2020,Gastrointestinal disorders,Bloating,abdominal,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1379,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,04-10-2020,05-05-2020,"Respiratory, thoracic and mediastinal disorders",Epistaxis,,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1380,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,04-20-2020,--,Investigations,Lymphocyte count decreased,,1,Possible,Possible,Probable,"BL, r/t prior chemotherapy & radiation",Not a Serious Adverse Event,None,None,
1381,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,04-29-2020,--,Gastrointestinal disorders,Ascites,,2,Unrelated,Definite,,,Not a Serious Adverse Event,None,Support,
1382,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,04-22-2020,05-01-2020,Musculoskeletal and connective tissue disorders,Back pain,,1,Unrelated,Unrelated,Probable,Urinary Tract Injection,Not a Serious Adverse Event,None,None,Recovered
1383,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,04-22-2020,05-01-2020,General disorders and administration site conditions,Fever,,1,Unrelated,Unrelated,Probable,Urinary Tract Injection,Not a Serious Adverse Event,None,None,Recovered
1384,a2eac1eb9ebb6ea61d9498fc9c813106,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,04-22-2020,05-05-2020,Infections and infestations,Urinary tract infection,,2,Unrelated,Unlikely,Possible,"Bacterial, has ureteral stent",Not a Serious Adverse Event,None,Symptom,Recovered
1385,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,1.0,06-09-2020,06-10-2020,Reproductive system and breast disorders,Vaginal hemorrhage,,1,Probable,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1386,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,12.0,11-10-2020,09-21-2021,Skin and subcutaneous tissue disorders,Urticaria,Facial areas,1,Unrelated,Unrelated,Probable,Skin reaction to surgical masks,Not a Serious Adverse Event,None,Symptom,Recovered
1387,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,12-08-2020,12-08-2020,Immune system disorders,Allergic reaction,pruritus and burning on extremities where cream is applied,1,Unrelated,Unrelated,Probable,Triamcinolone Cream,Not a Serious Adverse Event,None,None,Recovered
1388,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,14.0,12-08-2020,03-30-2021,Musculoskeletal and connective tissue disorders,"Musculoskeletal and connective tissue disorder - Other, specify",partial tendo rupture,1,Unrelated,Unrelated,Probable,daily activity,Not a Serious Adverse Event,None,None,Recovered
1389,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,19.0,02-16-2021,06-21-2021,Blood and lymphatic system disorders,Anemia,,2,Probable,Possible,Probable,Triamcinolone,Not a Serious Adverse Event,Regimen Interrupted,None,Recovered
1390,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,19.0,02-26-2021,06-22-2021,General disorders and administration site conditions,Edema limbs,,1,Unlikely,Possible,Probable,Dietary indiscretions,Not a Serious Adverse Event,None,None,Recovered
1391,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,2.0,07-01-2020,07-07-2020,Skin and subcutaneous tissue disorders,Rash maculo-papular,,1,Probable,Unlikely,,,Not a Serious Adverse Event,None,None,Recovered
1392,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,27.0,05-31-2022,08-30-2022,Investigations,Serum amylase increased,,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1393,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,27.0,05-31-2022,--,Vascular disorders,Thromboembolic event,,2,Unrelated,Unrelated,Probable,Implantable Port,Not a Serious Adverse Event,None,Symptom,
1394,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,28.0,11-07-2022,11-08-2022,Gastrointestinal disorders,Anal hemorrhage,,1,Unrelated,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1395,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,28.0,12-06-2022,--,Investigations,Creatinine increased,,1,Unrelated,Unrelated,,,Not a Serious Adverse Event,None,None,
1396,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,28.0,12-06-2022,--,General disorders and administration site conditions,Edema limbs,bilateral lower extremity,1,Unrelated,Unrelated,Definite,venous insufficiency,Not a Serious Adverse Event,None,None,
1397,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,3.0,07-08-2020,07-17-2020,Reproductive system and breast disorders,Vaginal hemorrhage,,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1398,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,4.0,07-22-2020,06-22-2021,Reproductive system and breast disorders,Vaginal hemorrhage,,1,Probable,Probable,,,Not a Serious Adverse Event,None,None,Recovered
1399,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,5.0,08-04-2020,09-15-2020,Skin and subcutaneous tissue disorders,Rash maculo-papular,,1,Possible,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1400,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,8.0,09-15-2020,--,Investigations,Platelet count decreased,,1,Probable,Possible,,,Not a Serious Adverse Event,None,None,
1401,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,9.0,09-29-2020,06-22-2021,Gastrointestinal disorders,Anal hemorrhage,,1,Probable,Unrelated,,,Not a Serious Adverse Event,None,None,Recovered
1402,4fd9ca376efebbf6ccc1cc88457d025c,2,Subjects  with non neuroendocrine  cervical cancer naive to checkpoint inhibit,POSITIVE,9.0,10-06-2020,03-30-2021,Skin and subcutaneous tissue disorders,Rash maculo-papular,"lichenoid dermatitis,Bilateral upper and lower extremity, back and chest",1,Possible,Unrelated,,,Not a Serious Adverse Event,Regimen Interrupted,Symptom,Recovered
